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 ABSTRACT 
 
The Placenta is an essential organ for all mammalian embryonic development as it 
provides the nutritional link between maternal and foetal blood streams. The cells 
which go on to proliferate and contribute to all the major cell types of the embryo 
derived placenta have been located to the trophoblast (TE) cells overlying the Inner 
Cell Mass (ICM) of the embryo. Immortal cell lines have been subsequentially derived 
from this tissue and called Trophoblast Stem (TS) cells. In parallel with their  in vivo  
counterparts they are also reliant on Fibroblast growth factor 4 (FgF4) (Tanaka et al., 
1998) and Activin/Nodal signalling (Guzman-Ayala et al., 2004).  
 
The Ets family transcription factor, Elf5, has been shown to be specifically expressed 
in the early placental trophoblast and subsequent derived tissues. Mice deficient in Elf5 
failed to form a placenta post implantation. Furthermore TS cells were unable to be 
derived from Elf5 knockout embryos (Donnison et al., 2005). This work suggested that 
Elf5 plays an essential role in TS cells and their differentiation. The aim of this study 
was to determine the downstream target genes of Elf5 in mouse TS cells. The target 
genes of Fgf4 and Activin/Nodal signalling in TS cells were also investigated.  This 
work is hoped to contribute to an overall greater understanding of the molecular 
networks underlying TS cell maintenance and to contribute to our knowledge of early 
placental development.  
 
Small interfering RNA (siRNA) targeted reduction of Elf5 mRNA expression in mTS 
cells was achieved using two independent siRNAs; with Elf5 reduction exceeding 80%. 
The resulting changes in gene expression were measured in order to determine the 
downstream targets of Elf5. Selected genes known to be important for trophoblast 
differentiation and maintenance were measured using real-time PCR in a candidate 
gene approach .Global changes in gene expression as a consequence of Elf5 silencing 
were measured using an Affymetrix microarray. Global changes in gene expression due 
to growth factor (Fgf4 and/or Activin) removal were also measured. Expression of 22 
genes was changed using either of the Elf5 siRNA oligonucleotides. Of these, 9 were 
also significantly changed by growth factor removal. Included in this set were Synopl, 
 ii
Hst3st3b1, Cyr61 and Sox2. In the overall analysis, many genes whose expression 
changed upon loss of Elf5 are known to play important roles in trophectoderm cell 
specification. Real-time PCR validation agreed closely with the up or down regulation 
measured using the microarray. This work has thus led to the discovery of sets of Elf5 
target genes potentially involved in trophoblast stem cell function and has provided the 
foundation for future work exploring the molecular pathways of trophoblast 
development.  
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CHAPTER 1 : LITERATURE REVIEW 
1.1 GENERAL INTRODUCTION 
The placenta is the essential organ for all mammalian development in the uterine 
environment as it mediates the interaction between the growing foetus and the 
maternal blood stream. Indeed, any genetic or environmental insult that affects the 
development of the placenta can lead to placental insufficiency, fetal growth 
retardation and death. Formation of the placental lineage has occurred by the 
blastocyst stage in the mouse embryo when two clearly defined lineages are seen; the 
Inner cell mass (ICM) which goes on to become all cell lineages of the embryo proper 
and the trophectoderm (TE) which proliferates and differentiates into extra-embryonic 
ectoderm tissue and is essential for the formation of all embryo derived placental cell 
types (Rossant & Cross, 2001). The proliferative cells of the trophectoderm are in close 
contact with the ICM and ICM derived tissues, and have been isolated as an immortal 
line of cells called trophoblast stem cells (TS cells) (Tanaka et al., 1998). These cells 
have been found to be reliant both in vitro and in vivo on growth factors such as 
Fibroblast growth factor 4 (Tanaka et al., 1998)  and Nodal (Guzman-Ayala et al., 2004).   
The Ets transcription factor Elf5 has been shown to play an essential role in early 
placental development (Donnison et al., 2005).  Elf5 homozygous mutant mice failed to 
develop the extra-embryonic ectoderm, and TS cells could not be derived from mutant 
blastocyts even though they were correctly specified. These results suggest Elf5 is 
essential for the maintenance of TS cell and extra-embryonic ectoderm precursors . 
Although several transcription factors are known to be specifically expressed in the 
trophectoderm, little has been done to investigate the molecular nature of their 
interactions in TS cells on a global genome scale or the probable over lapping 
molecular networks with Fgf4 and Nodal/Activin signalling; also so important to the 
trophectoderm .   
1.2 MOUSE TROPHOBLAST DEVELOPMENT  
1.2.1 Mouse Pre-Implantation Development 
At the early blastocyst stage of the mammalian embryo two morphologically distinct 
cell types are seen (Figure  1.2-1): the trophectoderm (TE), which is an epithelial outer 
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layer of cells that contributes solely to the embryo-derived placental tissues; and the 
inner cell mass (ICM), cells which become the embryo and contribute to 
extraembryonic endoderm and mesoderm (Kunath et al., 2004). The formation of the 
blastocyst, and hence of a new individual begins at fertilisation. Following fertilisation 
the zygote undergoes three rounds of cleavage division to form the eight cell stage. At 
this stage the embryo undergoes compaction; the blastomeres become polarised and 
express the membrane binding protein E-Cadherin (Kunath et al., 2004). Cellular 
division can then give rise to two types of daughter cells; asymmetric division gives an 
outer polar cell and an inner non-polar cell, while symmetric (radial) division results in 
two polar daughter cells (Johnson & Ziomek, 1981). If the embryo is left undisturbed 
the outer cells go on to form the trophectoderm; so it is though that the inheritance of 
different apical and basal regions leads to differences in cell fate (the cell polarity 
model) (Yamanaka et al., 2006). However, at the eight cell stage all cells retain the ability 
to form either trophectoderm or ICM  because experiments involving positional 
changing of the blastomeres at this stage show they are still able to contribute to both 
lineages (Rossant & Vijh, 1980; Ziomek et al., 1982). By the 16-cell stage first lineage 
decision has been made and cells no longer have the same plasticity (Ziomek et al., 
1982).  
 
Figure  1.2-1: Mouse Pre-implantation development. 
(source: (Yamanaka et al., 2006) 
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The ball like structure of the blastocyst is  formed by embryonic day (E) 3.5 in the 
mouse, as the outer TE cells pump fluid internally and form the blastocoel cavity, with 
the ICM lying to one side (Rossant & Cross, 2001). In the mouse a stem cell 
population (trophoblast stem cells) has been isolated from the outer cells of the 
blastocyst in the presence of Fgf4 and an embryonic fibroblast cell feeder layer (Tanaka 
et al., 1998). These cells have been shown to contribute solely to the placental cell 
lineages in vivo. The cells of the ICM have also been captured in immortal embryonic 
stem (ES) cell lines (Solter, 2006). A day later the mouse embryo is beginning to 
implant, and the ICM and TE have become several distinct cell types. The ICM has 
formed the epiblast (EPI) and the primitive endoderm and the TE is made up of the 
polar trophectoderm which overlies the ICM, and the mural trophectoderm (Rossant 
& Cross, 2001).  
1.2.2 Mouse Placental Development 
The placenta is the first organ to develop and performs a myriad of roles besides 
exchange of nutrients and wastes between the foetus and mother, including altering 
metabolic, endocrine, cardiovascular and immune functions of the mother (Cross, 
2005). The early derivatives of the trophectoderm also play an essential role in 
patterning and correct development of the embryo (Donnison et al., 2005; Georgiades 
& Rossant, 2006; Richardson et al., 2006). The embryonic portion of the placenta is 
formed from derivatives of both the ICM and TE. The specialised cell types derived 
from the polar and mural trophectoderm of the blastocyst play different roles in 
placental invasion and function and are formed in a hierarchical way. Sequential 
interactions of transcription factors give unique patterns of gene expression that cause 
the specification of each cell type (Figure  1.2-2).  
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 Figure  1.2-2: The different subtypes of the embryo derived placenta and expression of some of the genes 
important for their specification and maintenance (source: (Simmons & Cross, 2005). 
 
The first terminal cell type of the placenta to form are giant cells derived from the 
mural trophectoderm. Giant cells derived from the mural trophectoderm are called 
primary giant cells (Simmons & Cross, 2005) and are polyploid with large nuclei due to 
endoreduplication of their DNA. Giant cells express tissue remodelling genes (e.g 
matrix metalloproteinases) and mediate invasion of the conceptus into the maternal 
decidua. They produce vasodilators (e.g. vascular endothelial growth factor) and 
angiogenic factors (e.g. proliferin) as well as hormones (e.g. placental lactogen 1 [Pl1]) 
(Carney et al., 1993) to promote maternal blood flow to the implantation site and 
maternal responses to pregnancy (Simmons et al., 2007). Giant cells require the 
transcription factor Hand1 for their formation (Scott et al., 2000). Hand1 knockout 
mice (where both copies of the Hand1 gene have been made non-functional) die by 
embryonic day (E) 8.5 due to a failure in giant cell formation.  
 
The polar trophectoderm over laying the epiblast rapidly proliferates to form the extra-
embryonic ectoderm and the ectoplacental cone (Rossant & Cross, 2001) so that the 
embryo is elongated into a ‘cup shape’ with the extra embryonic ectoderm lying close 
to the epiblast and the ectoplacental cone further away. The proliferative maintenance 
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of the polar trophectoderm and subsequent extra-embryonic ectoderm is reliant on 
fibroblast growth factor-4 (Fgf4) and TGFβ signalling from the ICM and later the 
epiblast (Simmons & Cross, 2005).  
 
Fgf4 production is restricted to the ICM of the blastocyst and later to the epiblast 
(Rappolee et al., 1994 291), while its receptor, Fgfr2, is expressed specifically by the 
trophectoderm of the blastocyst, and later restricted to the extra-embryonic ectoderm 
(Haffner-Krausz et al., 1999).  Fgf4 and Fgfr2 null mutants have similar phenotypes; 
both knockouts fail just after implantation and trophoblast stem cells cannot be 
derived from blastocyst outgrowths, indicating Fgf4 signalling is essential for the 
trophectoderm lineage (Feldman et al., 1995) (Arman et al., 1998).  
 
The TGFβ member, Nodal, plays an important role in anterior-posterior patterning of 
the embryo (Beck et al., 2002) and it is also required for correct development of the 
placenta and maintenance of trophoblast stem cells in vitro (Guzman-Ayala et al., 2004). 
Nodal is expressed by the epiblast as a pre-protein which must be cleaved before it is 
active. The extra-embryonic ectoderm expresses two proteases, Furin and PACE4 
which cleave pro-Nodal (Beck et al., 2002). Nodal then maintains TS cells by 
upregulating Fgf4 expression in the epiblast and by acting directly on the extra-
embryonic ectoderm to maintain expression of Cdx2, Errβ, and Eomes (extra-
embryonic ectoderm markers) and to suppress Mash2  (an ectoplacental cone marker) 
(Guzman-Ayala et al., 2004). Activin, a protein closely related to Nodal which shares 
the same signalling receptors can also maintain expression of extra-embryonic 
ectoderm markers and prevent Mash2 expression (Guzman-Ayala et al., 2004). 
 
The ectoplacental cone is characterised by expression of Tpbpa and Mash2 (Simmons & 
Cross, 2005). The ectoplacental cone is thought to differentiate into secondary giant 
cells and spongiotrophoblast (Figure  1.2-3), since giant cells surround the outer limits 
of the conceptus and TS cells in culture have been shown to transiently express these 
markers before becoming giant cells (Carney et al., 1993). The transcription factor 
Mash2 is essential for development of the spongiotrophoblast (Guillemot et al., 1994). 
However it also inhibits giant cell formation (Scott et al., 2000) and is down regulated 
as differentiation to giant cells proceeds. Recent evidence also suggests that there is a 
greater diversity in secondary giant cells and that not all of them originate from the 
ectoplacental cone (Simmons et al., 2007). 
 5
 The extra-embryonic ectoderm proliferates to form the chorion and both tissues are 
characterised by a similar set of genetic markers. The allantois, which is derived from 
the extra-embryonic mesoderm, attaches to the chorion at around day E8.5 (Rossant & 
Cross, 2001). After this occurs, foetal blood vessels begin to develop from the allantois 
and invade the choiron to create the foetal derived vascular network of the placenta 
(Rossant & Cross, 2001). Chorionic trophoblast differentiates alongside the foetal 
blood vessels into densely branched villi made up of several specialised cell types 
including syncytiotrophoblast which are characterised by the expression of 
Gcm1(Simmons & Cross, 2005) and giant cells. The entire structure is known as the 
labyrinth (Figure  1.2-3) and is where nutrient exchange between foetal and maternal 
blood occurs. Gcm1 mutants fail to form syncytiotrophoblast cell types and the chorion 
remains flat (Anson-Cartwright et al., 2000). The structure of the labyrinth trophoblast 
is based around the maternal blood sinuses (Figure  1.2-3). Giant cells are in direct 
contact with the maternal blood followed by two layers of syncytiotrophoblast to form 
a three layered barrier adjacent to a foetal blood vessel (Cross, 2005).  
 
 
Figure  1.2-3: structure of the mouse placenta and of the trophoblast interface between maternal and fetal blood 
in the labyrinth. (source: (Rossant & Cross, 2001) 
1.3 TS CELLS AS A MODEL FOR EARLY PLACENTAL 
DEVELOPMENT 
1.3.1.1 Trophoblast Stem cell derivation and maintenance 
Trophoblast stem cell lines are able to be derived from the outer trophectoderm cells 
of the blastocyst and from the resulting extra-embryonic ectoderm and chorion until 
the first somite pair of development, however not from the ectoplacental cone (Uy et 
al., 2002). They recapitulate the in vivo situation closely  in that they are also dependent 
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on Fgf4 and Activin/Nodal signalling (Erlebacher et al., 2004; Tanaka et al., 1998) to 
maintain their multipotent stem cell capability, and deprived of either growth factor 
differentiate precociously to the giant cell fate (Hemberger et al., 2004; Ilgren, 1981). 
Because the process of differentiation is easily controlled by the removal of Fgf4 and 
Activin growth factors, TS cells are a powerful model system to investigate gene 
regulation of trophoblast differentiation (Winger et al., 2007). They also exhibit a 
similar pattern of gene expression as the extra-embryonic ectoderm (Cdx2, Eomes, 
Errβ); and in fact the ability to derive TS cells from a knockout mouse model has 
become a test to see if that particular gene is required for the extra-embryonic lineage. 
TS cells retain the ability to differentiate in vivo.  When injected into blastocysts, TS cells 
grown in embryonic fibroblast conditioned medium or medium supplemented with 
Activin/Nodal are able to contribute to all cell lines of the placenta but not the embryo 
itself (Erlebacher et al., 2004; Tanaka et al., 1998). This multipotent ability is 
recapitulated to a lesser extent in vitro, where upon differentiation most cells proceed to 
the giant cell type fate (Rossant & Tamura-Lis, 1981). However, syncytiotrophoblast 
derivatives have been reported (Hughes et al., 2004).  Several studies have already been 
carried out using TS cells as a model for placental development (Donnison et al., 2005; 
Hughes et al., 2004; Winger et al., 2007; Wu et al., 2003; Yan et al., 2001) and first lineage 
allocation (Tanaka et al., 2002). 
1.3.1.2 Genes Involved in TS cells and Early Placental Development 
There are over 100 genes known to be essential for correct placental development 
(Simmons & Cross, 2005), yet most of them are involved with morphogenesis and 
only a few are known to be important for trophoblast stem cell maintenance and 
differentiation (Papadaki et al., 2007). Cdx2, Eomes and Errβ are required for early 
placental development, and now with using the TS cell  model the precise functions of 
these genes in the extra-embryonic ectoderm is being elucidated.  
 
The earliest known transcription factor specifically expressed by the trophoblast and 
required for TE cell fate specification is Cdx2 (Strumpf et al., 2005). Cdx2 knockouts 
fail to implant suggesting a major defect in TE development. In addition in Cdx2 
knockouts the ICM marker Oct4 fails to be restricted correctly; all cells of the blastocyst 
aberrantly express this ICM marker gene. Forced over-expression of Cdx2 in 
embryonic stem (ES) cells promotes their differentiation into trophoblast like cells 
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(Niwa et al., 2005; Tolkunova et al., 2006) showing Cdx2 is sufficient to induce the 
trophectoderm lineage, however in the absence of Oct4, Cdx2 is not required for TE 
specification (Niwa et al., 2005). Instead Cdx2 is required for the maintenance of mTS 
cell renewal. A forced reduction of Cdx2 in TS cells leads to a failure of self renewal 
and differentiation (Niwa et al., 2005) indicating Cdx2 plays a role in maintaining the 
proliferative ability of the extra-embryonic ectoderm.  
 
Eomesodermin (Eomes) is expressed in the early placental lineages (polar trophectoderm 
and extra-embryonic ectoderm) and knockouts die at around 6 days post conception 
(d.p.c.) (Russ et al., 2000). Eomes mutants were shown to implant and are able to 
correctly specify the TE and ICM of the blastocyst; however, TS cells were unable to 
be derived indicating Eomes is also required for TS cell maintenance and hence extra-
embryonic ectoderm maintenance. A third well known gene required for mTS cells and 
placental development is Errβ (Luo et al., 1997). Errβ knockouts resulted in embryonic 
death by E9.5, with a failure to produce a chorion and an over production of giant 
cells. The synthetic inhibitor of Errβ, diethylstilbestrol (DES), disrupts the 
transcriptional activity of Errβ by preventing binding to its coactivator GRIP1 
(Tremblay et al., 2001). Treatment of mTS cells with DES results in differentiation to 
the giant cell fate even in the presence of Fgf4 and Activin. Additionally treatment of 
pregnant mice with DES early in pregnancy led to placental failure by E9.5. Placentas 
were characterised by an over abundance of giant cells. These results indicate Errβ 
plays an essential role in maintaining the stem cell population of the placenta. The 
studies on Cdx2, Eomes and Errβ show the close correlation between mTS cell 
expression/gene networks and the in vivo situation and the ability to use TS cells in 
determining the role of these genes in trophoblast cell renewal. Since these studies 
further genes have been discovered to play an important role in mTS cells. One gene 
recently found to be required in mTS cells is the Retinoblastoma (Rb) tumour 
suppressor gene. This gene was first identified as the gene responsible for human 
retinoblastoma cancers. Studies have shown that Rb-/- foetuses supplied with a wildtype 
placenta can survive to birth (Wu et al., 2003). Targeted deletion of Rb in vivo resulted in 
an increase in the proliferation of extra-embryonic/chorionic trophoblasts (as 
determined by Eomes expression) and a global disruption of placental architecture, 
particularly the labyrinth and death of the embryos by E15.5. Cre mediated Rb ablation  
in TS cells had a similar phenotype to Rb knockouts conversely in differentiated cell 
types such as spongiotrophblast had no effect. Therefore Rb plays a critical role in 
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placental development through its role in TS cell function (Wenzel et al., 2007). 
Another gene shown to be essential for mTS cells is Sox2. The primary defect in Sox2 
mutants occurs in the embryo proper, yet this is only partly rescued by using wild type 
ES to make chimeras. A secondary defect is observed to cause death through defects in 
development of the chorion. TS cells could not be derived from Sox2 mutants 
confirming its essential role in maintaining the placental stem cell potential. 
1.3.2 The Role of Elf5 in TS Cell and Trophoblast Development 
In 2005 two independent groups both produced a mutated non-functional Elf5 allele 
using ES cells. Zhou et al (2005) created a targeting construct which interrupted exon 3 
replacing it with a β-galactosidase construct, giving an Elf5 protein fused to β-
galactosidase. Donnison et al (2005) created a targeting construct which interrupted 
exon 2 replacing it with a puromycin cassette. The heterozygous Elf5 +/- mice generated 
were crossed to produce homozygous Elf5-/- pups. However no homozygous pups 
could be generated indicating an essential role for Elf5 in embryonic survival 
(Donnison et al., 2005; Zhou et al., 2005). Elf5 heterozygous females showed impaired 
alveolar development and were not able to produce milk, indicating Elf5 is also 
essential for mammary gland development (Zhou et al 2005). 
Elf5 belongs to the Ets family of transcription factors. It has been isolated from cDNA 
collected from adult mouse lung tissue using a probe for the Ets domain (Zhou et al., 
1998) and from differentiating keratinocytes (Oettgen et al., 1999). Elf5 contains the 
conserved 85 amino acid Ets DNA binding domain along with a pointed domain 
responsible for protein-protein interactions. Elf5 expression is restricted to epithelial 
tissue (mammary gland, lung, kidney, salivary gland, stomach, and early placental 
epithelia before embryonic day 13) and is therefore classed among the epithelial 
specific Ets factors (Zhou et al., 1998).  
 
The Ets family of transcription factors share a conserved DNA binding domain which 
binds to the core motif of GGA(A/T), found in the promoters and enhancers of 
various target genes (Sharrocks, 2001). DNA binding of Ets factors is usually caused 
by phosphorylation or interactions with a co-regulatory transcription factor. These 
protein-protein interactions between the other parts of an Ets protein determine its 
specificity; for example the pointed domain is found on a subset of Ets proteins and 
also found in receptor proteins and protein kinases which allow the formation of 
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homo or heterodimers (Sharrocks, 2001). Ets factors are commonly associated with 
tumourigenesis. For example the Ets-1 factor is an oncogene that can result in 
leukaemia (Sharrocks, 2001). More recently several Ets factors were found to be 
upregulated in human breast cancer cell lines including Elf5 (He et al., 2007). 
 
ETS factors also have important roles in development. For example Pointed P2 is 
essential for Drosophilia eye development (Treier et al., 1995) and several Ets proteins 
play an important role in vasculogenesis and angiogenesis such as Fli-1 and Tel 
(Sharrocks, 2001)Apart from Elf5, several Ets factors have been found to be important 
for placental development such as Ets2 (Georgiades & Rossant, 2006) and Erf 
(Papadaki et al., 2007).  
 
Investigation into the lethal phenotype generated in homozygous null Elf5 offspring 
phenotypes by Donnison et al (2005) showed that Elf5 mutants died by E9.5. Using in 
situ hybridisation for marker genes of the extra-embryonic ectoderm, ectoplacental 
cone and the epiblast, revealed that Elf5 mutants completely lacked the extra-
embryonic ectoderm. The epiblast of the embryo was fused directly to the 
ectoplacental cone. Spatio-temporal analysis of Elf5 expression showed that it was 
restricted to the extra-embryonic lineages; it was clearly detected at E5.5 to 8.5 in the 
extra-embryonic ectoderm and resulting chorion. Furthermore TS cells could not be 
derived from Elf5 mutants and Elf5 expression in wild type TS cells was reduced upon 
Fgf4 removal. Elf5 has also been shown to be a target of Fgf4 signalling in mouse 
embryonic lung tissue (Metzger et al.).  
 
Moreover, loss of the extra-embryonic ectoderm in Elf5 mutants resulted in embryonic 
patterning defects. Correct Nodal signalling is required for formation of the anterior 
visceral endoderm (AVE). Correct Nodal signalling has been shown to be reliant on 
the extra-embryonic ectoderm (Beck et al., 2002; Guzman-Ayala et al., 2004). Elf5 
mutants correctly formed an AVE which appeared to migrate successfully to the future 
anterior of the embryo. However gastrulation did not proceed as evidenced by the 
absence of mesoderm tissue. 
  
Taken together these results have shown Elf5 to be essential for placental development 
through its role in maintenance of the trophoblast stem cell population residing in the 
extra-embryonic ectoderm and chorion. Secondly, the extra-embryonic ectoderm plays 
 10
an important role for gastrulation although it is not required for AVE formation 
(Donnison et al., 2005). The authors suggest a model whereby Elf5 is a down stream 
gene of Cdx2 and Eomes and is required for maintenance of extra-embryonic 
proliferation. The reasoning behind this was Cdx2 was normally expressed in Elf5 
mutants up until E4.5 and polar trophectoderm was correctly specified; also the Elf5 
homozygous mutant dies at a later stage compared to Eomes knockouts.  
1.3.2.1 Other Ets Transcription Factors in Trophoblast Development 
The related Ets gene Ets2 has a very similar expression pattern and knock-out 
phenotype to Elf5 (Georgiades & Rossant, 2006). Ets2 expression is similar to Elf5 in 
that it is restricted to the extra-embryonic ectoderm. However following E 7.5 it is 
down regulated and unlike Elf5 it begins to be expressed in the primitive streak of the 
gastrulating embryo. Ets2 knockouts lack an extra-embryonic ectoderm and are able to 
specify the AVE. Formation of mesoderm also did not occur supporting the role of 
the extra-embryonic ectoderm as essential for gastrulation (Georgiades & Rossant, 
2006).  However, in contrast to Elf5 mutants, AVE migration to the anterior side was 
not completed correctly.  
Finally, the Ets transcriptional repressor Erf has been implicated in extra-embryonic 
maintenance (Papadaki et al., 2007). Erk mutants die by E10.5 due to an expanded 
chorion and a lack in chorion differentiation. Additionally, TS cells were able to be 
derived and exhibited delayed differentiation as indicated by the retention of 10-20 fold 
higher expression of Eomes, Errβ and Cdx2 compared to wild-type TS cells after Fgf4 
withdrawal. Therefore, in contract to Ets2 and Elf5, Erf expression is required for 
differentiation of the chorion and down-regulation maintains a stem cell state 
(Papadaki et al., 2007). 
Clearly Ets transcription factors play important roles in maintenance and 
differentiation of the stem cell populations in the extra-embryonic ectoderm and 
resulting chorion. The defects in the extra-embryonic ectoderm have given interesting 
opportunities to allow a study of the extra-embryonic ectoderm’s role in patterning 
through Nodal signalling and AVE formation and migration. However a detailed 
analysis of how Ets genes control maintenance or differentiation of the extra-
embryonic ectoderm through the identification of their target genes has not been 
performed. Although Ets genes share the Ets DNA binding domain, they have also 
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been shown to have very distinct biological roles (Sharrocks, 2001), so it cannot be 
assumed that Ets2 and Elf5 have the same target genes, although the similarity in 
phenotypes suggests that they have overlapping functions.  
1.3.3 The Purpose of this Study 
The research carried out in this study focused on the role of Elf5 in trophoblast stem 
cells as a model for the role of Elf5 in maintaining the extra-embryonic ectoderm. By 
modulating the expression of Elf5 using RNA interference (RNAi), it was hoped to 
ascertain the downstream target genes of Elf5 and shed some light on its pivotal role in 
TS cell maintenance. The change in expression levels of genes due to Elf5 modulation 
were measured using a candidate gene approach and a global approach. Candidate gene 
analysis measured the change in expression of selected genes known to be crucial for 
placental cell type specification using real-time PCR. A global approach was employed 
using an oligonucleotide-based microarray to simultaneously measure the change in 
expression of thousands of transcripts due to changes of Elf5 expression. Alongside 
Elf5’s role in TS cells, the impact of loss of Fgf4 and Activin signalling was also 
investigated as gene expression responses to these pathways are also essential for TS 
cell maintenance. 
Microarray analysis has been widely used to find the downstream targets of 
transcription factors in an attempt to identify gene regulatory networks in target cell 
lineages (Babaie et al., 2007; Saito et al., 2007; Tanaka et al., 2002; Wang et al., 2007). 
Microarrays have the advantage of being able to screen transcriptional level changes on 
a genome wide scale, allowing the identification of novel target genes, rather than the 
small set of candidate genes tested by other methods. Microarrays are often used in 
conjunction with chromatin immunoprecipitation assays (CHIP on chip) to isolate 
(CHIP) and then identify (chip) a set of DNA transcripts which are bound by the 
transcription factor of interest. However, this method does not provide information on 
whether target genes are activated or repressed (Matoba et al., 2006). By manipulating 
the expression of a transcription factor and then monitoring global expression, targets 
which are up or down regulated can be identified. A 24 hour time period following 
Elf5 mitigation with siRNA was chosen to allow the identification of immediate down 
stream genes. A longer time period would have a greater chance of allowing secondary 
targets to also be changed. A similar approach combining RNAi with microarray 
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analysis has been previously used to identify down stream targets of the Oct4 
transcription factor (Babaie et al., 2007). 
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CHAPTER 2 :MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1  Mammalian Cell culture Reagents 
2.1.1.1 Plasticware and consumables 
TrypLETM Express, trypsin replacement enzyme (Gibco, Invitrogen life technologies 
Auckland, NZ)  
Multidish 6 wells (Nunc, Kamstrupvej, Denmark) 
Multidish 12 wells (Nunc, Kamstrupvej, Denmark) 
Tissue Culture dish 60x15 (Nunc, Kamstrupvej, Denmark) 
Tissue Culture dish 100x20 (Nunc, Kamstrupvej, Denmark) 
Cryovials (Nunc, Kamstrupvej, Denmark) 
Crystal Violet (BDH Laboratory Supplies, England) 
Dimethyl Sulphoxide Hybri Max (DMSO) (Sigma-Aldrich, Ayrshire, UK) 
2.1.1.2  Cell Culture Media 
All cell culture media was stored at 4°C for no longer than 6 weeks. The protocols for 
all medias were obtained from Placenta and Trophoblast methods, volume 1.(Quinn et 
al., 2006) 
2x RPMI Medium 1640  
1 packet of RPMI Medium 1640 powder (Gibco, Invitrogen life technologies, 
Auckland, NZ) 
500ml MQ H2O 
2.0g NaHCO3 (Cell culture grade, Sigma-Aldrich, USA) 
pH adjusted with 10M HCl 
Filter Sterilised (0.22µm filter) 
2x DMEM F12 
1 packet of DMEM F12 medium powder (Gibco, Invitrogen life technologies, 
Auckland, NZ) 
500ml MQ H2O 
2.438g NaHCO3 (Cell culture grade, Sigma-Aldrich, USA) 
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pH adjusted with 10M HCl 
Filter Sterilised (0.22µm filter) 
Mouse trophoblast stem cell media (mTS media) 
1x RPMI 1640 (2x as described above) 
20% fetal bovine serum (FBS) (ICP biologicals, Auckland, NZ) 
1mM Sodium Pyruvate (100x Gibco, Invitrogen life technologies, Auckland NZ) 
0.1mM βMercaptoethanol (Sigma-Aldrich, USA) 
2mM L-Glutamine (200mM, 100x, Invitrogen life technologies, NZ) 
1x Antibiotic/Antimycotic (100x::10,000units of penicillin, 10,000µg of 
streptomycin, 25µg amphotercin B per ml) (Invitrogen life technologies, NZ) 
Reverse Osmosis mQ H2O (autoclaved to sterilise, Millipore Corporation, USA)  
Mouse embryonic fibroblast media (mEF media) 
1x DMEM F12 media (2x as described above) 
10% FBS 
1mM Sodium Pyruvate 
1x Antibiotic/Antimycotic 
0.05mM βMercaptoethanol (Sigma-Aldrich, USA) 
Reverse Osmosis mQ H2O (autoclaved, 121°C 15min) 
70% Conditioned media + Fgf4 and Heparin (70%CM + F4H)  
70% mEF Conditioned Medium ( 2.2.1.3) 
30% mTS media 
1xFgf4 
1x Heparin 
2x mouse trophoblast stem cell freezing media 
50% FBS 
30% mTS media  
20% DMSO (Sigma-Aldrich, UK) 
Cool to 4˚C  
2x mouse embryonic fibroblast cell freezing media 
50% FBS 
30% mEF media 
20% DMSO  
Cool to 4˚C  
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2.1.1.3 Growth Factors and Antibiotics  
Fibroblast growth factor-4 human recombinant, 25µg (Sigma-Aldrich, USA) 
Resuspend in 1ml PBS (Oxoid, UK) 0.1%Bovine Serum Albumin (Invitrogen 
life technologies, Aucklnad, NZ) w/v. This gives a 1000x solution. 
Make 50µl aliquots and store at -80°C 
Defrost as required and keep at 4°C 
Heparin 10,000 units (Sigma-Aldrich, USA) 
Resuspend in PBS to give a 1000x stock concentration of 1mg/ml 
Aliquot as 1ml lots and store at -80°C 
Thaw as required and store at 4°C 
Mitomycin C 2mg (Sigma-Aldrich, USA) 
Resuspend in 2ml of PBS 
Aliquot and store at -80°C 
Puromycin (Sigma-Aldrich, USA) 
Dissolve in mQ H2O 1mg/ml 
Filter sterilized 0.22µm syringe filter 
Doxycycline Hydrate (Sigma-Aldrich, USA) 
Dissolve in mQ H2O at a concentration 1mg/ml to give 1000x solution 
Filter sterilize through 0.22µm filter (Pall Corporation, Michigan, USA) 
Store at -20°C in the dark for up to one year 
Geneticin (G418 Sulfate) (Gibco, Invitrogen life technologies, NZ) 
Dissolve 1g in 70ml 1x RPMI to make a 10mg/ml stock  
2.1.1.4 Transfection Reagents 
 LipofectamineTM 2000 stored at 4°C (Invitrogen life technologies Auckland, NZ)  
1x Optimem reduced serum medium (Gibco, Invitrogen life technologies, Auckland 
NZ) 
Reduced serum mouse trophoblast medium for transfections 
1x RPMI 1640 (2x as described above) 
5% FBS  
1mM Sodium Pyruvate  
0.1mM βMercaptoethanol  
2mM L-Glutamine 
Sterile Reverse Osmosis mQ H2O  
 16
2.1.1.5 Transfected RNAi/DNA constructs: 
All RNAi molecules were stored at -80°C and all DNA constructs were stored at -
20°C. 
Stealth RNAi dsRNA x4, diluted to a working concentration of 20pmol/µl in RNAse 
free water (Invitrogen life technologies) 
Stealth RNAi Negative Control Duplexes, medium GC duplex 20pmol/µl stored at -
80°C (Invitrogen life technologies, Australia) 
Block-iT Fluorescent Oligo (Invitogen Corporation) 
pTracer-Elf5 DNA construct (supplied by B.Brophy, using pTracerTM –CMV2 plasmid 
backbone(Invitrogen life technologies)) 
pTet-On gene expression plasmids which includes pTet-On, pTre2hygLuc and 
pTRE2hyg (BD Biosciences-Clonetech, California, USA) 
pGL71 puromycin resistance vector fragment (kindly supplied by Craig Smith) 
PCH110 β-Galactosidase construct (kindly supplied by J.Bracegirdle) 
pRL Renilla Luciferase Vector (kindly supplied by J.Bracegirdle) 
pGL3P Firefly Luciferase positive control vector (kindly supplied by J.Bracegirdle) 
2.1.2 Biochemical analysis reagents 
All kit components were stored under the manufacturer’s instructions. In general this 
was at -20°C except for the luciferase substrate in both the luciferase and dual 
luciferase kits. Once reconstituted this was stored at -80°C. 
Luciferase Assay System (Promega, WI, USA).  
Dual-Luciferase Reporter assay system (Promega, Madison, USA) 
Β-Galactosidase Enzyme Assay System (Promega, Madison, USA) 
96-well flat bottomed polystyrene plate (Nunc, Kamstrupvej, Denmark) 
Parafilm (Pechiney plastic packaging, USA) 
 
2.1.3 Molecular Biology Reagents 
2.1.3.1 General Reagents 
TRIZOL Reagent (Invitrogen life technologies) 
RNase Away (Molecular Bioproducts Inc., USA) 
LightCycler 480 SYBER Green 1 Master (Roche Diagnostics, Manheim, Germany) 
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Applied Biosystems SYBER Green PCR Master Mix (Applied Biosystems, Victoria, 
Australia) 
Applied Biosystems 96 well plate (Applied Biosystems, Victoria, Australia) 
Oligo dT12-18 500µg/µl (Invitrogen life technologies) 
Glycogen 10mg/ml (Roche Diagnostics, Germany) 
DTT (Invitrogen life technologies, NZ) 
dNTPs 10mM (Roche, Germany) 
ABgene 1kb DNA ladder (ABgene, Surrey, UK) 
ABgene 100bp DNA ladder (ABgene, Surrey, UK) 
ReddyRun gel loading buffer (ABgene, Surrey, UK) 
UltrapureTM Agarose powder (invitrogen life technologies) 
Ethidium Bromide 10mg/ml (Sigma-Aldrich, USA) 
DEPC treated water 
0.01% diethyl pyrocarbonate (DEPC; Sigma-Aldrich, USA) 
mQ water 
Left mixing overnight at room temperature  
Autoclaved 
3M sodium acetate (BDH, England) 
DEPC treated water 
Adjusted to pH 5 with 3M acetic acid (J.T. Baker, USA) 
Filter sterilized with a 0.22µm acrodisc syring filter (Pall Corporation, USA) 
DNA purification Maxi Kit (QIAGEN Incorporated, BioLab Scientific Limited, NZ) 
Wizard gel clean up (Promega, Madison , USA) 
Geneclean II kit (QBiogene, USA) 
LB/Amp broth 
25g Luria Broth powder (Invitrogen life technologies) 
Dissolved in 1L mQ water 
pH 7, adjusted with 10M NaOH 
Autoclaved, stored at 4°C 
Just prior to use, add ampicillin to give a final concentration of 100µg/ml. 
LB + Ampicillin plates 
25g Luria Broth powder (Invitrogen life technologies) 
1.5g agarose  
Dissolved in 1L mQ water 
pH 7, adjusted with 10M NaOH 
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Autoclaved, allowed to cool 
When approximately 50°C add filter sterilised ampicillin (Sigma- Aldrich), to give 
a final concentration of 100µg/ml, pour into bacterial culture dishes and when 
set store at 4°C 
DH5αTM competent EColi cells (Invitrogen life technologies) 
QIAGEN Plasmid Maxi Kit (QIAGEN, USA) 
2.1.3.2 Buffers 
TE Buffer 
10mM Tris pH 8.0 with HCl (BDH, England) 
1mM EDTA 
DEPC treated water 
Autoclaved 
50x TAE buffer 
2M Tris pH 8.0 
0.57% acetic acid (J.T. Baker, USA) 
500mM EDTA 
mQ water 
Autoclaved 
Proteinase K Lysis Buffer 
100mM NaCl 
10mM Tris pH 8.0 with HCl (BDH, England) 
25mM EDTA 
0.5% SDS 
1mg/ml Proteinase K(Roche, Germany) added fresh  
2.1.3.2.1 Extraction/lysis Buffers used in miniprep plasmid preparation: 
Made using the protocol given in Molecular Cloning, appendix 1 (Sambrook & Russel, 
2001a), all made solutions were stored at 4°C. 
Alkaline Lysis Solution I 
50 mM glucose  
25 mM Tris-Cl (pH 8.0) 
10 mM EDTA (pH 8.0) 
Autocalved 
Alkaline lysis solution II (made up fresh each time) 
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0.2 M NaOH 
1% (w/v) SDS 
Alkaline Lysis Solution III 
3 M Potassium acetate 
5 M glacial acetic acid 
mQ water 
2.1.3.3 Enzymes 
Deoxyribonuclease 1, Amplification Grade (Invitrogen life technologies, NZ) 
SuperScriptTM III Reverse Transcriptase (Invitrogen life technologies, NZ) 
RNAseOUT TM Ribonuclease Inhibitor (Invitrogen life technologies, NZ) 
Calf Intestinal Phosphatase (Roche, Indianapolis, USA) 
Xho1 Restriction Enzyme (Roche, Indianapolis, USA) 
BamH1 Restriction Enzyme (Roche, Indianapolis, USA) 
Apa1 Restriction Enzyme (Roche, Indianapolis, USA) 
EcoRV Restriction Enzyme (Roche, Indianapolis, USA) 
Klenow Enzyme, DNA Polymerase I large fragment (Roche, USA) 
T4 DNA Ligase (Invitrogen life technologies) 
FastStart Taq DNA polymerase (Roche, Germany) 
Proteinase K 20mg/ml (Roche, Germany) 
2.1.3.4 Solvents 
Ethanol-absolute (analytical grade) (BioLab Australia Ltd) 
Propan-2-ol (analytical grade) (BioLab Australia Ltd) 
Chloroform (MERCK, Darmstadl, Germany) 
Phenol:Chloroform:Isoamyl alcohol (Invitrogen life technologies, NZ) 
2.1.3.5 Microarray Reagents 
GeneChip® Eukaryotic Poly-A RNA Control Kit (Affymetrix Inc, California, USA) 
GeneChip® One-Cycle cDNA Synthesis Kit (Affymetrix Inc, California, USA) 
GeneChip® Sample Cleanup Module (Affymetrix Inc, California, USA) 
GeneChip® IVT Labelling Kit (Affymetrix Inc, California, USA) 
GeneChip® Hybridisation Control Kit (Affymetrix Inc, California, USA) 
12x MES Stock Buffer 
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64.61g MES Hydrate (cat# M5287, Sigma-Aldrich) 
193.3 MES Sodium Salt (cat# M5057, Sigma-Aldrich) 
800ml mQ filtered H2O 
Mix, adjust to pH 6.5-6.7 with 10M HCL, Filter with 0.2µm filter 
2x Hybridisation Buffer (25mls) 
4.15mls 12x MES stock buffer 
8.85mls 5M NaCl (analytical grade) (BioLab scientific Ltd, Australia), dissolved in 
DEPC H2O and autoclaved to sterilise 
2.0mls 0.5M EDTA Disodium salt (Gibco ultrapure, Invitrogen life 
technologies) 
0.05ml 10% Tween 20 (BioRad Laboratories, C.A., USA) 
9.95mls DEPC H2O (Supplied by Molecular biology laboratory) 
Store at 2-8°C away from light 
Herring Sperm 10mg/ml (Promega Corporation, USA) 
Bovine Serum Albumin 50mg/ml (Invitrogen life technologies) 
DMSO (>99.9%) (Sigma-Aldrich) 
18x GeneChip® Mouse Genome 430 2.0 arrays (Affymetrix Inc, California, USA) 
2.1.3.6 Real-Time PCR primers 
Primers were dissolved in TE buffer to make 1000µM stock solution and stored at -
80°C. A working solution was made by diluting to 10µM in TE and these were stored 
at -20°C. Primers were purchased from Sigma GeneSys (Sigma-Aldrich, NSW, 
Australia) or from Invitrogen (Invitrogen life technologies, Auckland, New Zealand). 
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2.2 METHODS 
All Experimental work was carried out at AgResearch’s Ruakura Campus, Hamilton, 
New Zealand, except for hybridization and scanning of the microarrays which was 
carried out by Liam Williams at Auckland University’s Affymetrix facility. 
2.2.1 Cell Culture Protocols 
All cell culture work was carried out aseptically in a laminar flow cabinet 
(Westinghouse Pty Ltd, NSW, Australia) containing a 0.2µm HEPA (high efficiency 
particulate air) filter, which blows sterile air outwards. All surfaces and media bottles 
were sprayed with 70% ethanol before beginning. Cells were grown under 5% CO2 in a 
water jacketed incubator (Forma Scientific) and the pH of the culture media was 
monitored by the colour of phenol red in the media.  All medium added to the cells 
were pH adjusted to approximately 7.2-7.4 using sterile 1M HCl (as judged by the 
phenol red colour) and warmed to at least room temperature before use to prevent 
shocking the cells. All protocols regarding mTS and mEF cell culture except for cell 
counting and transfection are based on those taken from the book ‘Placenta and 
Trophoblast, methods and protocols, volume 1, chapter 11 (Quinn et al., 2006). 
2.2.1.1 Mouse Trophoblast Stem Cell Growth and Maintenance 
Mouse trophoblast stem cells (mTS cells) were provided by James Cross’ laboratory, 
University of Calgary Faculty of Medicine, Canada. mTS cells are maintained in 70% 
fibroblast conditioned mTS medium supplemented with Fgf4 and Heparin (F4H) 
( 2.1.1.2). All of these factors must be provided to prevent precocious differentiation of 
the mTS cells. The 70% conditioned medium + F4H was changed every second day to 
maintain a suitable concentration of growth factors. Cells were subcultured at 
approximately 80% confluence to prevent contact inhibition of cells which may also 
result in differentiation and normally split 1:4, as splitting at a too high dilution can also 
result in differentiation (Quinn et al., 2006).  MTS cells were also routinely 
cryopreserved and weren’t cultured when not needed to keep the passage number of 
the cells low (the cells from J.Cross were given a passage number of 0). 
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2.2.1.2 Mouse Embryonic Fibroblast Growth and Maintenance 
Mouse embryonic fibroblasts (mEFs) were supplied by D. Pearton and P. Pfeffer using 
day 13-14 mouse embryos. After the primary mEFS were established they were split 
1:6, grown to confluencey and then frozen and stored in liquid nitrogen ( 2.2.1.6). 
MEFs were grown in mEF media ( 2.1.1.2) and were grown to provide conditioned 
media for mTS cell maintenance. The passage number of mEFs was kept low (less 
than 5) to maintain their growth enhancing activity (Nagy et al., 2003). MEFs were 
grown in 100mm tissue culture plates, changing the media every two to three days.  
Once they reached confluency they were subcultured 1:5 or treated with mitomycin C. 
2.2.1.3 Mitomycin C treatment of mEFs and preparation of Conditioned Media 
MTS cells can either be grown on a feeder layer of mEFs or grown in 70% mEF 
conditioned mTS medium. MTS cells were grown in 70% conditioned medium so that 
there was no problem of ensuring the feeder layer was also resistant to the antibiotics 
used during antibiotic selection. Confluent mouse embryonic fibroblasts (mEFs) were 
treated with mitomycin C at a concentration of 10µg/µl for 4 hours at 37°C by adding 
100µl of a 1mg/ml solution of mitomycin C to 100mm plates of mEFs containing 
10mls of mEF media. MEFs were then rinsed twice with PBS. The PBS was aspirated 
and the mEFs were dissociated with TrypLE Express at 37°C for 5-10min. The treated 
mEFs were then pipetted into a centrifuge tube and centrifuged at 112 x g for 5min. 
The supernatant was aspirated and the cell pellet resuspended in 2ml of mTS media. 
An aliquot of 50µl was taken for counting using a haemocytometer ( 2.2.1.5). 2x106 
mEFs plated were plated into a 100mm tissue culture dish and 11ml of mTS media 
added. Seventy-two hours later the mTS media was collected and replaced. Collected 
mTS media was centrifuged at 112 x g for 5min to remove cell debris and filtered using 
0.2µm Serum Acrodiscs (Pall Corporation, MI, USA). This was stored at -20°C for 
long term. Short term storage (up to 2 weeks) was at 4°C. 
2.2.1.4 Subculturing of Mammalian Cells 
Cells were rinsed with PBS then a small amount of TrypLE was applied (just enough 
to cover the bottom of the dish). Cells were placed in a 37°C CO2 incubator for 5 
minutes and then checked every couple of minutes under a 40x inverted phase contrast 
microscope (Olympus) for rounding up of the cells and their loosening from the 
bottom of the dish. An equal volume of mTS medium was then added and the cells 
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were then pipetted into a centrifuge tube, while rinsing the bottom of the dish to 
collect all cells. This was spun at 110 x g for 5 minutes in a Mistral 1000 benchtop 
centrifuge (Labsupply, Auckland, New Zealand). The supernatant was then aspirated 
and the cells resuspended in 2mls of growth media. Cells were then either counted if a 
specific plating density was required or subcultured to continue growing. 
2.2.1.5 Counting of Mammalian Cells 
A total cell count was obtained by removing 50µl of a cell suspension and mixing with 
450µl of a 0.04% crystal violet solution in 0.5 M citric acid to stain the cell nulcei. This 
was warmed for a few minutes at 37°C and vortexed. A coverslip was placed on the 
ridges of a haemocytometer chamber and then some of the cell sample was pipetted on 
to the edge of the coverslip. The sample was drawn up by capillary action and then the 
haemocytometer was inspected using a 100x microscope. Four large squares on the 
haemocytometer were counted for cell nuclei. The cell count was given by: 
Cell count (cells/ml) = (number of cells counted/4) x 10(dilution factor) x 104
2.2.1.6 Cryopreservation and Thawing of Cells 
Cells were frozen at a final concentration of 1-2 x 106 cells/ml. After a cell count to 
ensure adequate numbers of cells, an equal volume of freshly made 2x solution of cell 
freezing media at 4°C was added ( 2.1.1.2). This contains DMSO which protects over 
dehydration of the cells during the freezing process.  The cells suspension was pipetted 
into 1ml cryovials; the vials were then clearly labelled and placed in a NALGENETM 
cryo 1°C freezing container filled with isopropanol which was placed in a -80°C freezer 
overnight. This allows slow freezing of the cells to prevent ice crystals forming 
intracellularly. The next day the vials were shifted to long term storage in liquid 
nitrogen. 
Thawing: 
Cells were rapidly thawed by placing vials in a 37°C water bath for 1-2minutes. The 
contents of the cryovial were then transferred to a centrifuge tube containing 5ml of 
fresh medium to dilute the DMSO slowly and spun at 100 x g for 5 minutes. The 
supernatant containing the DMSO was removed as this is toxic to cells and the cells 
were resuspended in normal culture media and plated. The media was replaced the 
following day. 
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2.2.1.7 Transfection of mTS Cells  
All mTS cell transfections were carried out using lipofectamine 2000 reagent 
(Invitrogen Corporation). Lipofectamine 2000 is a cationic lipid solution which works 
by interacting with the negative charges of DNA or RNA condensing these 
macromolecules into compact structures. It also forms a liposome structure in water 
and because of its cationic charge and lipophilic nature it interacts with the negatively 
charged hydrophobic membranes of cells (Ausubel et al., 1999). Lipofectamine 2000 
was mixed gently before use by inverting the tube a few times. DNA constructs or 
siRNAs were defrosted and kept on ice, they were mixed by flicking the tube a few 
times and then collecting the contents at the bottom of the tube by a minicentrifuge. 
DNA was not vortexed to avoid shearing. Protocols for siRNA and DNA 
transfections are all based on the manufacturer’s protocol (Invitrogen life technologies, 
2006). Four types of transfections were carried out:  
i. Stealth siRNA transfection for knockdown of Elf5 mRNA 
ii. Transient transfection of pTracer-Elf5 for Elf5 over-expression 
iii. Stable transfection of the pTetOn construct to develop an mTS cell line 
expressing the rtTA gene 
iv. Transient cotransfections of ‘mTS-pTetOn’ cells with pTre2hyg-Luc and a 
normalizing construct for use in screening rtTA gene expression and 
activation. 
2.2.1.7.1 Seeding the wells: 
In all cases the general protocol was to seed a 6 well or 12 well plate with mTS cells the 
day before transfection, this ensured cells were healthy and rapidly growing at the time 
of transfection, enhancing transfection efficiency (Ausubel et al., 1999). MTS cells were 
rinsed with PBS and then disassociated using TrypLE for 5-10 minutes at 37°C whilst 
monitoring progress by checking the cells with an inverted phase contrast microscope 
set to x40 magnification. TrypLE treatment for too long causes differentiated cell types 
such as giant cells which are much more resistant to disassociation to also become 
loose.  TrypLE was neutralized by adding an equal volume of mTS media, then the 
dish was shaken to loosen cells.  The cell suspension was pipetted into a centrifuge 
tube whilst washing loose cells off the bottom of the dish and spun for 3mins at 112 x 
g using a Mistral 1000 benchtop centrifuge (Labsupply, Auckland, New Zealand). The 
supernatant was aspirated and then the cells were resuspended in 2-3mls of 70% CM + 
F4H and a cell count was performed ( 2.2.1.5). The optimum seeding density was 
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determined previously experimentally in order to obtain the confluency required for 
each type of transfection. Cells were allowed to grow overnight in 70%CM + F4H. 
2.2.1.7.2 General Transfection Procedure 
The DNA/siRNA was diluted into Optimem reduced serum medium (Gibco) in a 
polypropylene tube or small glass bottle. Lipofectamine 2000 was then diluted into a 
separate tube containing an equal volume of Optimem and mixed gently. After 5 
minutes incubation at room temperature the Lipofectamine 2000 and DNA/siRNA 
solutions were mixed and left at room temperature for 20 minutes to form complexes. 
Optimem reduced serum media was used because it is recommended by the 
manufacturers; serum proteins in media can compete with DNA/siRNA for binding 
with cationic lipids (Ausubel et al., 1999).  
 
During the 20min incubation the 70%CM + F4H was removed from the wells to be 
transfected and replaced with enough reduced serum/ no antibiotics mTS media 
( 2.1.1.4) to give a total volume of 2mls for a 10cm2 well or 1ml for a 4cm2 well once 
the complex mixture was added. The presence of antibiotics can kill the cells during a 
transfection (Invitrogen life technologies, 2006). 
 
After the 20minute incubation the siRNA/DNA/lipofectamine 2000 complex was 
added to each well drop-wise, and then mixed in by gently rocking the plate back and 
forward. 4-5 hours later the media was replaced with 70%CM + F4H to increase the 
serum and the growth factors for the cells. According to the manufacturers 4-6hours is 
adequate time for the transfection to occur. 24 or 48 hours after the commencement of 
the transfection the cells were harvested and their mRNA extracted for analysis of gene 
expression ( 2.2.3.2.1) or cell lysate collected for biochemical analysis ( 2.2.2) 
2.2.1.7.3 Transfection of mTS Cells with siRNA 
Stealth siRNAs were designed using an Invitrogen program available over the internet 
(Invitrogen life technologies, 2004a)  using the mouse mRNA sequence for the Elf5 
gene (NCBI accession number NM-010125). Four proposed siRNAs were designed  
and tested for efficacy in mTS cells.  
 
Cells were seeded into wells at a density of 2x104 cells/cm2 for a 24 hour long 
transfection or 1.5x104cells/cm2 for a 48 hour long transfection. This enabled cells to 
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be at 30-40% confluency at the time of transfection and also that cells did not 
overgrow by the time of harvesting.  Each transfection also included at least one 
control well which was transfected with the siRNA negative control oligo. This 
provided a control for sequence independent RNAi effects (Invitrogen Life 
Technologies, , 2004b) and was transfected in an identical manner to the Elf5 target 
siRNAs. Transfection was generally carried out in a 6 well plate (10cm2) well using 
100pmol of siRNA as this seemed to give the best knockdown efficiency. 
 
The stealth siRNA was diluted by mixing 5µl of 20pmol/µl siRNA in 250µl of 
Optimem per well (this gives 100pmol stealth siRNA). 5µl of Lipofectamine 2000 was 
diluted in 250µl of Optimem per well.  
2.2.1.7.4 Transient Transfection with the pTracer-Elf5 Construct 
On the day before the transfection, cells were seeded as mentioned above ( 2.2.1.7.1) at 
a density of 4x105cells/ 10cm2 well to obtain a confluency of 70-80% at transfection. 
The general transfection procedure given in  2.2.1.7.2 was followed. At least one 
control  well was included for each experiment; which was not transfected and used to 
check basal Elf5 expression. 4µg of circular pTracer-Elf5 DNA was transfected by 
diluting in 250µl Optimem  for each well. 10µl of Lipofectamine was added to 250µl 
Optimem per well. 24 hours after transfection the cells were harvested in Trizol for 
RNA extraction ( 2.2.3.2.1). 
2.2.1.7.5 Stable Transfection  
In order to develop an mTS cell line expressing the rtTA protein for the inducible 
expression of Elf5 (chapter 4) mTS cells were co-transfected with a puromycin 
resistance gene under the control of the mouse phosphoglycerine Kinase (PGK) 
promoter, a ‘strong housekeeper’ (Sun & Storb, 2001), and linearised pTetOn plasmid. 
A co-transfection had to be done because the mTS cells used were already resistant to 
G418, the antibiotic resistance gene carried on the pTetOn construct (section  4.2.1.1).  
This was transfected at a molar ratio of 10 pTetOn: 1puromycin to ensure any 
puromycin resistant mTS cells would have a high chance of also carrying the pTetOn 
construct. On the day before the transfection cells were seeded as mentioned above 
( 2.2.1.7.1) at a density of 4x10^5cells/ 10cm2 well to obtain a confluency of 70-80% at 
transfection. The general transfection procedure given in  2.2.1.7.2 was followed. The 
total amount of DNA transfected was 4µg diluted in 250µl of Optimem per well. 10µl 
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of Lipofectamine 2000 also diluted in 250µl of Optimem was also used. The amount of 
each construct was calculated as follows to achieve a 10:1 molar ratio in a total of 4μg 
DNA: 
pTetOn=7.4kb Puromycin=6kb,  
 pTetOn  Puromycin
Plasmid size 7.4kb 6kb 
Wanted molar ratio 10 1 
Ratio (7.4/6) x 20 x 1µg 1µg  
Amount needed for 24.7µg           x 4µg 1µg 
a total of 4µg 24.7µg + 1µg       25.7µg 
 =3.8µg                 =0.2µg 
        
The control for DNA transfection was a well which was not transfected. During 
antibiotic selection cells from this well should all eventually die, enabling the time for 
antibiotic selection to be judged. 24hours post transfection the cells were subcultured 
( 2.2.1.4); each well of cells plated into 2x 10cm dishes (total surface area 120cm2) the 
seeding density for antibiotic selection was found during the pilot experiments 
(section 4.2.1.3). This was to give a low cell density for selection so there is a small 
chance of selecting a colony which originated from two separate transfection events. 
The following day the media was replaced with fresh growth media containing the 
antibiotic for selection. In the case of puromycin this was added at an optimised 
concentration of 1µg/ml ( 4.2.1.2). The media was changed every second day for fresh 
70%CM + F4H + puromycin until all negative control cells were dead and well 
separated colonies of about 0.5cm-1cm in diameter could be seen. Colonies were then 
‘picked’ ( 2.2.1.8) 
2.2.1.7.6 Transient Transfection for Reporter Assay Screening 
To establish the Tet-On inducible expression system in mTS cells the pTet-On vector 
which carries the rtTA gene was co-transfected with a puromycin resistance vector 
( 2.2.1.7.5). Cells were then plated at a low density and subjected to antibiotic selection 
and then colonies of antibiotic resistant clones were picked and grown individually 
( 2.2.1.8). These ‘mTS-pTetOn’ cell lines were then screened for expression of the rtTa 
protein. On addition of doxycycline, cells expressing rtTA should be able to induce 
expression of a reporter gene carrying the TRE (Tetracycline response element).  A 
Luciferase reporter vector (pTRE2Hyg-Luc) was transiently transfected into the ‘mTS-
 28
pTetOn’ cells to screen for cells with the greatest expression of rtTA. To control for 
variation in transfection efficiency and cell number pTRE2Hyg-Luc was always 
cotransfected with another vector, either PCH110 which expresses β-Galactosidase or 
pRl which expresses Renilla (Renilla reniformis) luciferase. Two 4cm2 wells for each line 
were seeded at a density of 8x104cells/4cm2, to obtain a confluency of 40-50% at 
transfection. Although a higher confluency is recommended at transfection for DNA 
transfections the ‘mTS-pTetOn’ cells were not harvested until 48hours after 
transfection to give adequate time for the expression of the transgene proteins; the 
maximum confluency at harvesting was suggested to be 95% in order to obtain 
efficient lysing of the cells. 
A total of 1.6µg of DNA was transfected per well. For co-transfections a mass ratio of 
1:1 was used. Each transfection included four wells of mTS cells that had not been 
previously transfected with pTetOn to act as controls: 
i. A positive control, which was cotransfected with 0.8µg of pGL3P (5kb), this 
expresses firefly luciferase under control of an SV40 promoter and 0.8µg of the 
normalizing vector (PCH110 [7.1kb] or pRL [4.1kb] ) 
ii. Negative control; ‘mock transfected’ to give basal measurements  
iii. Inducible positive control; transfected with 0.53µg each of pTetOn (7.4kb), 
pTre2hyg-Luc (7kb) and normalizing vector. After transfection doxycycline is 
added. Gives maximum expected induced luciferase expression. 
iv. Inducible negative control; as in inducible positive control above however with 
no doxycycline added. Gives uninduced background expression. 
 
The general transfection procedure was followed ( 2.2.1.7.2). 1.6µg of DNA was diluted 
in 100µl of Optimem for each well. 4µl of Lipofectamine 2000 was diluted into the 
same volume of Optimem for each well. After the transfection the media was changed 
for 70%CM +F4H, to one well of each mTS-pTetOn cell line was added 1µl of 
1mg/ml doxycycline. Doxycycline was also added to all of the control wells except the 
inducible negative well. 48hours after the transfection the cell lysates were assayed 
( 2.2.2). 
2.2.1.8 Picking Stable mTS Cell Lines 
This protocol is based on one accessed on the Corning website (Ryan, 2005).Using an 
inverted phase contrast microscope (Olympus) set to x 4 magnification circles were 
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drawn around each colony on the bottom of the dish. These were then ‘picked’: 
growth media was aspirated and the dish was rinsed in PBS. This was aspirated and 
then using sterile forceps ‘cloning rings’ (made by cutting the wide 0.5cm end of a 
pipette tip, and then autoclaving to sterilise) were dipped in sterile silicon grease. A 
cloning ring was placed firmly over a colony to create a seal and then 0.2ml of TrypLE 
was added to the cylinder. The dish was incubated for 5 minutes at 37°C and then 
checked to see cells had started to round up and come off the bottom of the dish. A 
few drops of mTS media were added and cells were aspirated using a pipette and 
plated into a well of a 12 well plate in 70%CM + F4H. The next day the media was 
changed and puromycin 1µg/ml added to maintain the selective pressure. 
2.2.1.9 Screening of mTS Cells for Insertion of Foreign DNA 
Isolated antibiotic resistant mTS cell lines were screened for a transgene by firstly 
extracting their DNA, running a PCR reaction using primers for the transgene (section 
 2.2.2.9) and finally running about 1/5th of the PCR reaction on an agarose gel 
containing ethidium bromide to check for the presence of the target DNA band 
(section  2.2.2.6).  
2.2.1.9.1 Extraction of Genomic DNA from mTS Cells 
Cells around 60-90% confluent in a 10cm2 well were rinsed with PBS (Oxoid) and 
treated with TRYple (Invitrogen) until they had lifted. They were then transferred to a 
0.65ml microcentrifuge tube and centrifuged for 10minutes, 1400rpm at 4°C 
(Eppindorf centrifuge 541D, Germany). The supernatant was aspirated and the pellet 
resuspended in 5µl of proteinase K lysis buffer which contained freshly added 
proteinase K (Roche, Germany) at a final concentration of 1mg/ml. The cell samples 
were heated at 55°C for 1 hour. The contents of each tube were collected at the 
bottom by briefly centrifuging and then 45µl of PCR grade water (Roche, Germany) 
was added to each sample and mixed by pipetting. 0.5µl was then used in a PCR 
reaction.  
2.2.1.10 Media changes 
mTS cells are known to require two growth factors; Fgf4 and Nodal. Removal of either 
of these results in the TS cells beginning to differentiate and no longer be pluripotent. 
To determine the underlying molecular changes that occur in this process mTS cells 
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were grown in mTS medium containing different combinations of growth factors as 
detailed in Table 1: 2.2-1.  
 
The cells were seeded as described in  2.2.1.7.1 except at a density of 4x105 cells/well in 
a 10cm2 well. The following day the normal growth media was exchanged for one of 
the four types mentioned in Table 1: 2.2-1. The cells were grown in this media for 24 
hours and then harvested for RNA extraction ( 2.2.3.2.1). 
 
Table 1: 2.2-1 Media combinations for mTS cell 
experiments 
Media Type 
 
Nodal/Activin FgF4 
Normal mTS cell growth media (70%CM + F4H) Yes Yes 
mTS media only No No 
mTS media + recombinant Activin Yes No 
mTS media + FgF4 No Yes 
 
2.2.1.11 Flourescent Microscopy 
As a means of analyzing transfection efficiencies the mTS cells were transfected with 
DNA or siRNA constructs which express flurochromes that could be visualized under 
fluorescent microscopy. Cells could be visualized in their growing state (in tissue 
culture dishes) or after being fixed on slides and stained with a fluorescent dye such as 
Hoest which marks DNA and hence cell nuclei. A Leitz DMIRB fluorescent 
microscope was used (Leica, Germany).  
2.2.1.12 Flow Cytometry Analysis of DNA content 
Approximately 1x106 cells were harvested using Tryple (Invitrogen Life Technologies) 
to disassociate cells from culture dishes. Cells were then spun at 1000rpm for 5 
minutes in a Mistral 1000 bench top centrifuge (Labsupply, Auckland, New Zealand). 
The supernatant was discarded and cells resuspended in 70% fridge cold ethanol 
(BioLab Australia Ltd). Cells were fixed in ethanol for a minimum of 30 minutes 
before centrifuging the cells again at 1000 rpm for 5 minutes. The supernatant was 
discarded and cells resuspended in 1ml of PBS (Oxoid, UK). This washing step was 
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repeated twice. 100µl of DNAse free ribonuclease (100µg/ml; Sigma) was added and 
left at room temperature for 5 minutes. Finally 400µl of propidium iodide was added 
(50µg/ml) to stain the DNA. Flow cytometry analysis was performed on the samples 
by Sue Beaumont at 488nm. 
2.2.2 Biochemical Analysis Protocols 
Biochemical analysis was performed on ‘mTS-pTetOn’ cells to assay for the ability of 
each cell line to inducibly express the transiently transfected firefly (Photinus Pyralis) 
luciferase gene under the control of the TRE in the presence of doxycycline (for 
further background see Chapter 4). To control for variable transfection efficiency and 
cell number pTRE2hyg-Luc was cotransfected with either a β-Galactosidase expressing 
DNA construct (PCH110) or a Renilla (Renilla reniformis) luciferase expressing construct 
(pRL) ( 2.2.1.7.6) and the expression of the reporter firefly luciferase normalized to 
either β-galactosidase or Renilla luciferase measurements. Three different assays were 
performed: Firefly luciferase assay, βGalactosidase assay and a dual luciferase assay 
which measured both types of luciferase in one assay.  
2.2.2.1 Luciferase Assay System  
The Luciferase Assay System kit (Promega, USA) was used to measure firefly luciferase 
expression.The firefly luciferase enzyme produces light by oxidizing luciferin in the 
prescence of ATP. The protocol for this assay was performed with a modified version 
of the protocol by Promega. Lysis of the cells was by reporter lysis buffer from the β-
galactosidase enzyme assay (Promega, USA) and the protocol for lysis with this buffer 
was followed from the β-galactosidase enzyme assay protocol (protocol available at 
www.promega.com/tbs/tb097/tb097.pdf) this is because the lysis reagent supplied in 
the luciferase assay kit is incompatible with the β-Galactosidase assay. The volume of 
cell lysate and luciferase assay buffer was halved in the assay following advice from J. 
Bracegirdle who routinely performs this assay. Protocol A for a manual luminometer 
was followed (protocol available at http://www.promega.com/tbs/tb281/tb281.html).  
2.2.2.1.1 Lysis of Cells using Reporter Lysis Buffer 
Four volumes of sterile mQ water was added to one volume of the 5x reporter lysis 
buffer. Lysis buffer was equilibrated to room temperature before use. The growth 
medium was removed from the reporter gene transfected ‘mTS-pTetOn’ cells (section 
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 2.2.1.7.6) and cells rinsed in PBS being careful not to dislodge cells. As much PBS as 
possible was then removed by aspirating the PBS, leaving the plate tilted to drain and 
aspirating again. 200µl of 1x reporter lysis buffer was added to each of the wells and 
the cells were left slowly rocking on a plate rocker (Ratek Instruments, Australia) for 15 
minutes at room temperature. The wells were then scraped using a sterile 1ml pipette 
tip and the cell lysates transferred to a microcentrifuge tube on ice. Cell lysates 
vortexed and then frozen at -80°C until the day of the assay (within 2 weeks). On the 
day of the assay the lysates were thawed at room temperature and vortexed for 15 
seconds. They were then centrifuged at 12,000xg for 2 minutes at 4°C. The 
supernatant was transferred to a new microcentrifuge tube and kept on ice.  
2.2.2.1.2 Preparation for the assay 
The lyophilized luciferase substrate was reconstituted in the luciferase assay buffer. 
Unused reconstituted substrate was aliquoted and stored at -80°C. Reconstituted 
substrate was equilibrated to room temperature and mixed well before use. It is also 
light sensitive and therefore protected from light as much as possible. 
2.2.2.1.3 Manual Luminometer protocol 
A Turner Design manual luminometer (Alphatech systems ltd, Auckland) was used to 
measure the bioluminescence of the samples. The assay was carried out at room 
temperature, so both Luciferase substrate and cell lysates were equilibrated to room 
temperature before beginning. The luminometer had previously been calibrated so that 
an error reading would show at signal saturation intensities. Before beginning the assay 
the inducible positive control was tested, this will give the highest reading possible. If 
this sample was still within in the linear range duplicates of 10µl of cell lysate for each 
sample were pippetted into clear 1.5ml microcentrifuge tubes. If it wasn’t cell lysates 
were diluted 1 in 10 in reporter lysis buffer and then 10µl duplicates dispensed. 50µl of 
the luciferase assay reagent was added to the sample. The mixture was pipetted 2-3 
times to mix then immediately placed in the luminometer. The luminometer was 
programmed to have a 2 second delay followed by a 10second measurement of 
activity. Light intensity production should be constant for about 1 minute after 
substrate addition before decaying away. The measurement for each sample was 
recorded and the average taken for use in normalizing calculations with β-
Galactosidase enzyme assay measurements.  
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2.2.2.2 β-Galactosidase Enzyme Assay System 
All components for this assay and the protocol followed were from the β-
Galactosidase Enzyme Assay Kit using protocol B (Promega, USA, protocol available 
at www.promega.com/tbs/tb097/tb097.pdf). The β-Galactosidase enzyme hydrolyses 
colourless ONPG (o-nitrophenyl-β-D-galactopyranoside) to o-nitrophenol which is 
yellow and is measured using spectrometry. This assay was done on the same day as 
the luciferase assay and measurements taken were used to normalise results from the 
luciferase assay for cell number and transfection efficiency.  
2.2.2.2.1 Lysis of Cells with Reporter Lysis buffer 
 2.2.2.1.1. See section 
2.2.2.2.2 β-Galactosidase 96-well plate assay 
The 2x assay buffer was thawed and then stored on ice. 50µl, 30µl and 10µl of one of 
the sample lysates was put in 3 wells of a 96well plate on ice and the total made up to 
50µl with reporter lysate buffer. 50µl of 2x assay buffer was added and then the plate 
covered in parafilm and placed in a 37°C incubator (Sanyo) for 30 minutes. The plate 
was checked to see development of a faint yellow colour and the optimum 
concentration of lysate was determined. Duplicates of cell lysate samples were put into 
the wells and made up to 50µl using reporter lysis buffer. 50µl of 2x assay buffer was 
added and the plate incubated for 30min at 37°C. The plate was then read using a 
Versa max microplate reader (Molecular Devices, USA) and accompanying software 
(Softmax® Pro, Molecular Devices, USA). The measurement was carried out at a 
wavelength of 405nm. Average values for each sample were used to normalize 
luciferase results. 
2.2.2.3 Dual-Luciferase Reporter Assay System. 
The components of this system were all supplied in the dual luciferase reporter assay 
system kit (Promega, USA) The standard protocol for a manual luminometer was 
followed (available at www.promega.com/tbs/tm040/tm040.pdf). In this assay firefly 
luciferase expression is normalized to Renilla luciferase expression and each luciferase is 
measured sequentially from a single sample. The system works because although both 
enzymes produce photons of light measured in a luminometer they use different 
substrates; firefly luciferase oxidizes beetle luciferin, while Renilla luciferase oxidizes 
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coelenterate-luciferin. All components were stored at -20°C except reconstituted 
luciferase assay substrate which was aliquoted and stored at -80°C. 
2.2.2.3.1 Lysis of Cells using Passive Lysis Buffer 
Four volumes of sterile mQ water was added to one volume of 5x passive lysis buffer. 
Passive lysis buffer was equilibrated to room temperature before use. The growth 
medium was removed from the reporter gene transfected ‘mTS-pTetOn’ cells (section 
 2.2.1.7.6) and cells rinsed in PBS being careful not to dislodge cells. As much PBS as 
possible was then removed by aspirating the PBS, leaving the plate tilted to drain and 
aspirating again. 200µl of 1x passive lysis buffer was added to each of the wells and the 
cells were left slowly rocking on a plate rocker (Ratek Instruments, Australia) for 15 
minutes at room temperature. Cell lysates were transferred to microcentrifuge tubes on 
ice and vortexed they were then centrifuged at 4°C at 12,000xg (epindorf centrifuge 
5415D, Germany) for 30 seconds and lysates transferred to a new tube. Cell lysates 
were frozen at -80°C until the day of the assay (within 2 weeks). On the day of the 
assay the lysates were thawed at room temperature and vortexed. 
2.2.2.3.2 Preparation for the assay 
The lyophilized luciferase substrate was reconstituted in the luciferase assay buffer II. 
Unused reconstituted substrate was aliquoted and stored at -80°C. Reconstituted 
substrate was equilibrated to room temperature and mixed well before use. It is also 
light sensitive and therefore protected from light as much as possible. Before each 
assay fresh Stop & Glo reagent was prepared. 1 volume of 50x Stop & Glo Substrate 
was added to 50 volumes of Stop & Glo Buffer in a siliconised microcentrifuge tube to 
give enough for 50µl of reagent per assay, this was also equilibrated to room 
temperature. 
2.2.2.3.3 Dual Luciferase Assay in a Manual Luminometer 
50µl of luciferase assay reagent II was predispensed into 2 clear microcentrifuge tubes 
for each cell lysate sample. 10µl of room temperature cell lysate was added to the tube, 
pipetted to mix and then immediately placed in a TD-20 luminometer (Alphatech 
systems ltd, Auckland). After a 2 second delay a 10 second period measurement was 
taken. The firefly luciferase measurement was recorded and then the tube removed and 
50µl of Stop & Glo reagent added. The Stop & Glo reagent quenches the firefly 
reaction and activates the Renilla luciferase enzyme within 1 second. The tube was 
replaced and after a 2 second delay a further 10 second measurement was taken. If an 
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error message on the luminometer was given due to saturation, the cell lysate was 
diluted 1 in 10 in 1x passive lysis buffer and the readings repeated. The Renilla 
measurement was then used to normalize the firefly measurement.  
All reagents were thoroughly mixed by vortexing (except enzymes) and then briefly 
centrifuged before use. Enzymes were briefly centrifuged before use and kept in a        
-20°C cold block for a minimum amount of time whilst they were in use.  
2.2.2.4 Transformation of Bacteria with plasmid DNA 
In order to propagate a particular plasmid for use in later down stream applications an 
intact plasmid was transformed into commercially available competent E.Coli strain 
DH5α cells with an efficiency of 1x106 transformants/µg of DNA (Invitrogen 
Corporation).  Two 50µl aliquot of DH5α cells were removed from -80°C storage and 
thawed on ice. 1µl of 1ng/µl plasmid DNA was added to one of the aliquots the and 
gently tapped to mix. This was left to incubate on ice for 30 minutes. The other aliquot 
was used as a negative control and did not receive any DNA. After the incubation both 
tubes were heatshocked at 42°C for 75seconds. Cells were then plunged into ice and 
allowed to cool for 2 minutes. 1ml of SOC medium (Invitrogen Corporation) was 
added and the cells put into a 37°C shaking incubator (300rpm) for 60 minutes (New 
Brunswick Scientific, USA). 100µl of the transformed cells were aseptically spread onto 
an LB-ampicillin plate. The tubes were centrifuged at 10,000rpm for 1 minute (Biofuge 
pico Heraeus, Germany) and 800µl of supernatant removed. The rest of the contents 
of each one were aseptically spread on LB-ampicillin plates. Plates were allowed to dry 
and then incubated upside down overnight (~16 hours) in a 37°C incubator (Sanyo). 
The following morning the negative control plate was checked to ensure no colonies 
had grown, and then an isolated colony of transformed bacteria was selected using a 
sterile 200µl pipette tip.  
 
2.2.2.5 Maxipreparation of Plasmid DNA 
The QIAGEN Plasmid Maxi Kit was used for preparation of high quantities of 
plasmid DNA (QIAGEN, USA). The manufacturer’s protocol was followed with 
some modifications. All reagents were supplied in the kit unless otherwise stated. 
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2.2.2.5.1 Growth of Bacterial cells 
A colony of bacteria containing the plasmid was picked using a sterile pipette tip and 
used to inoculate a starter culture of 3mls of LB + 100µg/ml ampicillin in a sterile 
13ml snap-cap tube (Sarstedt, Germany) and grown for the day at 37°C in a shaking 
incubator (~7 hours). This was added to 250ml of LB + ampicillin in a 1 litre flask and 
grown overnight (~16 hours) at 37°C in a shaking incubator at 300rpm (Edison, New 
Jersey, USA). 
2.2.2.5.2 Cell Harvesting and lysis 
 The cells were transferred to a 250ml centrifuge tube and centrifuged at 6000 x g for 
15minutes at 4°C (Sorvall RC5C, USA). The supernatant was discarded and centrifuge 
tube left to drain upside down to remove all traces of supernatant. The pellet was 
resuspended in 10ml of buffer P1 which contained 100µg/ml of RNase. The pellet was 
thoroughly resuspended by pipetting up and down. 10ml of buffer P2 was added and 
gently mixed by inverting 4-6 times to avoid shearing of genomic DNA. 
2.2.2.5.3 Purification of Plasmid DNA 
Immediately after, 10ml of chilled (4°C) P3 buffer was added. This was also mixed 
gently by inverting 4-6 times and then the tube was left to incubate on ice for 
20minutes. A precipitate of genomic DNA, proteins and SDS forms. The sample was 
mixed again and then centrifuged at 16,000 rpm using a SS-34 rotor (Sorvall RC5C, 
USA) for 30 minutes at 4°C. The clear supernatant was transferred to a new centrifuge 
tube and centrifuged again at 16,000 rpm for 15minutes at 4°C. During this time a 
QIAGEN-tip 500 column was equilibrated using 10ml of buffer QBT, flow through 
was discarded. The clear sample supernatant was promptly loaded on the column and 
allowed to flow through under gravity flow. The column was then washed twice with 
2x 30ml lots of buffer QC and flow through discarded. Plasmid DNA was then eluted 
with 15ml of buffer QF. The flow through was collected into a 30ml centrifuge tube. 
DNA was precipitated by adding 10.5ml of isopropanol (BioLab Australia Ltd) and 
mixing. The solution was centrifuged at 11,000rpm in a SS-34 rotor for 30minutes at 
4°C. The supernatant was carefully removed so as not to disturb the DNA pellet and 
the pellet was washed with 5ml of room-temperature 70% ethanol (BioLab Australia 
Ltd) and spun again at 11,000rpm for 15 minutes at 4°C. The ethanol was removed 
using a pipette and then the pellet left to air dry for 5-10minutes. The DNA pellet was 
resuspended in 100-300µl of TE buffer. 
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2.2.2.6 Agarose Gels 
Agarose powder (Invitrogen life Technologies, NZ) was added to 0.5 x TAE buffer, 
heated to dissolve in a microwave and cooled before adding 10µg/ml ethidium 
bromide (Sigma-Aldrich, USA) to generate a final concentration of 0.5ng/ml. Gels 
were 1% 1.5%, 1.7% or 2% depending on the expected size of the DNA fragments 
analysed. The melted agarose was then poured into a block containing a comb and 
allowed to set. For RNA samples gel tanks and all blocks/combs to be used were first 
treated with 3% H2O2 (Sigma-Aldrich, USA) for 2 hours to remove RNases. Gels were 
run at 5-10 volts per cm until satisfactory separation of bands could be seen. Ethidium 
bromide staining was visualized using ultraviolet light and gel images were generated 
using the Quantity One Gel Doc system (Bio-Rad Laboratories, 2001, USA). 
 
2.2.2.7 Restriction Enzyme Digest of Large Amounts of Plasmid DNA 
To prepare large amounts of plasmid cut with a restriction enzyme (in general this was 
used to linearise plasmids for transfection) the following general protocol was 
followed: to 30µg of DNA (x µl) was added 20µl of the appropriate restriction buffer, 
H2O to give final total of 200µl and 5µl of restriction enzyme (10U/µl). An Important 
consideration in performing restriction enzyme digests is that the concentration of the 
enzyme is not too high in the reaction mix. This is because the enzymes are stored in 
50% glycerol and a final concentration of glycerol greater than 5% in the reaction mix 
can inhibit the digestion of the enzymes and also cause unspecific cleavage of DNA 
(“star” activity). The restriction enzyme was always added last to the reaction mix and 
mixed by pipetting up and down; avoiding production of air bubbles. The tube was 
placed in a thermomixer (epindorf thermomixer compact, Germany) at the appropriate 
temperature (generally 37°C) for 1-2hours. A phenol/chloroform extraction was done 
by adding 200µl phenol/chloroform (Invitrogen life technologies, NZ), vortexing and 
centrifuging (Biofuge pico Heraeus, Germany) at maximum speed for 5 minutes. The 
supernatant was transferred to a fresh tube and 20µl 3M sodium acetate (pH 5) and 
300µl of ethanol added and vortexing. The tube was centrifuged (epindorf 5415D, 
Germany) at 4°C for 15 minutes at maximum speed, the supernatant was discarded 
and the pellet washed with 0.5ml 70% ethanol, centrifuged again at max speed, 4°C, 
and the ethanol aspirated. The DNA pellet was allowed to dry by leaving the cap off at 
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room temperature for 5 minutes, resuspended in 25µl T0.1E and then the 
concentration measured using the nanodrop. 
 
2.2.2.8 Restriction Enzyme Digest of Small Amounts of DNA 
About 1µg of DNA was cut in a 20µl digest mixture which included 2µl of the 
appropriate buffer (10x, supplied with the enzyme), 1µl of restriction enzyme (10U/µl) 
and sterile water to make the total volume up to 20µl. This was allowed to digest for 
1hour at 37°C. 
2.2.2.9 PCR Amplification of DNA 
For a 25µl PCR reaction about 100ng of genomic DNA or 0.1ng of a plasmid was 
used for the initial quantity of template DNA. This was added to 2.5µl of 10x PCR 
buffer containing MgCl2 (supplied with FastStart Taq DNA polymerase; Roche, 
Germany), 0.5µl each of a working solution of the forward and reverse primers, 0.5µl 
of 10mM dNTP’s (Roche), PCR grade water (Roche, Germany) to 25µl, 0.2µl of 
FastStart Taq DNA polymerase (Roche, Germany). This was placed in a thermocycler 
(BioRad, Australia) with the following programme: 95°C for 7 minutes, followed by 35 
cycles of 95°C for 30 seconds, 55°C for 40 seconds and 72°C for 1 minute. A final 
extension of 72°C for 7 minutes was then run. 
2.2.3 mTS Analysis of Gene Expression Using Real-Time PCR 
 2.2.1.10Analysis of mTS cell gene expression after media treatments (section ) or 
siRNA mediated Elf5 knockdown (section  2.2.1.7.3) was performed by extracting 
RNA extraction from mTS cells using TRIZOL reagent (invitrogen life technologies), 
removing contaminating DNA, reverse transcribing purified mRNA to cDNA and 
then measurement of relative target gene expression by real-time PCR. During RNA 
extraction and handling special care was taken to avoid contamination of samples with 
RNases. This included wiping down surfaces and pipettes with RNase away (Molecular 
Bioproducts Inc., USA) wearing powder free gloves, using filter tips and ensuring all 
reagents and consumables were RNase free. DEPC treated water was used and all 
RNA samples stored at -80°C. The first section gives the original protocol used when 
work was first started. The second section gives the modified protocol. Rationale for 
modifications is given in Chapter 3.  
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2.2.3.1 mTS analysis of Gene Expression: Original Protocol 
This protocol is an ‘inhouse’ protocol which was currently in use when I started work; 
therefore initial attempts at quantifying gene expression were carried out using this 
protocol. 
2.2.3.1.1 Cell Harvesting for RNA Extraction 
Cell growth media was aspirated and cells washed in PBS (Oxoid) by adding 2-3mls of 
PBS per 10cm2 well, rotating the dish and then aspirating PBS. 0.6mls of TrypLE 
(Gibco) was added to each well the plate returned to the 37°C incubator for 10 
minutes. 0.8mls of mTS media was added to neutralize the TrypLE enzyme and the 
contents of each well was pipetted up and down to ensure all cells were dissociated 
from the bottom. The cell suspension was then transferred to a microcentrifuge tube 
and centrifuged (epindorf centrifuge 541D, Germany) at 4°C for 5 minutes at 4000 
rpm. The supernatant was discarded and the cells resuspended in 400μl of TRIZOL 
(Invitrogen Life Technologies, NZ). The cell pellet was vortexed and pipetted up and 
down through a 200μl pipette tip to thoroughly dissolve the cells. 
2.2.3.1.2 RNA extraction   
80μl of Chloroform (MERCK, Darmstadl, Germany) and 1µl of RNase free 10mg/ml 
glycogen (Roche Diagnostics, Germany) was added to each sample. Glycogen acts as a 
carrier to the aqeous phase and is co-precipitataed with RNA (Invitrogen life 
technologies, 2003). Samples were vortexed for 30 seconds and then centrifuged 
(epindorf centrifuge 541D, Germany)  for 5 minutes at maximum speed to separate the 
phases. The upper aqueous layer was transferred to a new tube and then 200μl of ice-
cold isopropanol (BioLab Australia Ltd) added. Samples were vortexed to mix and 
then placed in a -20°C freezer and RNA precipitated overnight. The RNA was pelleted 
by centrifugation at max speed in a microcentrifuge at 4°C for 15minutes. The 
supernatant was aspirated and a small while glycogen pellet could be seen. The pellet 
was washed in 100μl of 75% ethanol (BioLab Australia Ltd) and spun again at 
maximum speed for 10 minutes at 4°C. The ethanol was aspirated and then the pellet 
allowed to air dry for 5 minutes. The RNA was resolubilised in 15μl of DEPC treated 
H2O. 
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2.2.3.1.3 DNAase treatment 
This step is necessary for real-time PCR when amplicons do not span introns and to 
avoid the amplification of potential pseudogenes in contaminating genomic DNA. A 
master mix per tube of 1µl DTT (Invitrogen Life Technologies, NZ), 2μl of 10x 
DNAseI reaction buffer, 1μl of RNaseOut (Invitrogen Life Technologies, NZ) and 
1μl of amplification grade DNase I (Invitrogen Life Technologies, NZ) was added to 
each sample. The samples were placed at 37°C for 30minutes (epindorf thermomixer 
compact, Germany). After DNase and an equal volume (20μl) of phenol/chloroform 
(Invitrogen life technologys,NZ) and 2μl of 3M sodium acetate (pH 5) was added. 
Samples were vortexed and centrifuged (epindorf centrifuge 541D, Germany) for 
10min at maximum speed at 4°C for 5 minutes and the top layer transferred to a new 
tube. 120μl of ethanol (BioLab Australia Ltd) was added and the RNA precipitated at -
20°C for 2-3hours. The RNA was pelleted by centrifugation (epindorf centrifuge 
541D, Germany) at maximum speed for 15minutes at 4°C and then washed with 200μl 
of 75% ethanol and the centrifugation step repeated. The 75% ethanol was aspirated 
and the pellet dried for 5 minutes before resuspending it in 11μl of DEPC treated 
H2O. RNA was stored at -80°C. 
 
2.2.3.1.4 Reverse Transcription 
10µl of each RNA sample was transferred to a thin-walled PCR tube and to this was 
added 1μl of Oligo(dT)12-18 primer (500ng/µl; Invitrogen Life Technologies, NZ) 
and 1µl of 10mM dNTP mix (10mM each nucleotide; Invitrogen Life Technologies, 
NZ). This was put into a thermocyler (PTC-200, MJ Research, USA) with heated lid 
and set to 65°C for 5 minutes to denature the RNA. The tubes were immediately 
transferred to ice and rapidly chilled for at least two minutes. A master mix was 
prepared on ice consisting of 4μl 5x 1st strand buffer (supplied with Superscript III, 
Invitrogen) 1μl 0.1 M DTT (supplied with Superscript III)1 μl RnaseOut  (Invitrogen 
life technologies, NZ) and 1 μl Superscript III (Invitrogen life technologies, NZ) and 
added to each tube. The PCR tubes were spun (Labnet International Inc, USA) to 
collect their contents to the bottom and then returned to the thermocycler. They were 
then incubated for 1 hour at 50°C followed by 15 minutes at 70°C to stop the reaction; 
the cDNA produced was stored at -20°C.  
 41
2.2.3.2 mTS analysis of Gene Expression: Modified Protocol 
2.2.3.2.1 Cell Harvesting for RNA Extraction 
This protocol is based on the manufacturer’s protocol for TRIZOL (Invitrogen Life 
Technologies, , 2003) for a 10cm2 well: Cells were rinsed with PBS; this is aspirated, the 
plate is left tilted to drain further and any residual PBS is aspirated. 1ml of TRIZOL 
was then added to each well. The TRIZOL was then vigorously pippetted up and 
down using a 1ml pipette tip to aid in dissolving the cells. It is important this step is 
carried out as rapidly and thoroughly as possible to avoid degradation of mRNA which 
accounts for only 1-5% of a cells total RNA. TRIZOL contains phenol and 
guanidinium isthiocyanate. Guanidinium isthiocyanate disrupts cells, solubilises their 
components and denatures endogenous RNAses (Sambrook & Russel, 2001b). Cell 
homogenates were stored at -80°C until RNA isolation could be performed. 
2.2.3.2.2 RNA extraction 
0.2ml of Chloroform (MERCK, Darmstadl, Germany) and 1µl of RNase free 
10mg/ml glycogen (Roche Diagnostics, Germany) was added to each sample. 
Glycogen acts as a carrier and has been shown to improve RNA yields. The samples 
were vortexed for 15 seconds. They were then centrifuged at 12,000 x g for 15 minutes 
at 4˚C. The RNA goes into the aqueous layer on the top, while proteins accumulate at 
the aqeous/organic interface. The top layer (~600µl) was transferred to a fresh 
microcentrifuge tube. 0.5ml of isopropanol alcohol was added (BioLab Australia Ltd) 
and then the samples vortexed to mix. The samples were then put in a -20˚C freezer 
overnight to allow for precipitation of the RNA. The samples were centrifuged at 
12,000 x g for 15 minutes at 4˚C and the supernatant aspirated using an RNase free 
200ul pipette tip being careful to avoid the pellet. The pellet was washed with 1ml 70% 
ethanol (BioLab Australia Ltd) and then centrifuged again at 4˚C for 5 minutes at 7500 
x g. The alcohol was aspirated carefully and the samples briefly centrifuged to collect 
any remaining alcohol. Any visible droplets of alcohol were removed as alcohol can 
inhibit down stream enzymatic reactions. The samples were left at room temperature 
with the caps off to dry and then resuspended in 28µl of DEPC treated H2O. 
  
2.2.3.2.3 DNase treatment 
As in section  2.2.3.1.3 except the volumes for the components DTT, DNase reaction 
buffer and RNaseOut were doubled and the volume of DNase I was increased to 4µl.  
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These were added to the 28µl RNA sample to give a total volume of 40µl. The time for 
the digestion was increased to 1 hour at 37°C. The volumes of Phenol/chloroform and 
sodium acetate were also doubled. The concentration and quality of the RNA was 
routinely checked using the NanoDrop spectrometer (Nanodrop technologies, USA).  
2.2.3.2.4 Reverse Transcription  
As in section  2.2.3.1.4, however the volume of RNA sample was reduced to 1µl and 
11µl of DEPC water was added at the first step before denaturation at 65°C. 
2.2.3.3 SYBER-Green Real-time PCR 
Expression of target genes was assessed by relative quantitative real-time PCR. (qRT-
PCR). A target gene was amplified in “real time” and the number of cycles taken for 
the fluorescence of SYBER-Green to reach a certain threshold (Ct) recorded, using an 
ABI 7900 HT (Applied Biosystems, Singapore) or  later the ‘takeoff’ cycle  was 
recorded when using the Rotor-Gene 6000 (Corbett Life Science, Australia). The gene 
target Ct or take off was then normalized to a reference gene; a gene whose expression 
is thought to remain stable in the different samples compared. Several different 
algorithms were used to normalize gene expression and are discussed in chapters 3. In 
preparing qRT-PCR runs all reagents were thoroughly mixed and briefly centrifuged in 
a minicentrifuge (BioRad, USA) before use. Master mixes and samples were kept on 
ice and kept away from light to avoid SYBER-Green dye bleaching. qRT-PCR reaction 
mixtures and set up was carried out just prior to each run to avoid primer-dimers. 
Filter tips were also used throughout to avoid contamination as this is a very sensitive 
technique. 
2.2.3.3.1 Reverse Transcription Negative Control 
1ul of the DNase treated RNA for each sample was diluted in 19µl of TE buffer to 
make a reverse-transcription negative control (RT-). This control was used run in at 
least one real-time PCR assay to check for contamination of the RNA sample with 
genomic DNA (i.e. an incomplete DNase reaction). Preferably a gene primer set was 
chosen which did not cover introns in screening the RT- controls. 
2.2.3.3.2 Sample preparation  
Sample cDNA was diluted 1/20 and 1/40 in PCR grade water (Roche, Germany). One 
sample also had dilutions made up of 1/80 and 1/160 and was used to determine the 
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amplification efficiency (not required when using the Corbett). Diluted cDNA was 
stored at 4°C short term (less than a week) when samples were being continuously 
used to avoid multiple freeze/ thaw cycles. Longer term diluted cDNA storage was at -
20°C. 
2.2.3.3.3 qRT-PCR Primer Design and Testing 
Publicly available mouse sequence data was used to generate primers for amplification 
of a selected gene (available from 
http://www.ensembl.org/Mus_musculus/index.html.) A gene name was searched in 
http://www.ncbi.nlm.nih.gov/sites/entrez under nucleotide or in the case of the 
microarray the Affymetrix probe number was matched to a gene using Ingenuity 
Pathway Analysis 4.0 version 3. When available the mRNA reference sequence was 
used (NM_######). The mRNA sequence was pasted into BLAT 
(http://genome.ucsc.edu/cgi-bin/hgBlat?command=start) and a search performed 
against the mouse genome to find the location of introns. The mRNA sequence was 
then used to design primers which where possible the amplicon spanned an intron to 
ensure any contaminating genomic DNA was not amplified. Primers were also 
designed to amplify the 3’ end of a gene so as to minimize the impact of reverse 
transcription inefficiencies. For use in the ABI 7900 qRT-PCR machine primers were 
kindly designed by Peter Pfeffer using GCG (eXcursion software, version 5.1B, 2003, 
Hewlett-Packard Development Company, California, USA). The criteria used for 
primer design was a length between 18-22 bases, 40-50% GC content, melting 
temperature between 50°C-65°C together with a PCR product length between 200-
500bp. Primers designed for the Corbett machine used the Vector NTI 10.1.1 
(Invitrogen Corporation, 2005) software, the same criteria was applied except that 
Corbett PCR product length was designed to be 200-300bp in due to the shorter time 
allowed for extension. The 3’ end of the primers was chosen so the last 5 base pairs 
contained a maximum of two G’s or C’s (the GC clamp). Primers were prepared as 
given in section  2.1.3.6. Before using a new primer pair for analysis each primer set 
was run in trial qRT-PCR reaction using one of the cDNA samples. The melting curve 
was checked to ensure only one product was formed; the DNA product of the reaction 
was run on an agarose gel and checked for correct size, and a single band.  
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2.2.3.3.4 qRT-PCR using the ABI 7900 HT Machine 
Each run was carried out in a MicroAmp Optical 96-well plate (Applied Biosystems, 
USA). A master mix was prepared for each primer pair and the reference gene which 
consisted of: 7.5µl of SYBER-Green master mix (Applied Biosystems, USA), 6.2µl of 
PCR grade water (Roche, Germany), 0.1µl forward primer, 0.1µl reverse primer, 0.1µl 
Taq Fast start (Roche Diagnostics, Germany). This was pipetted to mix and then 14µl 
pipetted into each well. Triplicates were done for each sample/gene combination; two 
using a cDNA concentration of 1/20 and one 1/40. A dilution series was also included 
for each gene and used to calculate the amplification efficiency (used in the 
normalisation calculations). Each run also included a negative control of PCR grade 
water instead of template cDNA to check for contamination. An optical adhesive 
cover (Applied Biosystems, USA) was applied to the plate and then the plate was spun 
in a salad mixer. The plate was put into the ABI machine and the program run: 50°C 
for 2 minutes (UTP degrading enzyme works), 95°C for 5 minutes (activation of fast 
start TAQ polymerase) followed by 40 cycles of 95°C for 15 seconds (denaturation), 
56°C for 30 seconds (annealing), 72°C for 30 seconds (DNA polymerization) and 
78°C for 10seconds (SYBER-Green fluorescence measurement taken). Then a 
dissociation analysis was done: 95°C for 15 seconds followed by 60°C for 15 seconds 
(to allow the PCR product to anneal) then slowly ramping up to 95°C measuring 
fluorescence at every °C. After the run the data was analysed using ABI software, with 
an automatic threshold of 0.01 used. Data was exported to an Excel spreadsheet 
(Microsoft Office 2003)for analysis. 
2.2.3.3.5 qRT-PCR using the Rotor-Gene 6000 
Triplicates for each sample/gene combination of two times  2µl of 1/20 diluted cDNA 
and one 1µl diluted cDNA + 1µl of PCR grade water (Roche, Germany) were pipetted 
into each tube of either a 72 well rotor or a gene-disc 100 well rotor (Corbett life 
Science, Australia). Each run also included a negative control of PCR grade water 
instead of template cDNA for each primer pair used. A master mix was prepared of 
5µl lightcycler 480 SYBER Green I Master (Roche, Germany), 0.1µl forward primer, 
0.1µl reverse primer and 2.8µl of PCR grade water. This was mixed and then 8µl 
aliquoted into each tube.  The program run was: 10 minutes at 95°C then 40 cycles of: 
10 seconds at 95°C, 15 seconds at 60°C (or other depending on primers), 20 seconds 
at 72°C followed by a dissociation curve of 72°C for 90 seconds then 72°C to 95°C at 
1°C every 5 seconds. Rotor-gene 6000 series software (version 1.7, Corbett research, 
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Australia) was used to analyse the raw data.  The Takeoff point was exported to Excel 
(Microsoft Office, 2003) for each reaction. “The Takeoff point is defined as the cycle 
at which the second derivative (of the amplification plot) is at 20% of the maximum 
level, and indicates the end of the noise and the transition into the exponential phase.” 
(Rotor –gene 6000 series software help) 
This was treated the same way as a Ct value. 
 
2.2.3.3.6 qRT-PCR Analysis 
After each run several parameters were checked to ensure the validity of the run: 
i. That the Ct (takeoff) for the water control was near 40 to indicate there was no 
contamination. 
ii. That the RT- control for each sample is at least 5 cycles higher than samples 
using a primer set for an intron-free amplicon (e.g. actin primers). If there was 
a similar Ct to samples, then the samples were discarded.  
iii. The melt curve was checked to ensure a single peak was observed (single 
product) 
iv. Duplicate variation should vary by less than 0.2 Ct units 
v. The 1:2 dilution of a sample should have a Ct (takeoff) between 0.6-1.4 units 
greater than the 1:1 that is higher than Ct of undiluted sample as determined by 
reaction efficiency. If the difference was outside this boundary it indicates that 
one is no longer measuring in the linear range of the PCR curve and the 
sample was discarded from analysis. 
Relative PCR compares the difference between a treated sample and a control sample 
for a particular gene. The relative expression of each gene was calculated based on the 
2-ΔΔCt method (Livak & Schmittgen, 2001), except that a gene specific amplification 
efficiency was used instead of 2. Each gene is first normalized by dividing its 
expression by a reference or housekeeper gene which should not be affected by any of 
the treatments studied.  The efficiency of the reaction (a) was found by either using as 
dilution series of one of the samples and graphing Log[sample/plasmid/amplicon 
concentration] versus Ct; then efficiency can be calculated by : 
 
a = 10-(slope of (log[conc])/Ct). Equation 1 
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On the Rotor-gene 6000 machine the efficiency is calculated for each individual 
reaction tube using the accompanying software (Corbett, Australia) and the average 
efficiency for all the reaction tubes of a particular primer set was used in copy number 
the calculations. The efficiency should be greater than 1.6 but not greater than 2.1  
 
The amplification efficiency was then used to calculate a ‘copy number’ (NI) for each 
sample for the gene of Interest, and the reference gene (NR). Copy number is given by 
the equation: 
N=a-Ct Equation 2 
Each gene of interest copy number (NI) is then normalised against the reference gene 
copy number (NR) or the geometric mean (Ng) of many reference genes may be used: 
 
n
ng NNNNN ...321=  Equation 3 
Where n is the number of housekeepers used and Nn is the copy number of the nth 
reference gene. 
 
The normalised gene copy number (XI) is given by: 
 
R
I
I N
NX =  Equation 4 
XI is then divided by the normalised gene copy number of the control sample (XIC) to 
give the relative expression for the gene of interest in the treated sample (RI). 
 
IC
I
I X
XR =  Equation 5 
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2.2.4 Subcloning 
Subcloning is the transfer of a gene of interest from one vector construct to another. 
The exact protocol depends on the restriction enzyme sites available and their 
compatibility in the vector containing the gene of interest and then vector to which the 
gene will be ligated into. 
2.2.4.1 Subcloning strategy 
The vector constructs containing the DNA fragment and the target vector were 
analysed for restriction sites which occur in the same 5’ to 3’ order to see if compatible 
sites were available. If the ends of the target vector and the DNA fragment are not 
compatible then ‘sticky’ ends may be ‘blunted’ by filling in the 3’ recessed ends using 
klenow enzyme (Roche, Germany). 
2.2.4.2 Preparation of DNA Fragment of Interest for Ligation 
2.2.4.2.1 Restriction Enzyme Digest 
The original vector was digested using the restriction enzymes decided on according to 
the protocol given in section  2.2.2.8.  
2.2.4.2.2 Klenow ‘Fill in’ of Sticky Ends  
To fill in the sticky ends (if required) the Klenow enzyme (Roche, Germany) was used. 
This enzyme is the large fragment of DNA polymerase I after digestion with subtilisin 
protease. It catalyses the addition of deoxynucleoside-5’-triphosphates (dNTPs) to the 
3’-hydroxyl terminus of a primer-template DNA and also retains 3’ to 5’ exonuclease 
activity, however it lacks 5’ to 3’ exonuclease activity (information and protocol 
available from Roche: www.roche-applied-science.com/pack-insert/1008404a.pdf). It 
therefore fills in recessed 3’ ends or digests away protruding 3’ ends to give blunt ends. 
To the restriction enzyme digest mixture (20µl) was added 2.3µl of a mixture of all four 
dNTPs each at 10mM and 1µl of Klenow enzyme. This was incubated at 37°C for 30 
minutes, then the enzyme heat killed by heating to 65°C for 10 minutes.  
2.2.4.2.3 Geneclean DNA purification from Solutions 
To prevent the Klenow enzyme filling in desired sticky ends, compatible restriction 
enzyme digests were performed after blunting of incompatible ends and after the 
Klenow enzyme had been removed using the Geneclan kit (QBiogene, USA). The 
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protocol from the kit was followed (Geneclean II kit, QBiogene, USA); all reagents 
were supplied in the kit unless specified, the kit was stored at 4°C. The glass milk was 
first vortexed vigorously for 1minute to suspend the silica particles. Three volumes of 
NaI added were added to the DNA mixture, then 5µl of glass milk was added and the 
mixture vortexed gently. This was left to incubate at room temperature for 5 minutes 
to allow DNA to bind to the silica particles, mixing again after 2 minutes to keep the 
silica particles in suspension. The glassmilk bound to the DNA was then pelleted by 
centrifuging for 5 seconds at full speed (Biofuge pico Heraeus, Germany). The 
supernatant was aspirated and the pellet resuspended in 500µl of icecold NEW Wash 
by gently pipetting up and down with a 1ml pipette. The NEW Wash solution had 
previously been made up with ethanol (BioLab Australia Ltd) according to the 
manufacturer’s instructions. This was centrifuged for 5 seconds at maximum speed, the 
supernatant discarded and then the wash and centrifuge repeated. After the second 
wash the tube was again briefly centrifuged and all traces of ethanol removed. The 
pellet was dried for 5 minutes at room temperature with the cap removed then 5µl of 
DEPC water was added to elute the DNA. This was mixed gently by pipetting up and 
down. Finally the tube was centrifuged for 30 seconds at maximum speed and the 
supernatant containing the eluted DNA transferred to a new tube.  After this the 
second restriction enzyme digest was performed. 
2.2.4.2.4 Separation of Target Fragment 
The DNA fragment of interest was then separated from the vector by running the 
restriction enzyme digest on an agarose gel containing ethidium bromide 
(section 2.2.2.6). The desired band was cut out of the gel by viewing the gel under low 
powered UV light (to avoid strand breaks). A scalpel blade cleaned with ethanol was 
used to rapidly cut the band out, minimizing UV light exposure. The gel slices were 
placed in pre-weighed microcentrifuge tubes. The DNA was then purified from the gel 
using the Geneclean kit (QBiogene, USA). 
2.2.4.2.5 Geneclean DNA Purification from Agarose Gels 
The protocol from the kit was followed (Geneclean II kit, QBiogene, USA); all 
reagents were supplied in the kit unless specified, the kit was stored at 4°C. The gel 
slice containing the target DNA was weighed then 3 volumes of NaI added. This was 
incubated at 55°C for 5 minutes to dissolve the gel. If after 5 minutes the gel was not 
fully dissolved it was incubated for 1 minute longer. During melting of the agarose gel 
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the glass milk was vortexed for a minute. The gel mixture was mixed by tapping the 
tube and then 5µl of glass milk was added and the mixture vortexed gently. This was 
left to incubate at room temperature for 5 minutes to allow DNA to bind to the silica 
particles, mixing again after 2 minutes to keep the silica particles in suspension. The 
glassmilk bound to the DNA was then pelleted by centrifuging for 5 seconds at full 
speed (Biofuge pico Heraeus, Germany). The supernatant was aspirated and the pellet 
resuspended in 500µl of icecold NEW Wash by gently pipetting up and down with a 
1ml pipette6. The NEW Wash solution had previously been made up with ethanol 
(BioLab Australia Ltd) according to the manufacturer’s instructions. This was 
centrifuged for 5 seconds at maximum speed, the supernatant discarded and then the 
wash and centrifuge repeated. After the second wash the tube was again briefly 
centrifuged and all traces of ethanol removed. The pellet was dried for 5 minutes at 
room temperature with the cap removed then 5µl of DEPC water was added to elute 
the DNA. This was mixed gently by pipetting up and down. Finally the tube was 
centrifuged for 30 seconds at maximum speed and the supernatant containing the 
eluted DNA transferred to a new tube. The DNA was quantified using the Nanodrop 
(Nanodrop technology, USA) 
2.2.4.3 Preparation of Target Vector for Ligation 
The target vector had to be prepared to receive the DNA fragment, by first cutting 
with the appropriate restriction enzymes and then removing the 5’ terminal DNA 
phosphosphate to prevent the vector joining to itself during the ligation step. Finally 
the cut vector was purified using the Geneclan kit (QBiogene, USA) 
2.2.4.3.1 Restriction Enzyme Digest of Target Vector 
The target vector was digested using the appropriate enzymes, for double digests the 
total volume of the reaction was increased to 30µl and a buffer which allowed both 
enzymes to work was used. If this was impossible then two sequential digests were 
performed, with the enzyme requiring the lowest salt concentration first.  
2.2.4.3.2 Dephosphorylation of Cut Vector 
To the restriction digest mixture was added mQ sterile water to give a total volume of 
44µl, 5µl of 10x CIP buffer (supplied with CIP enzyme) and 1µl of 1U/µl Calf 
Intestine alkaline Phosphatase (CIP; Roche, USA). The reaction mix was incubated at 
37° for 15minutes, followed by 15 minutes at 56°C, then 1µl of CIP was added and the 
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incubations repeated. The CIP was then heat inactivated by heating to 75°C for 10 
minutes.   
2.2.4.3.3 Purification of Cut Vector 
The dephosphorylated cut vector was then run on an agarose gel containing ethidium 
bromide. A narrow band of the correct size cut out from the gel under UV light using 
a sterile scalpel blade and put into a pre-weighed microcentrifuge tube. The target 
vector was then purified from the gel using the Geneclean kit as described in section 
 2.2.4.2.5. 
2.2.4.4 Ligation of DNA Fragment into Target Vector 
This protocol is based on the manufacturer’s protocol for T4 DNA Ligase 
(Invitrogen). A 3:1 molar ratio of insert to vector is suggested. To this was added 3µl of 
5x Ligase reaction buffer (supplied with T4 Ligase; Invitrogen) and 1µl of T4 DNA 
Ligase (Invitrogen) and sterile mQ water to give a total volume of 15µl. This was 
incubated at 4°C for 24 hours (not 14°C as suggested in the protocol for a blunt ended 
ligation). A control ligation was also performed which was identical except that only 
vector DNA was used. This checks for the frequency of vector self ligation, i.e. how 
efficient was the dephosphorylation reaction by CIP. 
2.2.4.5 Transformation  
5µl of the ligation mix was added (in place of the 1µl of 1ng/µl DNA) to competent 
DH5α cells on ice and the transformation procedure given in section  2.2.2.4 followed. 
2.2.4.6 Minipreparation of Ligated Vector 
In the late afternoon (to prevent overgrowth of liquid cultures) 18 colonies were 
picked using sterile 200µl pipette tips and used to inoculate separate numbered 13ml 
snap cap tubes (Sarstedt, USA) containing 3ml LB/Amp broth. These were grown 
overnight at 37°C in a shaking incubator at 300rpm.The following day 1.5ml of culture 
was poured into labeled 1.5ml microcentrifuge tubes and then centrifuged for 1 minute 
at maximum speed (Biofuge pico Heraeus, Germany). The supernatant was aspirated 
(it is important to remove all supernatant as cell wall components present in the 
supernatant can inhibit the action of restriction enzymes) and then a miniprep was 
performed following the protocol given in “Molecular Cloning (Sambrook & Russel, 
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2001b). The solutions used were made according to the protocol given in molecular 
cloning (section  2.1.3.2.1) and the procedure was carried out with the tubes in ice: 100 
µl of ice cold Solution I was added to each miniprep and vortexed vigorously until fully 
dissolved. 200 µl of freshly made Solution II was then added and mixed by inverting 
the tube 5 times. 150µl of ice cold solution III was added and the tubes inverted a few 
more times. The bacterial lysate was then centrifuged at maximum speed at 4°C 
(epindorf centrifuge 541D, Germany) for 5 minutes. The supernatant was transferred 
to a new tube and 450 µl of room temperature isopropanol (BioLab Australia Ltd) 
added. This was vortexed briefly before centrifuging again for 5 minutes at 4°C. The 
supernatant was aspirated taking care not to suck away the DNA pellet then the DNA 
was washed in 700 µl cold 70 % ethanol (BioLab Australia Ltd), centrifuged at 
maximum speed for 2 minutes and  the ethanol aspirated trying to remove any traces 
of ethanol. The tubes were air dried by leaving them at room temperature for 3 
minutes with the lids off and then the DNA resuspended in 30 µl TE containing 1:200 
dilution of 10 mg/ml DF-RNAaseA (Invitrogen). This was incubated at 37°C for 30 
minutes. The DNA can then be analysed by restriction digest using 3µl of sample in a 
20µl reaction (section  2.2.2.8) and running on a gel to check for correct insert and 
orientation.  
 
2.2.4.7 Preparation of a Glycerol Stock 
One or two colonies analysed showing the correct restriction digest result were then 
made into a glycerol stock using some of the remaining bacterial culture: 150µl of pure 
sterile glycerol (Invitrogen) was added to 850µl of bacterial suspension in a cryovial. 
This was mixed and flash frozen by submerging in liquid Nitrogen (-196°) and then 
stored at -80°C, recording details as this is an ERMA requirement.  
2.2.4.8 Sequencing 
Selected colonies were used to inncoulate 250ml of LB/ampicillin broth and grown 
overnight to make a maxiprep. The DNA was then sequenced using two primers 
located before and after the insert. Sequencing was carried out by Waikato University 
DNA sequencing facility. 
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2.2.5 Microarray 
The Affymetrix GeneChip® Expression platform was chosen for global analysis in the 
change of gene expression due to the various treatments detailed above. The array 
chosen was the GeneChip® Mouse Genome 430 2.0 Array. This array screens the 
expression of the entire mouse genome, and has 45,000 different probes. Cells were 
treated as specified in sections  2.2.1.7.3 and  2.2.1.10 with siRNA or by changing the 
media cells were grown in. RNA was then isolated from the cells following the 
modified RNA isolation protocol given in section  2.2.3.2. Following the DNAse 
treatment the ‘One-Cycle Target Assay’ protocol was followed closely adhering to the 
manufacturer’s instructions. All reagents were supplied in the Affymetrix kits 
purchased unless specified.  
2.2.5.1 Microarray Experimental Design 
Three mRNA samples were pooled together for each microarray. And each treatment 
had either two or three microarrays performed ion each. Because Affymetrix arrays 
give an absolute expression value for each gene, any two arrays can be compared and 
all samples can be treated identically without the need for labeling samples to be 
compared with different dyes. A diagram of the different treatments and the number 
of arrays used for each treatment is given in brackets below: 
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2.2.5.2 Collection and Pre-Analysis of mRNA Samples  
Cells were grown in six well plates and transfected or treated as given in the section on 
cell culture protocols. Because each treatment required between six and nine different 
samples (each well can be considered a separate experiment/sample) two six well plates 
of cells were treated. Isolation of mRNA from mTS cells was carried out according to 
the protocol given in section  2.2.3.2. 1µl of the sample was reverse transcribed as 
described in the protocol and used in real-time PCR analysis (section  2.2.3.3) using the 
ABI machine. The remainder of the RNA (10µl) was stored at -80°C.  
1µl of RNA sample was removed form each stored sample and analysed on the 
Nanodrop (Nanodrop technologies). Before applying RNA samples to the Nanodrop 
the surface was wiped with RNase Away (Molecular BioProducts). RNA concentration 
and RNA quality were measured. The absorbance ratio A260/A280 should be 
approximately 2.0 for pure RNA; values between 1.9 and 2.1 are acceptable 
(Affymetrix Inc., 2006a). The 1µl of RNA sample was then recovered from the 
Nanodrop and run on a gel, to check 18s and 28s rRNA bands could be clearly seen. 
An excess of samples meant any samples with low RNA quality or which did not show 
sufficient siRNA knockdown could be discarded. After DNAse treatment RNA 
samples were analysed on a gel for quality by assessing the prescence of 28s and 18s 
rRNA bands (indicating little degradation) and on the Nanodrop (Nanodrop 
Technologies, USA) for concentration to ensure the RNA isolation process had been 
successful and the samples all contained a similar level of RNA. Any samples which 
did not meet the criteria were discarded. 
2.2.5.3 Pooling of mRNA samples 
Three samples of the same treatment were pooled together to give a total starting RNA 
concentration of 10µg. Samples containing similar quantities as measured by the 
Nanodrop were pooled together to try and minimize the influence of a single sample. 
The volume was adjusted with DEPC water to give a total volume of 7µl. The pooled 
RNAs sample were placed in a PCR tube, all together there was 18 samples. 
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2.2.5.4 One-Cycle cDNA Synthesis 
2.2.5.4.1 Poly-A RNA Control Addition 
This step uses the Eukaryotic Poly-A RNA control kit (Affymetrix, USA). The Poly-A 
RNA control stock was diluted serially in the Poly-A Control dilution buffer following 
the dilutions prescribed for a 10µg starting amount of total RNA. Non-stick RNAse 
free microcentrifuge tubes were used for the dilutions. The first dilution was a 1:20 
dilution (2µl of stock into 38µl of buffer). 2µl of this was then diluted in 98µl of buffer 
to give a 1:50 dilution, and finally 10µl of the resultant solution was diluted 1:5 in 40µl 
of buffer. Between each dilution the tube was vortexed to mix and spun down. 2µl of 
the final solution was spiked into each pooled sample. 
 
2.2.5.4.2 First-Strand cDNA Synthesis 
The One-Cycle cDNA Synthesis kit (Affymetrix, USA) was used for this step. 2µl of 
T7-Oligo(dT) primer was added to each pooled sample to give a total volume of 11µl. 
The samples were flicked to mix and then the contents spun to the bottom (Labnet 
International Inc, USA). Samples were placed in a PCR machine set to 70° for 10 
minutes, they were then plunged into ice for 2 minutes. During this time a first-strand 
master mix was prepared: 4µl of 5x 1st strand master mix, 2µl of 0.1M DTT and 1µl of 
dNTP 10mM were placed in a tube per sample (x 18.1). 7µl of the master mix was 
added per pooled sample, the samples mixed by flicking and the contents centrifuged 
briefly to collect their contents to the bottom. The samples were placed in a PCR 
machine (PTC-200, MJ Research, USA) set to 42°C for 2 minutes, then removed and 
2µl of SuperScript II added. The samples were returned to the PCR machine and 
incubated at 42°C for one hour. The samples were then placed on ice and cooled to 
4°C. this was followed immediately by the second strand cDNA synthesis. 
 
2.2.5.4.3 Second Strand cDNA Synthesis 
Immediately following the first strand synthesis the second strand cDNA synthesis was 
performed. The One-Cycle cDNA synthesis kit (Affymetrix, USA) was also used for 
this step. A second strand master mix was prepared by mixing together for each tube: 
91µl RNase free water, 30µl of 5x 2nd strand reaction mix, 3µl of dNTP (10mM), 1µl of 
E.coli DNA ligase, 4µl of E.coli DNA polymerase I and 1µl of RNase H. 130µl of this 
master mix was added to sample. This gave a total volume in the PCR tube of 150µl. 
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The tubes were flicked to mix and then centrifuged to collect their contents to the 
bottom (Labnet International Inc, USA). Then they were placed in a PCR machine 
(PTC-200, MJ Research, USA) programmed to do 16°C for 2 hours, followed by a 4°C 
hold, during which time 2µl of T4 DNA Polymerase was added to each tube. Then the 
samples were returned to the PCR machine and incubated at 16° for 5 minutes, 
followed by a 4°C hold. Then 10µl of 0.5M EDTA was added to each tube. Samples 
were immediately cleaned as detailed in the next section. 
 
2.2.5.4.4 Cleanup of Double-Stranded cDNA 
The Sample Cleanup module was used for this step (Affymetrix, USA). 24ml of 100% 
RNAse free Ethanol (BioLab Australia Ltd) was first added to the supplied cDNA 
wash buffer. All steps of this protocol were carried out at room temperature as 
specified. Firstly cDNA was transferred to 1.5ml microcentrifuge tubes. 600µl of 
cDNA binding buffer was added to each tube and mixed by vortexing. The colour of 
the mixture was checked to ensure it was yellow and not too alkaline (orange or violet). 
500µl of the mixture was loaded on to a cDNA Cleanup spin column sitting in a 2ml 
collection tube and centrifuged for 1 minute at 10,000 x g (Biofuge Pico Heraeus, 
Germany). The flowthrough was discarded. The column was then reloaded with the 
remainder of the mixture and centrifuged again. The column was then transferred to a 
new 2ml collection tube and 750µl of the cDNA wash buffer applied to the column. 
This was centrifuged as above and the flow-through discarded. The caps on the 
columns were then opened and then spun for 5 minutes at maximum speed. The 
columns were then transferred to a 1.5ml collection tube and 14µl of RNase free water 
applied to the column. This was supposed to be cDNA elution buffer. The columns 
were incubated for 1 minute and then centrifuged for 1 minute at maximum speed. 
The procedure may be stopped at this point. The cDNA was stored in a fridge at 4°C 
overnight.  
2.2.5.4.5 Synthesis of Biotin-Labeled cRNA 
The GeneChip IVT Labeling kit was used for this step (Affymetrix, USA). 6µl of 
double-stranded cDNA was added to a new microcentrifuge tube. A master mix was 
prepared per sample (x18) at room temperature (to avoid precipitation of the cDNA in 
the presence of spermadine)of : 14µl of RNase free water, 4µl of 10x IVT labeling 
buffer, 12µl of IVT labeling NTP mix, and 4µl of IVT labeling enzyme mix. 20µl of 
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the master mix was added to each tube and mixed by flicking. The tubes were 
centrifuged briefly and then incubated overnight (16 hours) at 37°C in an oven 
incubator (Sanyo). 
 
2.2.5.4.6 Cleanup and Quantification of Biotin-Labeled cRNA 
The Sample Cleanup kit (Affymetrix, USA) was used for this step. Before beginning 
20ml of 100% ethanol (BioLab Australia Ltd) was added to the IVT cRNA wash 
buffer concentrate to make the working solution. All steps were carried out at room 
temperature. 60µl of RNase free water was added to the IVT reaction and mixed by 
vortexing for 3 seconds. 350µl of IVT cRNA binding buffer was then added to the 
sample and mixed by vortexing for 3 seconds. 250µl of 100% ethanol was added to 
each sample and mixed by pipetting. The entire sample (700µl) was then applied to a 
IVT cRNA cleanup spin column sitting in a 2ml collection tube. This was centrifuged 
for 15 seconds at 10,000 x g (Biofuge pico Heraeus, Germany). The flow through and 
collection tube were discarded and then the spin column transferred to a new 
collection tube. 500µl of IVT wash buffer was applied to the spin column and it was 
centrifuged again as before, discarding the flow-through. 500µl of 80% ethanol 
(BioLab Australia Ltd) was applied to the spin column and then it was centrifuged 
again and the flow-through discarded. The caps were removed on the spin column and 
they were centrifuged at maximum speed for 5 minutes to allow drying of the 
membrane. The flow-through and collection tubes were discarded and the spin column 
transferred to a new 1.5ml collection tube. RNA was eluted by pipetting 10µl of RNase 
free water directly on to the column membrane and centrifuging at maximum speed 
for 1 minute. This step was repeated using 10µl of RNase free water. 
 
 The RNA concentration was then checked by measuring RNA absorbance at 260nm 
and 280nm on the Nanodrop (Nanodrop technologies, USA). Pure RNA should have 
a ratio of A260/A280 of 2.0. For quantification of cRNA an adjusted cRNA yield had to 
be calculated to reflect carryover of unlabelled total RNA. Using an estimate of 100% 
carryover: 
 
Adjusted cRNA yield = RNAm-(total RNAi)(y) Equation 6  
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Where:  RNAm = the amount of cRNA measured after IVT (µg) 
 Total RNAi=the starting amount of total RNA (µg) 
 y=the fraction of cDNA reaction used in IVT  
 
cRNA samples were stored at -80°C until fragmentation. 
2.2.5.4.7 Fragmenting the cRNA samples 
Fragmentation of cRNA target is critical for obtaining optimal assay sensitivity. The 
Sample Cleanup module was used for this step (Affymetrix, USA). 20µg of cRNA (the 
volume of which was calculated using the adjusted cRNA concentration) was 
transferred to a new RNase free microcentrifuge tube. 8µl of fragmentation buffer was 
added along with RNase free water to give a final volume of 40µl. This was incubated 
at 95°C for 35 minutes then placed on ice. 2µl was removed and run on a gel to check 
fragmentation. The remainder of the cRNA samples were stored at -20°C. The 
fragmentation procedure should produce a distribution of RNA fragment sizes from 
35 to 200 bases.  
2.2.5.5 Eukaryotic Target Hybridisation 
2.2.5.5.1 Preparation of the Hybridisation Cocktail 
The 12x MES stock buffer was prepared as detailed in section  2.1.3.5 using MES 
hydrate (Sigma-Aldrich) and MES Sodium Salt (Sigma-Aldrich). 4.15mls of the 12x 
mES stock buffer was used to prepare the 2x hybridisation buffer along with 8.85mls 
5M NaCl (BioLab scientific Ltd, Australia), 2.0mls 0.5M EDTA Disodium salt (Gibco, 
Invitrogen life technologies), 0.05ml 10% Tween 20 (BioRad Laboratories, USA) and 
9.95mls DEPC H2O. 
The following was pipetted into an RNase free microcentrifuge tube: 15µg of the 
fragmented cRNA (30µl), 5µl of Control Oligo B2 (GeneChip® Hybridisation Control 
Kit Affymetrix, USA), 15µl of 20x eukaryotic hybridisation controls (GeneChip® 
Hybridisation Control Kit Affymetrix, USA), 3µl of 10mg/ml herring sperm (Promega 
Corporation, USA), 3µl of Bovine Serum Albumin 50mg/ml (Invitrogen life 
technologies), 150µl of 2x hybridisation buffer, 30µl of DMSO (Sigma-Aldrich) and 
64µl of RNase free water to give a total volume of 300µl. The cocktail for each array 
was heated to 95°C for five minutes in a heat block (epindorf, Germany) and then the 
hybridisation cocktail samples for each array were placed on ice and driven to Liam 
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Williams at Auckland University’s Affymetrix facility. The samples were stored at -
70°C until hybridisation was carried out according to the Affymetrix protocol in an 
Affymetrix hybridisation oven 540 for 16 hours at 45°C. Each pooled and labelled 
sample was hybridised to a GeneChip® Mouse Genome 430 2.0 array (Affymetrix, 
USA) 
2.2.5.6 Washing and Scanning of Arrays  
Washing and scanning of the arrays was carried out by Liam Williams at the University 
of Auckland according to the manufacturer’s instructions. 
2.2.5.6.1 Washing and Staining of Arrays in the Fluidics Station. 
An Affymetrix Fluidics station was used which was automated through use of the 
associated GeneChip® Operating Software version 1.4 (GCOS; Affymetrix Inc, 2005). 
Briefly : after hybridisation the arrays were washed with 10 cycles using Wash Buffer A 
(a non-stringent wash buffer) at 25°C, then 4 cycles using Wash Buffer B (stringent 
wash buffer) at 50°C. The array was then stained with a solution containing 
Streptavidin Phycoerythrin (SAPE) for 10 minutes at 25°C. This is a fluorescent 
molecule which binds to biotin.  This was followed with 10 wash cycles using Wash 
Buffer A. Then a second stain was performed for 10 minutes at 25°C with an antibody 
solution containing Goat IgG Anti-strepavidin and biotinylated antibody to give a 
signal amplification effect. A third SAPE stain was applied for 10 minutes at 25°C 
before a final 15 cycle wash with Wash Buffer A at 30°C, a diagram of the stain is 
shown in  
Figure  2.2-1: Staining of the biotin labelled RNA in an Affymetrix array. SAPE is a 
fluorescent dye which binds to biotin. The staining includes an amplification step 
which uses antibodies. After washing and staining the arrays were ejected from the 
fluidics station and transferred to a scanner.  
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Figure  2.2-1: Staining of the biotin labelled RNA in an Affymetrix array. SAPE is a fluorescent dye which binds 
to biotin. The staining includes an amplification step which uses antibodies (Source: Oregon Health and Science 
University, http://www.ohsu.edu/gmsr/amc/amc_technology.html). 
2.2.5.6.2 Probe Array Scan 
Arrays were scanned using an automated system run by GCOS software v 1.4 
(Afyymetrix Inc. 2005). Arrays were scanned in an Affymetrix GeneChip Scanner using 
a pixel value of 3µm and a wavelength 570nm. The laser scans the array and the image 
file data is stored as a .dat file in the GCOS software.  
2.2.5.7 Microarray Analysis 
The raw image file data (.dat file) generated by the scanner for each array was then 
automatically converted by the GCOS software to a cell intensity file (.cel file).   
GCOS uses the Cell Analysis Algorithm to compute a single intensity value for each 
probe cell on the array from the primary image file and saves this as the cell intensity 
file.  
From this stage on analysis was carried out with the assistance of Harold Henderson 
and David Baird statisticians who work at AgResearch. Raw intensity data was 
analysed by GenStat basically following the procedure given in the GenStat manual 
for analysis of microarray data, pages 59 to 62 (Baird, 2006).  
2.2.5.7.1 GenStat Analysis 
The Cell Intensity file was imported into the GenStat software program (9th Edition, 
VSN International Ltd, UK) along with the mouse 430_2.CDF file. The CDF file 
provides information to GenStat about the location of each of the probes, and what 
gene each probe corresponds to. An algorithm was then applied to the data called the 
robust means analysis (RMA) algorithm. RMA involves three steps: background 
correction to remove an error component in the intensity readings; quantile 
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normalisation where each side is normalised to have the same cumulative frequency 
distribution; and summarisation where the median value for each probe set is 
calculated. The result is a log base 2 expression value for every gene on every slide 
(Baird, 2006). The expression value given is the log base 2 of the average intensity. 
This file was saved as ‘Expressions.GSH’. 
A spreadsheet file was then created which told GenStat the structure of the targets 
applied to the slides; that is it related the name of the .cel file (the slide name) to the 
treatment of the sample applied to that slide. This file was saved as ‘Hybfiles.GSH’.  
A spreadsheet describing the contrasts in a matrix was also prepared. This sheet 
described the treatment and the relevant control it needed to be compared to; it was 
called ‘Contrasts.GSH’. The contrasts explored and the matrix used is shown below. 
Table  2.2-2: Matrix showing the contrasts applied in Genstat. 
_Rows_ Normal TS + activin 
TS + 
F4H 
TS 
Only 
si 
negative 337 773 
TSA vs N -1 1 0 0 0 0 0 
TSF vs N -1 0 1 0 0 0 0 
TS vs N -1 0 0 1 0 0 0 
337 vs Si- 0 0 0 0 -1 1 0 
773 vs Si- 0 0 0 0 -1 0 1 
N vs Si- 1 0 0 0 -1 0 0 
 
To estimate the differences between treatments and the relevant control a single 
channel ANOVA was performed on the data (since the arrays were single colour 
arrays). The sheets loaded were Expression.GSH, Hybfiles.GSH and Contrasts.GSH. 
This produced a spreadsheet which had the mean log2 expression of each 
gene/probe set for each treatment, the contrast log2 expression for each probe 
(simply the mean log2 expression of a treatment – the mean log2 expression of the 
control) and a p-value for the contrast. These results were stored in Excel. There was 
45,101 different probe sets in total. 
2.2.5.7.2 Identification of Genes of interest 
Using Excel (Microsoft Corporation, 2003) fold change cut-offs were used to filter the 
log2 contrast values to find a set of probes which was differently expressed between 
two treatments. The fold change cut off was chosen to obtain a target set which was 
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not too stringent so that genes that were truly changed would not be discarded, 
however the number of ‘interest genes’ also had to be of a manageable size. The 
contrasts and their fold-change cut offs are given in Table  2.2-3. The list of probes and 
their accompanying expression data/p-values for all contrasts was combined into a new 
spreadsheet and then any duplicate probe sets removed.  
Finally a set of filters were applied to search for intersections, i.e. to find genes which 
were changed when more than one contrast was applied for example the set of genes 
which changed when 773 AND 337 siRNA treatments were done as compared to the 
siRNA negative control. For the siRNA experimental data probe sets which had a 
greater than 1.5 fold change between the siRNA negative control treated samples and 
the ‘normal’ treated samples were discarded. The p-value was also evaluated to ensure 
that probe sets which did meet the fold change cut off for a contrast also had a p-value 
of less than or equal to 0.05. 
Table  2.2-3: Contrasts and foldchange cut-offs used in obtaining a target set of interest genes 
Contrast Fold Change Cut-Off 
TS medium without growth factors vs N 
(Normal 70%CM + F4H) 
2 
TS medium + Activin vs N (Normal 70%CM + 
F4H) 
2 
TS medium + Fgf4 vs N (Normal 70%CM + 
F4H) 
2 
337 siRNA vs siRNA negative control 1.4 
773 siRNA vs siRNA negative control 1.5 
337 siRNA vs N (Normal 70%CM + F4H) 1.5 
773 siRNA vs N (Normal 70%CM + F4H) 1.5 
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2.2.5.7.3 Annotation and Verification of Interest Genes 
Probe sets from the intersections of contrasts were then matched to gene names using 
Ingenuity Pathway Analysis software 4.0 Version 3. Ingenuity is a software package 
which uses peer reviewed scientific journals (approximately 400 journals) to give 
information about gene product interactions and pathways, functional analysis of data 
and gene ontology. Information on each probe set for each intersection studied was 
tabulated to give summary gene ontology for each probe set identified. Information 
included canonical pathway, molecular function and biological process.  
 
Using this information a subset of genes was chosen which were of interest. Real-time 
PCR primers were designed for these and then the expression of these genes was 
analysed by quantitative real-time PCR to check their expression was truly significantly 
different (section  2.2.3). The cDNA used for the verification was derived from the 
same samples used for microarray analysis. 
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CHAPTER 3 : siRNA INDUCED Elf5 KNOCKDOWN 
3.1 OVERVIEW 
Targeted Elf5 mRNA degradation using siRNA was used to modulate Elf5 expression 
as a means of identifying Elf5 target genes. Elf5 knockdown was achieved using two 
25-mer siRNA oligonucleotides and an optimised protocol was established. 
Measurement of Elf5 knockdown and other candidate genes known to be involved in 
TS cell differentiation was achieved using real-time PCR.  
3.1.1 RNA Interference 
RNA interference or RNAi was discovered by Craig Mello and Andrew Fire in 1998 
when they observed that double stranded RNA could induce a sequence specific 
silencing response in the nematode worm Caenorhabditis elegans (Fire et al., 1998). Not 
long after double stranded RNA (dsRNA) was shown to also work in mammals when 
it was used to inhibit the function of three genes in the mouse embryo (Wianny & 
Zernicka-Goetz, 2000). Double stranded RNA has been found to cause silencing 
through targeted degradation at the mRNA level (Cullen, 2005). Since the discovery of 
dsRNA interference a greater understanding into the mechanisms and essential 
characteristics of successful RNAi molecules has allowed gene specific design and the 
reduction in non-specific effects, so that almost any gene can be selectively targeted 
with high success. One of the important discoveries has been that a sequence of just 
21-25 nucleotides in length (small interfering RNA; siRNA) is able to elicit a gene 
specific response. 
RNAi experiments to reduce gene expression are advantageous over classic knockout 
experiments because they take a much shorter time to achieve success. Commercial 
companies such as Invitrogen Life Technologies can quickly design and manufacture 
RNAi molecules so that successful gene knockdown may be achieved within weeks, 
rather than laborious gene targeting experiments which take months (Weber et al., 
1999). A disadvantage of RNAi experiments is that they can elicit an interferon 
response, normally reserved for viral infections (Bridge et al., 2003) and therefore cause 
changes in gene expression other than the target. Also, due to the high tolerance for 
mismatches between the 2-8 nucleotide ‘seed’ region of a siRNA  other genes than the 
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target may be affected in so called off target effects (Echeverri et al., 2006). To ensure 
responses are specific for a given target sequence, and result in a reduction in transcript 
number (“knock-down”) it is recommended that multiple siRNAs targeting different 
regions of the same gene be used. If they give the same phenotype then it is very 
unlikely to be an off-target effect (Echeverri et al., 2006). The efficiency of knockdown 
can also greatly depend on the location of the targeted sequence within the mRNA (Li 
et al., 2006).  
 
A disadvantage of RNAi experiments is that the effect of RNAi induced knockdown is 
only transient. Transfection with siRNA is thought to have an effect for up to five days 
following transfection (Dykxhoorn et al., 2003); however longer lasting gene 
inactivation of up to 13 days has been reported (Li et al., 2006). 
 
Four Elf5 mRNA targeted siRNA molecules were designed (Section  3.2.1) using the 
Invitrogen website (Invitrogen Life Technologies; www.invitrogen.com). These 
‘stealth’ siRNAs have a chemically modified RNA back bone which is supposed to 
reduce non-specific effects and minimise the chance of an interferon response 
(Invitrogen Life Technologies). Elf5 mRNA knockdown was quantified using reverse-
transcription (RT) real time PCR. 
3.1.2 Real Time PCR 
The siRNA knockdown of Elf5 and the subsequent changes in gene expression were 
analysed using the method of real-time RT-PCR (reverse transcription-polymerase 
chain reaction). Real time PCR measures the level of DNA which has been amplified 
after each cycle of a PCR, hence the term ‘real time’. This is achieved through the 
detection of a number of fluorescent probes which are directly correlated to the 
amount of amplified product. A widely used fluorescent probe is SYBER-Green. 
SYBER-Green intercalates into the DNA helix giving an 11 fold greater fluorescence 
signal in double stranded DNA then in single stranded DNA at 530nm (Zipper et al., 
2004); therefore SYBER-Green fluorescence is directly correlated to the level of 
double stranded DNA. Because SYBER-Green measurement does not depend on the 
sequence of template/primers the same dye can be used for different reactions. A 
downside of this is that other double stranded DNA molecules may be present and 
also contribute to fluorescence, such as primer-dimers. To ascertain the contribution of 
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primer duplexes to fluorescence the melt curve for each reaction was checked. Primer-
dimers have a low melting point, therefore a DNA product melt curve with a low 
melting point or multiple melting peaks is indicative of primer-dimers. Primers were 
designed using software which minimises complementarity between primers and 
prevent primer dimmers (section  2.1.3.6). 
 
The initial starting level of a template is estimated by the cycle at which fluorescence of 
the product crosses a threshold; the more templates at the beginning of the reaction 
the lower the number of cycles it takes to cross the threshold. The ‘threshold’ cycle 
(Ct) is the cycle at which the level of fluorescence is significantly higher than 
background fluorescence and the reaction is in the early exponential phase, with 
maximum amplification efficiency (Wong & Medrano, 2005). At this phase in a real-
time PCR reaction the amplification efficiency is constant and is not limited by 
reagents. As the reaction proceeds, reagents become limiting and the amplification 
efficiency is reduced (the plateau phase) (Wong & Medrano, 2005). In the ABI 
machine the cycle at which fluorescence crosses the threshold level is called the Ct 
(Applied Biosystems, USA). In the Rotor-gene 6000 the ‘takeoff’ point can be used: 
  “The second derivative of the amplification plot produces peaks corresponding to the maximum rate of 
fluorescence increase in the reaction. The Takeoff point is defined as the cycle at which the second 
derivative is at 20% of the maximum level, and indicates the end of the noise and the transition into 
the exponential phase” (Rotor-Gene 6000 Series Software version 1.7.61, help menu). 
 
Real time PCR assays are 1000 times more sensitive than dot-blots (Wong & Medrano, 
2005) and can detect small variances in gene expression; as little as a 25% gene 
expression difference can be detected between samples, provided enough replicates are 
done (Gentle et al., 2001). This is important in the context of this experiment, because 
transfection efficiency varies among cells; different cells will have different degrees of 
Elf5 knockdown or over-expression. However all cells are harvested and their RNA 
extracted for use in gene expression measurements. This means changes in gene 
expression as a result of Elf5 modulation will be averaged across the cells, and cells 
with very low transfection efficiency will muffle the effect, so a sensitive technique 
needs to be utilised for gene expression.  
 
A two step RT-PCR method was chosen, where cDNA synthesis and PCR 
amplification were carried out separately. After reverse transcription cDNA was diluted 
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at least 1:20 in PCR grade water. This method was chosen because it is known that 
reagents in the reverse transcription such as DDT and reverse transcription can inhibit 
the reaction (Liss, 2002). Furthermore, by diluting the cDNA 1:20 many different 
genes can be assayed using one cDNA sample, so reference gene assays do not need to 
be carried out as often. A DNase step was included in the procedure directly after 
TRIZOL extraction because DNA contamination can make up to 80% of purified 
nucleic acid and therefore changes in DNA contamination may be interpreted as 
changes in gene expression (Bustin, 2002). 
3.1.2.1 Normalisation of RT-PCR  
The procedure from cell harvesting and RNA isolation through to RT-PCR involves a 
number of steps (section  2.2.3), all of which can be variable between samples (for 
example starting material, cell transcriptional activity, RNA isolation efficiency). A 
particular source of variation is the efficiency of reverse transcription which can range 
from 5% to 90% and is influenced by salts, alcohols or phenols remaining from RNA 
isolation giving inter-tube and inter-experimental variability (Freeman et al., 1999). To 
allow for comparison between samples the variation between genes and samples needs 
to be normalized using a control. The sequence and secondary structure of mRNA also 
influences RT efficiency; this can cause the enzyme to stop and dissociate from the 
mRNA (Bustin, 2002). To minimize these effects primers were chosen which amplified 
the 3’ end of a gene, which is the first part to be reverse-transcribed when using an 
oligo dT primer. 
 
Normalisation can be done using a number of controls; addition of synthetic RNA (or 
later DNA), total RNA or ribosomal RNA. However all of these have their drawbacks 
such as not being present in all the steps and therefore not controlling for variation in 
previous steps or that total RNA and rRNA measurements can bear little correlation to 
mRNA levels since mRNA makes up only a small percentage (~7.5%) of total RNA 
and this proportion can vary with transcriptional activity (Vandesompele et al., 2002). 
Ribosomal RNA is also not suitable as a control in this experiment since it is not 
reverse transcribed using an oligo dT primer, and therefore cannot be measured using 
RT-PCR. An internal control gene does not have any of these problems since it is itself 
an expressed gene and is therefore treated identical to target genes. However it is 
important that the internal control gene does not vary with the treatment because then 
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it could increase the significance of a result (if it had the opposite effect of the target 
gene upon treatment) or it could reduce the significance of a result (if it had the same 
effect as the target gene from treatment). It has been reported in a number of papers 
that supposed ‘housekeeping genes’ can change during the differentiation of stem cells 
(Hamalainen et al., 2001; Willems et al., 2006). The resounding advice is to screen a 
myriad of housekeeping genes until a suitable candidate is chosen to use in 
normalization calculations which does not vary with treatment. (Hamalainen et al., 
2001; Livak & Schmittgen, 2001; Perkel, 2006; Pfaffl et al., 2004; Willems et al., 2006; 
Wong & Medrano, 2005), or to use multiple housekeeping genes, and use the 
geometric mean of these (Vandesompele et al., 2002). 
3.1.2.1.1 Analysis of RT-PCR Data Generated by the ABI 7700 
Relative quantification was used to calculate the changes in gene expression for a 
sample compared to an untreated control. The calculations used were based on the     
2-ΔΔCt method (Livak & Schmittgen, 2001). The difference in Cts between the target 
gene and the normalizing gene is first calculated (ΔCttreatment) for a treated sample and 
the control sample (ΔCtcontrol) to normalize the expression. The difference between the 
treated normalized sample and the control sample is then calculated (ΔCttreatment- 
ΔCtcontrol). This is then converted into initial expression of the target compared to the 
control by using the equation:  
 
Relative Target expression =E-( ΔCttreatment- ΔCtcontrol)  Equation 1 
Where E is the amplification efficiency and using the assumption amplification efficiency is equal for the 
normalizing gene and the target gene. 
This is then changed to the equation: 
Relative Target Expression =2-( ΔCttreatment- ΔCtcontrol) Equation 2 
Using the assumption amplification efficiency is 2. 
 
A problem with this method of calculation is that it assumes that amplification 
efficiency is perfect (i.e. 2 represents a doubling every cycle), the amplification 
efficiency is also assumed to be equal for the target template gene and the 
housekeeping gene. However this is often not the case and an amplification efficiency 
difference of just 5% between two initially equal targets can result in one target 
appearing twice as abundant after 26 cycles of PCR (Freeman et al., 1999). To avoid 
 68
this error, the efficiency for primer pairs was determined as follows: a standard curve 
was made by making a dilution series of one of the samples. The –log10(dilution) was 
plotted against the Ct. Points which were obviously not in the linear part of the curve 
were discarded. The efficiency of each gene reaction could then be calculated by : 
 
E=10slope Equation 3 
3.1.2.1.2 Analysis of RT-PCR Data Generated by the Rotor-Gene 6000 
 
It has been suggested that amplification efficiency calculated from raw data is more 
accurate than that from a standard curve (Tichopad et al., 2003; Wong & Medrano, 
2005).  The Rotor-Gene 6000 software (v1.7, Corbett Research, Australia) uses the 
average increase in raw data for the 4 cycles following the Takeoff to calculate a 
sample’s amplification. Therefore each individual reaction has associated amplification 
efficiency. The Takeoff, as described above, is used in an analogous way to Ct in 
relative expression calculations.  
3.2 ATTAINMENT OF Elf5 KNOCKDOWN 
Four Elf5 targeted siRNAs were trialled for their ability to achieve Elf5 knockdown in 
TS cells when transfected using Lipofectamine 2000 (Invitrogen Life Technologies). 
Two of these were successful and used to establish a standard protocol to achieve 
greater than 80% Elf5 knockdown. Knockdown of a gene using RNAi can also induce 
an interferon response (Bridge et al., 2003). The induction of two viral responsive 
Interferon genes were measured in 337 siRNA treated cells compared to un-
transfected TS cells to ensure an interferon response was not being activated. 
3.2.1 Design of Stealth siRNAs 
Four siRNAs were designed using the reference sequence for Elf5; NM_010125.  
The sequences of the Elf5 targeted siRNA oligonucleotides were designed using the 
BLOCK iTTM siRNA designer available at:  
https://rnaidesigner.invitrogen.com/sirna/setOption.do?designOption=stealthit 
(Invitrogen Life Technologies). Several possible 25-mer siRNAs were returned ranked 
in order of predicted knockdown efficiency. The top four sequences were selected and 
StealthTM synthetic RNA of their sequences ordered from Invitrogen Life Technology. 
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StealthTM siRNA is chemically modified so to give greater stability, less cellular toxicity 
and higher specificity (www.invitrogen.com). The siRNAs were designated names 
based on the starting position of the Elf5 mRNA to which they are targeted. The 
names and rating of the siRNAs are given below.  
 
Table  3.2-1: The top four results from the Block it siRNA designer. Each siRNA is named based on the start of 
its corresponding targeting sequence in the Elf5 mRNA. 
Start  Position Sense RNA Sequence 5'-3' GC% Rank (out of 5) 
337 CCAACUGCAUCUCCUUCUGUCACUU 48 5 stars 
811 GGGUUGACCGGAGGUUAGUGUACAA 52 5 stars 
770 CCGAGCCCUGAGAUACUACUAUAAA 44 5 stars 
733 GGAAGAAGAAUGACAGGAUGACGUA 44 4 stars 
 
3.2.2 Optimisation of Elf5 Knockdown 
Transfections of siRNA were carried out in 10cm2 well dishes following the 
Lipofectamine 2000 protocol for siRNA transfection (section  2.2.1.7). The day after 
transfection cells were harvested and total RNA extracted using TRIZOL (Invitrogen 
Life Technologies) followed by reverse transcription and real-time PCR to measure 
relative expression of Elf5 compared to a siRNA control treated sample (section  2.2.3). 
Expression levels were normalised to a housekeeping gene such as β-Actin before 
relative expression was calculated.  
Two factors could influence the level of Elf5 mRNA expression knocked-down in 
mTS cells:  
• The efficiency of the particular siRNA at knock-down the Elf5 mRNA due to 
its ability to interact with the RNAi cellular machinery; in particular its ability to 
direct the RNA induced silencing complex (RISC) to the target mRNA. 
(Hannon, 2002). 
• The transfection efficiency of the siRNA complex into the TS cell. 
Both of these factors were optimised in the course of this work. 
3.2.2.1 Trial of the Elf5 targeted siRNAs  
The Lipofectamine 2000 (Invitrogen Life Technology) protocol was followed which 
recommends using 100pmol of siRNA per transfection (Invitrogen life technologies, 
2006). In order to measure transfection efficiency 20pmol of a fluorescently labelled 
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control siRNA oligo (Invitrogen Life Technologies) was also transfected into one of 
the wells. The relative expression of Elf5 in each if the siRNA treated samples 
compared to a non-treated control well is shown below (Figure  3.2-1) as measured by 
real-time PCR following RNA extraction and reverse transcription (section  2.2.3). 
Elf5 expression was normalised to β-Actin expression before relative expression was 
calculated. There were clear differences in the efficacy of Elf5 knockdown between 
different siRNAs. The two Elf5 targeted siRNA molecules which showed the greatest 
knockdown were 337 and 733; however un-optimised knockdown was only about 
40%. These siRNAs were then used further to optimise transfection efficiency. 
Surprisingly the fluorescent siRNA molecule appeared to show an increase in relative 
Elf5 expression. On closer inspection it was found that the absolute Elf5 Ct was the 
same as the non-treated control sample and instead the Ct of β-Actin had increased. 
This indicated that the fluorescent control siRNA was having non-specific effects on  
β-Actin and was not a suitable control. Following this experiment a stealth siRNA 
negative control duplex (Invitrogen Life Technologies) was used to transfect the 
control samples.  
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Figure  3.2-1: Trial experiment on the Elf5 targeted siRNAs. Elf5 expression was normalised to β-Actin expression 
before being expressed relative to the no-treatment control (the control treatment was set at 100%). The 
fluorescent oligo appeared to have non-specific effects on β-Actin expression. (Relative Elf5 expression +/- sem, 
n=2). 
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3.2.2.2 Transfection Optimisation 
3.2.2.2.1 Optimal Seeding Density 
The cationic lipid transfection reagent, Lipofectamine (Invitrogen Life Technology) 
was used to transfect siRNA into mTS cells. The main factor influencing the 
transfection efficiency of cells when using cationic lipid solutions, is the  ability to 
transfect cells in a healthy and growing state (Ausubel et al., 1999). Therefore a seeding 
protocol needs to be established which allows cells to be exponentially growing at the 
time of transfection.  The manufacturers recommend a cell confluency of 30% at 
transfection (Invitrogen Life Technologies). By trial and error an optimal seeding 
density protocol was established to enable cells to be at the correct confluency at the 
time of transfection (section  2.2.1.7.1). Cells were seeded the day before a planned 
transfection to allow them to recover and be proliferating at the time of transfection. 
 
3.2.2.2.2 Optimal siRNA Concentration 
The Lipofectamine 2000 protocol suggests altering the final concentration of 
transfected siRNA to optimise transfection efficiency (Invitrogen life technologies, 
2006). Three amounts of the best siRNA (337) were tested (100, 150 and 200pmol). 
Two amounts of 733 siRNA were tested (100 and 200pmol). Included in the 
experiment was the effect of using a combination of the two best siRNA oligos to see 
if Elf5 knockdown could be improved. The results from this set of experiments are 
shown in Figure  3.2-2. The 337 siRNA when transfected at 100pmol gave an average 
of 95% knockdown of Elf5 expression relative to the 100pmol control. Further 
increases in the amount of siRNA transfection only reduced the relative knockdown. 
The 733 siRNA showed a smaller knockdown efficiency. 
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Figure  3.2-2: Optimisation of Elf5 knockdown by altering siRNA concentration. Elf5 expression was 
normalised to β-Actin expression and is given relative to the appropriate control transfected with the same 
amount of siRNA control oligonucleotide. The average control normalised expression was set at 1. Bars 
show relative Elf5 expression +/- sem, n=3. 
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3.2.2.3 Estimation of Transfection Efficiency 
Once the optimal efficiency had been achieved as measured by Elf5 knockdown, to 
allow an estimate of transfection efficiency, the siRNA fluorescent oligo (Invitrogen 
Life Technologies) was transfected into TS cells following the optimised protocol. 
Unfortunately 100pmol of fluorescent oligonucleotide was unable to give a strong 
enough signal (photo not shown) to be detected by fluorescent microscopy (section 
 2.2.1.11). The fluorescent labelled siRNA had to be transfected at 240pmol for a clear 
signal to be seen. Although this deviated from the optimised protocol it still gives some 
indication of transfection efficiency.  The fluorescent siRNA oligo is designed to 
localise primarily to the nucleus. Figure 3.2-3 shows a merged bright field and 
fluorescent photo taken of TS cells using a 10x objective. Fluorescence was mainly 
concentrated in the nucleus of cells; however, a high proportion of cells showed a 
green hue indicating high transfection efficiency. At least some fluorescence was 
estimated to be seen in 80-90% of cells.  
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Figure  3.2-3: x10 bright field and fluorescent merged photo of TS cells transfected with 240pmol of fluorescent 
oligonucleotide. Fluorescence has been artificially coloured green. 
3.2.3 Measurement of an siRNA Induced Interferon Response 
To ensure an interferon response was not being initiated by treatment of TS cells with 
siRNA, the expression of the genes Interferon α-4 (Ifnα4) and Interferon-β (Ifnβ) were 
measured. Both of these genes are members of the type I interferons, which are 
induced by viral infection (Samuel). Primers were designed using the mRNA reference 
sequence for these genes ( 2.1.3.6). The Interferon genes did not contain any introns. 
To ensure the primer pairs worked the primers were used in a PCR reaction (section 
 2.2.2.9) with mouse genomic DNA. Each primer set gave a product of the correct size 
as indicated by running the PCR products on an agarose gel (not shown).  An aliquot 
of the PCR product for each primer pair was used as a positive control for real-time 
PCR analysis. Figure  3.2-4 shows the results of the relative expression of both Ifnα4 
and Ifnβ in 337 siRNA treated TS cells and non-transfected control cells. There was no 
significant difference in expression between siRNA treated cells for Ifnα4 (P=0.60) or 
Ifnβ (P=0.46). 
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Figure  3.2-4: Relative Expression of Interferon-alpha4 and Interferon-beta in TS cells transfected with 337 
siRNA and non-transfected controls. Interferon expression was normalised to Gapdh expression and expressed 
relative to the control (set at 1) +/- standard deviation; n=5. There was no significant difference berween siRNA 
treated cells with the control: Interferon-alpha 4 P=0.60; Interferon-beta P=0.46. 
3.3 EFFECTS OF Elf5 KNOCKDOWN ON TS CELLS: CANDIDATE 
GENE EXPRESSION AND MORPHOLOGICAL CHANGES 
Subsequent to achieving an acceptable level of knockdown, the effects of reduction of 
Elf5 expression in TS cells were studied. Real-time PCR analysis was done on samples 
successfully showing Elf5 knockdown for selected genes reported to be involved in 
trophoblast maintenance and differentiation. This candidate gene approach was hoped 
to identify downstream target genes of Elf5 in TS cells. During the course of this work 
several problems were identified in the protocol used for isolation of RNA through to 
analysis of expression using real time PCR ( 2.2.3.1) to develop a new protocol 
( 2.2.3.2).  
3.3.1 Protocol changes 
The original procedure given in section  2.2.3.1 was taken from an in-house lab 
protocol. Following siRNA transfection ( 2.2.1.7.3), cells were harvested with Tryple 
(Invitrogen Life Technologies) and then RNA extraction done with TRIZOL reagent 
(Invitrogen life technologies, NZ). A DNase treatment was performed, and the total 
RNA reverse transcribed to produce cDNA. Finally, real-time PCR was used to 
 75
measure the relative expression of cDNA transcripts. During the course of this work a 
number of problems were encountered with this protocol. Subsequently modifications 
were made to this protocol. The modifications and reasons for the changes are given 
for each section. 
3.3.1.1 Original Results 
Original real-time PCR results showed several problems:  
1. The raw Ct data for the housekeeper gene (β-Actin) was highly variable  
This observation could not be explained simply by different numbers of cells harvested 
because all wells in an experiment were seeded in an identical way, and therefore 
should have relatively consistent levels of RNA. However the Ct value for β-Actin 
could vary by 9 units (Table  3.3-1). Given an amplification efficiency of 2, that is a 
doubling every cycle, 9 Ct units corresponds to a 29 fold difference, i.e. greater than a 
500 fold difference in the level of β-Actin between two samples. Although the relative 
level of Elf5 was of interest, which did change as β-Actin changed, this problem was of 
concern as it indicates large variation in the efficiency of RNA extraction and/or 
reverse transcription between samples. 
Table  3.3-1: An example of the variation in β Actin Ct which could be measured using real-time PCR following 
RNA harvesting and reverse transcription. The cells were all seeded at the same density so variation in cell 
number does not account for observed variation. 
Treatment Average β- Actin Ct Standard deviation (n=2) 
Elf5-337 33.82 0.05 
siRNA negative control 24.96 0.52 
Elf5-337 32.14 0.49 
siRNA negative control 30.04 0.12 
Flourescent Oligo 38.30 0.13 
TS medium  32.70 0.02 
TS medium +F4H 32.64 0.01 
Normal growth medium 25.84 0.34 
TS medium + activin 28.81 0.12 
Normal growth medium 37.11 0.12 
 
2. The DNase treatment was not very efficient 
After RNA isolation with TRIZOL and an ethanol precipitation RNA was 
resuspended in 15µl of RNase free water and treated with 1µl of amplification grade 
DNase enzyme to remove contaminating DNA. Contaminating DNA can also be 
amplified during the quantitative RT-PCR reaction (especially for genes not containing 
introns and for which pseudogenes exist). The reaction proceeded at 37°C for 30 
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minutes. After this the RNA sample was purified using ethanol precipitation and 
resuspended in 11µl of RNase free water. The entire total RNA sample was used in the 
reverse transcription reaction except for 1µl, which was resuspended in 19µl of TE 
buffer to give the reverse transcription negative (RT-) control. Each sample analysed 
by real time PCR had its corresponding RT- sample analysed with a housekeeping 
primer set, such as β-Actin or Gapdh, to check for the level of DNA contamination. 
DNA contamination is indicated by the β-Actin/Gapdh Ct of the RT- sample being 
similar to the cDNA β-Actin/Gapdh Ct. Although some experiments had very high Cts 
for the RT- sample (indicating low DNA contamination), others showed definite DNA 
contamination, and therefore had to be discarded.  
 
To correct for this error the amplification grade DNase I enzyme (Invitrogen Life 
Technologies) protocol was consulted. The protocol suggests 1µl of DNase enzyme 
per 1µg RNA sample. By analysing a selection of total RNA samples with the 
Nanodrop spectrometer (Nanodrop Technologies, USA) it was found these varied 
considerably in concentration, however the average sample amount was about 4µg of 
total RNA. The level of DNase used in each DNase reaction was increased 4-fold to 
4µl, and the time of incubation increased to 1 hour. Corresponding changes in volume 
were made for the other reagents. 
Table  3.3-2: Changing the DNase protocol reduced the level of DNA contamination. The Ct for Gapdh is shown 
for a cDNA and corresponding RT- sample using the original protocol of 1µl of DNAse I. The results from an 
experiment where 4µl of DNase I were used are also shown. The change in the amount of enzyme used greatly 
reduced the level of DNA contamination. 
  1µl of Dnase I for 30 minutes 4µl of Dnase I for 60 minutes 
Sample 
Number 
1/20 cDNA Gapdh 
Ct 
1/20 Gapdh 
Rt- 
1/20 cDNA Gapdh 
Ct 
1/20 Gapdh 
Rt- 
1 24.45 26.58 22.07 30.47 
2 24.16 23.80 26.93 32.31 
3 24.21 24.21 21.85 29.63 
4 24.63 25.78 19.07 30.37 
5 24.28 24.24 20.61 30.15 
6 22.91 22.07 18.10 29.21 
7 23.41 23.99 21.52 32.77 
8 23.77 23.13 17.86 29.88 
9 23.22 22.22 16.66 31.46 
10 24.38 25.28 19.56 28.55 
11 24.84 25.13 20.08 28.58 
12 25.32 25.03 22.85 30.65 
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3.3.1.2 RNA degradation during the Cell harvesting 
During isolation of RNA for the microarray the total RNA samples were run on a gel 
to check RNA quality as indicated by the clear presence of sharp ribosomal RNA 
bands. Unfortunately most of the isolated RNA samples showed RNA 
degradation/poor isolation as seen in Figure  3.3-1: RNA samples showing 
degradation. 1µl of isolated RNA was run on a 1.4% agarose gel to check to see that 
the two rRNA bands could clearly be seen. One sample was chosen at random from 
the 12 samples of RNA which were to be used for the microarray. The TS only sample 
could easily be seen, however the other samples run did not have clear rRNA bands 
indicating possible RNA degradation.. Upon suggestion of a colleague (Dr. David 
Pearton) the dispersion of the cells using the recombinant Trypsin enzyme could be a 
possible source of RNases. The TRIZOL information sheet was obtained from 
Invitrogen (Invitrogen life technologies, 2003) and this also mentioned Trypsin 
digestion of cells as a source of RNases. The manufacturers advise applying TRIZOL 
directly to cells in the culture dishes after rinsing with PBS. This advice was followed. 
 
TS         TS +       TS  +    siRNA   Normal   1kb 
Only     f4H       Activin       733     medium ladder  
 
Figure  3.3-1: RNA samples showing degradation. 1µl of isolated RNA was run on a 1.4% agarose gel to check to 
see that the two rRNA bands could clearly be seen. One sample was chosen at random from the 12 samples of 
RNA which were to be used for the microarray. The TS only sample could easily be seen, however the other 
samples run did not have clear rRNA bands indicating possible RNA degradation. 
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RNA samples extracted after this protocol change showed good quality as seen by gel 
analysis (Figure  5.1-1) and the raw housekeeper Ct was also a lot less variable between 
samples. These results indicate the recombinant Trypsin enzyme had been a likely 
source of RNase contamination. 
3.3.2 Candidate Gene Analysis 
Using a set of RNA samples which had greater than 80% Elf5 knockdown, the relative 
expression of a number of genes known to be involved in TS cell differentiation was 
analysed by real time PCR. The ABI machine was used and the amplification calculated 
for each gene primer set using a dilution series of one of the samples (section  2.2.3.3). 
The relative expression was calculated compared to a siRNA negative control set of 
samples. The candidate genes screened and a brief description of their role in TS cells 
is given in Table 1: 2.2-1. A total of 16 genes were screened, however primer sets for 
Ets2, Stra13, Gcm1 and Mash2 did not give a DNA product, or if there was one it was 
at the limit of detection and not linear in amplification. The results from the relative 
expression of the primer sets are shown in Figure  3.3-2. Also included is a sample 
grown in medium without Fgf4 or Activin. No error bars or p values could be calculated 
for the relative expression of this sample because it was a single sample. 
 
Table  3.3-3: Candidate genes analysed in Elf5 siRNA samples. TE= trophectoderm, EXE=extra-embryonic 
ectoderm, TS= trophoblast stem cell 
Gene Name Function in Trophoblast Stem Cells/Mouse Embryo 
Esrrb 
Required for maintenance of ExE and chorion, knockout gives over-production of 
giant cells 
Mash2/Ascl2 
Spongiotrophoblast marker, deletion results in loss of spongiotrophoblast and 
increase in giant cells 
Hand1 
Expressed in EPC and giant cells, required for giant cell formation, over-expression 
causes TS cells to differentiate in to  giant cells 
Gcm1 Required for syncytiotrophoblast formation 
Tbr2/eomes Extra-embryonic ectoderm marker, required for maintenance of proliferation 
Fgfr2 Receptor for Fgf4 signalling, required for proliferation of TS cells and the ExE 
Tcfap2c 
Required for extra-embryonic lineages, knockouts die by E8.5, however still are able 
to gastrulate 
Bmp4 Expressed in ExE 
Ehox 
Expressed in EXE, chorion and chorionic trophoblast of the labyrinth, also in TS 
cells 
Stra13 
Expressed in  giant cells, required for giant cell formation, over-expression in TS 
cells leads to giant cell formation 
Cdx2 Earliest known TE specific gene. Required for ExE formation 
Spc4/Pace4 Protease secreted by the ExE, cleaves Nodal 
Furin/Spc1 Protease secreted by the ExE, cleaves Nodal 
Nodal Expressed in the TE, required for up regulation of Fgf4 signalling from the epiblast 
Ets2 Required for development of the extra-embryonic ectoderm 
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Figure  3.3-2: Relative Expression of candidate genes measured in TS cells treated with Elf5 337 siRNA. The average of three samples is shown +/- the standard deviation. The candidate gene 
expression of a sample deprived of Fgf4 and Activin for 24 hours is also shown, however no error bars can be shown since itt was a single sample *=significant (P<0.05)n=3 except for the no growth 
factor sample where n=1.
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The only gene that was significant after calculation of P values using the students T test 
was Elf5with a p value of 0.002. Eomes and Furin had low p values just above 0.05 of 
0.06 and 0.08 respectively.  
3.3.3 Morphological Effects of transient Elf5 knockdown 
Elf5 is known to be important for maintaining the stem cell nature of mTS cells; 
down-regulation of Elf5 occurs concomitantly with differentiation (Donnison et al., 
2005) The predominant differentiated cell type observed in cell culture is the giant cell.  
As the name implies giant cells are much larger than their TS cell precursors, they are 
flat cells with large nuclei containing many copies of the DNA due to their interesting 
ability to replicate their DNA without undergoing mitosis (Simmons et al., 2007). The 
day after Elf5 337 siRNA transfection, mTS cells were observed to see if there was an 
increase in the frequency of giant cells. A sample grown for twenty four hours without 
Fgf4 or Activin growth factors was also analysed. No morphological changes in the 
cells were observed in either siRNA treated TS cells or TS cells deprived of growth 
factors. This observation was also confirmed by using flow cytometery (FC) to see if 
an increase in DNA (stained with Propidium Iodide) per cell could be observed.  
The reason for this observation is that the time period is too short to allow 
morphological changes to occur. In other reports differentiation of mTS cells to the 
giant cell fate is only clearly observed four days after removal of growth factors 
(Erlebacher et al., 2004). 
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Figure  3.3-3: DNA content analysis by flow cytometry showed no increase in DNA content twenty four hours 
following Elf5 337 siRNA transfection or growth factor removal. Cells were gated depending on their DNA 
content and are expressed as a % of the total cells analysed by flow cytometry.  
 
3.4 SUMMARY 
Successful siRNA mediated Elf5 knockdown was achieved. The siRNA which targets 
nucleotide position 337 in the Elf5 mRNA was optimised to give a greater than 80% 
knockdown. Furthermore, an interferon response was not induced with siRNA 
treatment.  
 
Elf5 knockdown and candidate gene expression as a result of Elf5 reduction were 
measured using real time PCR. The process from TS cell harvesting, following a 
siRNA experiment, to real time PCR analysis of the cDNA synthesised from extracted 
RNA involved many steps (including RNA isolation, DNase treatment and cDNA 
synthesis). Any one of these can introduce variation into the measured expression of a 
gene. To mitigate this, a housekeeping gene which is supposed to remain stable over 
different treatments is also measured and used to normalise samples. A large variation 
in the expression of the housekeeping gene (β-Actin) suggested there was significant 
loss of RNA in some of the samples during the steps prior to real time PCR analysis. A 
second problem observed in this process was the DNA contamination of samples 
which prevented accurate quantitation of expression. Both of these problems were 
mitigated following consultation with the manufacturer’s guides on the reagents. In 
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particular changing the protocol to lyse the cells while still in culture dishes with 
TRIZOL (Invitrogen Life Technologies) considerably improved the quality and 
consistency of RNA extracted. A recombinant Trypsin enzyme used previously to 
harvest the cells was probably a source of RNase contamination.  
 
Candidate gene analysis did not result in any genes known to be important for 
trophectoderm development as significantly changing with Elf5 knockdown. However 
Furin and Eomes could be possible targets as the p values calculated from the relative 
changes in their expression were 0.08 and 0.06 respectively. One factor contributing to 
the low significance (high p values) of candidate genes is the large standard deviation 
between samples. This is due in part to inherent biological variability, however errors in 
calculating the relative expression, such as errors in the amplification efficiency are also 
likely to contribute to this.  
 
The method of calculating the amplification efficiency was not ideal. Four serial 
dilutions were made of one of the samples being analysed and then the Ct’s graphed 
versus the dilution. Pipetting errors often resulted in graphs with a non-linear 
relationship. The amplification efficiency estimated from this therefore could contain 
considerable error. This in turn has a profound error on the calculated relative 
expression because small errors in the amplification efficiency are amplified in an 
exponential calculation.  
 
A second source of error is variation in the expression of the housekeeping gene with 
treatment (Bustin, 2002). A more accurate method of normalisation is the use of a 
normalising factor calculated from the geometric mean of multiple housekeeping genes 
(Vandesompele et al., 2002). Validation of the microarray results (Chapter 5) used this 
method of normalisation.  
 
Morphological changes such as an increase in cell ploidy were not observed. This is 
most likely due to the short time period (24 hours) following transfection. Changes in 
morphology (giant cell formation) are not reported to be seen until four days following 
complete growth factor removal(Simmons et al., 2007). 
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CHAPTER 4 : ESTABLISHING A SYSTEM FOR 
INDUCIBLE ELF5 OVER-EXPRESSION 
4.1 OVERVIEW 
The principal aim of this study was to determine the down stream targets of the Elf5 
transcription factor in mousetrophoblast stem cells (mTs). MTs cells are are in-vitro 
models for early placental development and require Elf5 for their maintenance 
(Donnison et al., 2005). One method of identifying Elf5 target genes is by artificially 
increasing the level of Elf5 expressed by mTS cells and then searching for changes in 
candidate gene expression via quantitative real time PCR or by using a microarray to 
measure global changes in gene expression. The Tet-On system (BD Biosciences-
Clontech, USA) was used to try and develop a system, whereby upon addition of 
tetracycline, Elf5 could be inducibly expressed. Development of a tetracycline 
inducible expression system for Elf5 in mTS cells involves three steps: 
1. Stable transfection of the inducing plasmid pTet-On and screening for the cell line 
which produces the greatest induction using a tet-responsive luciferase reporter gene. 
This was assayed using either the dual or single luciferase assay systems (Promega 
Corporation, 2005). 
2. Construction, using standard molecular biology cloning techniques, of the 
tetracycline responsive Elf5 expression plasmid, ‘pTRE-Elf5’. 
3. Stable transfection of the best pTet-On cell line with pTRE-Elf5 and screening of 
this using RT-real time PCR to check for best induction of Elf5 mRNA. 
4.1.1 Target Gene Over-Expression Systems 
One way of artificially increasing Elf5 expression is to transiently transfect growing 
cells with a vector expressing the Elf5 gene or cDNA under the control of a strong 
mammalian promoter such as the human cytomegalovirus promoter/enhancer (pCMV).  
However during a transfection experiment not all cells take up the foreign DNA and 
those that do can take up different numbers of copies; therefore the expression of the 
exogenous gene varies between cells. To measure gene expression changes using real-
time PCR or a microarray cells, are harvested and their mRNA extracted. If all cells 
from a transfection experiment are harvested, then the effects of the exogenous gene 
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are averaged across all cells, many of which will not have received any copies of the 
transgene. One way to obtain a more pure population of transfected cells is to sort the 
cells using fluorescent activated cell sorting (FACS), however the transfected vector 
must also code for a fluorescent protein for this system to be used. Long term effects 
of a change in gene expression cannot be analysed using a transient transfection 
because as cells grow and divide the number of copies each cell carries is diluted, until 
eventually the level of exogenous expression per cell is too small to have a significant 
effect.  
These drawbacks can be overcome by stably integrating the gene of interest (Elf5) into 
the genome under the control of an inducible system; such that expression of the gene 
can be turned on or off. This allows a homogeneous population of cells expressing the 
Elf5 gene under the experimenters control to be used in analyzing the effects of 
increasing Elf5 expression. Because expression is inducible the length of time of ‘over-
expression’ can be controlled, allowing a time course of expression changes to be 
measured and a suitable control of non-induced cells is easily obtained. 
 
4.1.2 The Tetracycline Inducible system 
Various inducible eukaryotic promoters exist can which be used to induce an adjacent 
target gene’s expression in response to a stimuli, for example heavy metal ions, heat 
shock or hormones. However the effects of the stimuli can also induce undesirable 
changes in gene expression, induction of the gene be slow (up to days) and can have a 
low induction due to the leakiness of the commonly used eukaryotic promoters 
(Gossen et al., 1993). In contrast, use of a tetracycline-response promoter gives tight 
on/off regulation in a short amount of time (30 minutes), high levels of induction 
compared to other promoters (Yin et al., 1996) and because it recognises a prokaryotic  
target sequence it is highly specific and does not induce other genes (BD Biosciences 
Clontech, 2005) 
Tetracycline and its derivatives all share an identical four-ringed carbo-cyclic skeleton. 
In Prokaryotes tetracycline based antibiotics bind to the 30s ribosomal subunit and 
prevent protein synthesis.  Resistance is obtained in E.coli by expressing the TetA 
protein which exchanges a proton for the outward transport of tetracycline-Mg2+ 
complex from the cytosol. However at high concentrations of TetA protein, cations 
 85
are transported at such a high rate the cell can become depolarised and die. Therefore 
expression of the TetA protein is tightly regulated by the Tetracycline repressor protein 
(TetR). In the absence of tetracycline the Tet-Repressor protein (TetR) binds to the tet 
operator sequence and prevents transcription of the tetracycline resistance operon. In 
the presence of tetracycline the TetR protein cannot bind to the promoter sequence of 
the tetracycline resistance operon and transcription can proceed (Sambrook & Russel, 
2001a). 
Gossen and Bujard (1992) fused the TetR protein with the VP16 C-Terminal activation 
domain of the Herpes Simplex Virus (HSV) to create a hybrid activator protein called 
the tetracycline-controlled transactivator (tTA). The tTA protein, upon tetracycline 
removal, could be used to induce expression up to 100,000 fold of a luciferase reporter 
gene fused to a minimal CMV promoter (lacking the enhancer) and seven repeats of 
the TetR binding sequence from the tetracycline operator (Gossen & Bujard, 1992). Of 
interest is the fact that after HeLa cell lines had been established which stably 
expressed the tTA protein and were screened by transient transfection with the 
luciferase reporter construct, in those which showed induction of luciferase the tTA 
protein could not be detected by western blot. This shows that the cells which were 
active had a very low intracellular concentration of tTA protein. The authors suggest 
that there could be a selection against effects caused by high concentrations of the 
VP16-activating domain. One of these positive clones was then stably transfected with 
the luciferase reporter construct and the cells screened again for their ability to induce 
luciferase when tetracycline was removed. Once again of interest is the fact that a 
greater than 500 fold variation in luciferase protein expression (relative light units/μg 
of protein) was seen both with and without tetracycline induction. The authors suggest 
this is due to differences in the integration site and the number of units integrated. 
These observations highlight the need to screen a large number of clones before a 
suitable clone is found which shows high induction of the response gene and a low 
background. A disadvantage of the system described by Gossen and Bujard (1992) is 
that to prevent expression of the response gene, cells must be maintained in a 
tetracycline containing medium. An advance on this system was later developed 
(Gossen et al., 1995b) where four amino acids in the tTA protein were exchanged 
to allow the protein to act in reverse; upon tetracycline addition it bound DNA, 
and in the absence of tetracycline it was no longer active. This protein is given 
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the name of reverse tetracycline controlled transactivator (rtTA) and this forms 
the basis for the tetracycline on (Tet-On) system. More than a 1000-fold 
induction was achieved using this system. 
4.1.2.1 The Tet-On system 
The Tet-On system works by firstly the constitutive expression by mammalian cells of 
the rtTA protein which is stably integrated into the genome. Secondly, a construct 
containing the gene of interest fused to the tetracycline response element (TRE) which 
contains seven repeats of the rtTA binding element. Upon addition of tetracycline (or a 
tetracycline analogue such as doxycycline) the rtTA protein binds to the TRE element 
and induces expression of the gene of interest. Therefore there are two steps to 
establishing an Elf5 inducible system in mTS cells: the integration of the rtTA coding 
sequence into the genome and screening of these to find the best cell line;* followed by 
stable integration of a construct, where the Elf5 gene is expressed under the control of 
the TRE element into the best pTetOn cell line selected previously and screening of 
these clones.                                                                                                                           
*(Cells can be transfected with a vector carrying the gene of interest and an antibiotic 
selection marker. Selection over a period of time for cells resistant to the antibiotic 
gives several cell lines which have integrated the foreign gene into their genome. 
Integration of foreign DNA into the genome is a random process which is not well 
understood, however colonies of cells which originated from a single cell precursor can 
be isolated and analysed for their expression of the exogenous gene.  ) 
4.1.3 Preparation of DNA Vectors Used in the pTet-On System 
4.1.3.1 Propagation of Vectors 
The pTRE2hyg vector and pTetOn vector supplied by Clontech (BD Biosciences-
Clontech, California, USA) were transformed into DH5α competent cells (Invitrogen) 
following the protocol given in section  2.2.2.4. An isolated colony of each was selected 
and also grown up overnight in 250ml of LB/ampicillin broth and used to make a 
maxi-preparation. After the maxi-preparation the purified DNA was resuspended in 
TE buffer and the concentration measured using the NanoDrop spectrometer 
(NanoDrop technologies, USA); the pTetOn vector had a concentration of 1500ng/µl 
and the pTRE2hyg vector had a concentration of 4100ng/µl. To verify the correct 
 87
vectors had been transformed the pTetOn and pTRE2Hyg vectors were cut wilt 
restriction enzyme (section  2.2.2.8) pTetOn was linearised with Sca1 to give a 
characteristic 7.4kb product; pTRE2hyg was cut with Xcho1 which cuts twice giving 
3.8kb and 1.6kb products. Digests were run on a 1% agarose gel stained with ethidium 
bromide. The gel shown below after the restriction digest shows the correct vectors 
has been transformed into the bacteria and isolated successfully (Figure  4.1-1).  
The pTRE2Hyg-luciferase plasmid is also supplied in the pTet-on kit (BD Biosciences-
Clontech, USA) and expresses a luciferase reporter gene under the control of the tet-
response element. This vector can be transiently transfected into cells which are hoped 
to be expressing the rtTa (tet-activator) protein as a means of screening for induction. 
The pTRE2Hyg-luciferase plasmid was transformed into DH5α E.Coli and then a 
maxiprep prepared as described in sections  2.2.2.4 and  2.2.2.5. After maxiprep the 
concentration in TE buffer was 4320ng/µl as measured on the Nanodrop. The 
pCH110 vector (expressing β-Galactosidase enzyme) and the pRL vector (expressing 
the Renillla luciferase vector) and the pGL3P (positive luciferase control vector) were 
all obtained in-house as glycerol stocks from J. Bracegirdle. These were streaked on to 
LB/amp plates and then a colony selected which was used to make DNA 
maxipreparations. The concentration of pCH110, pRL and pGL3P following maxiprep 
was 711ng/µl, 1234ng/µl and 490ng/µl respectively.  All prepared vector DNA was 
stored at -20°C. 
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Figure  4.1-1: 1% agarose gel showing pTetOn and pTRE2hyg vectors which had been cut with Sca1 and Xcho1 
respectively.  
4.1.3.2 Subcloning the Elf5 gene into the pTRE2Hyg Vector 
For the inducible over-expression of Elf5 using the Tet-On system (Clonetech, USA) 
the Elf5 cDNA transcript was subcloned into the pTRE2Hyg vector using the 
methods described in section  2.2.4. The Elf5 gene was inserted into the pTRE2Hyg 
vector after the TRE (tet response element) so Elf5 expression could be controlled by 
this element.  
4.1.3.2.1 Subcloning Strategy 
As described in section  2.2.4.1 the vector from which the Elf5 gene was being 
removed and the pTRE2hyg vector into which Elf5 was being inserted, were analysed 
for compatible restriction sites in the correct orientation. Elf5 was removed from the 
‘BRETS-Long’ plasmid constructed by P.Huilier/B. Brophy. This vector had been 
constructed using the pcDNA3 vector (Invitrogen) and an EcoR1-Xho1 fragment of 
mouse cDNA containing the Elf5 gene with a 1kb trailer. An excerpt from the 
BRETS-Long vector is shown below in Figure  4.1-2. 
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BamH1  Sma1  Pst1  EcoR1 Xho1  Xba1  Apa1 Elf5 cDNA fragment 2195kb
 
Figure  4.1-2: excerpt from the BRETS-Long vector 
showing the Elf5 cDNA fragment and flanking restriction 
enzyme sites (not to scale). 
The pTRE2Hyg multiple cloning site (MCS) is shown in Figure  4.1-3. This also 
contains a BamH1 site at the 5’ end; however no matching restriction enzyme site was 
available at the 3’ end. It was decided to cut the Elf5 fragment with Xho1, this gives a 5’ 
overhang which could then be filled in using the Klenow Enzyme (Roche, Germnay) 
to give a blunt end. The target vector could be cut with EcoRV to give a corresponding 
blunt end.  
BamHI (2)
ClaI (41)
HindIII (46)
PvuII (16) NotI (33) EcoRV (60)SalI (52)
 
Figure  4.1-3: Excerpt from the pTRE2hyg vector showing 
the multiple cloning site and restriction sites 
4.1.3.2.2 Preparation of the Elf5 cDNA fragment from BRETS-Long 
The BRETS-Long vector had previously been transformed into a DH5α strain of 
E.Coli. The glycerol stock of this was streaked on to an LB-ampicillin plate. The 
following day one colony was selected and used to inoculate 250ml of LB broth 
containing ampicillin. This was grown up overnight and then used to do a maxi-
preparation as described in section  2.2.2.5. The double digest of the BRETS-Long 
vector was performed sequentially. Firstly BRETS-Long was cut with Xho1, and then a 
Klenow fill in was performed (section  2.2.4.2.2) to produce blunt ends, followed by 
Geneclean purification (QBiogene, USA; section  2.2.4.2.3). Then a restriction digest 
using BamH1 was carried out. Restriction digests were carried out according to the 
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protocol given in section  2.2.2.8. The rationale behind this was so that Klenow 
(Roche) could be used to fill in only Xho1 5’ overhang and would not interfere with the 
BamH1 cut. After this the Elf5 cDNA fragment was separated using a 1% agarose gel 
and purified from the gel using the Geneclean kit (section  2.2.4.2.5). The agarose gel 
after the restriction digest is shown in Figure 4.1-4, two products are formed; the 2.2kb 
Elf5 cDNA segment and the 5.4kb vector. 
4.1.3.2.3 Preparation of the pTRE2Hyg target Vector 
pTRE2Hyg was cut using BamH1 and EcoRV in a single digestion as described in 
section  2.2.4.3.1.  Two fragments should be produced, one of 5.3kb and the other of 
only 60bp, as a section from the multiple cloning site is removed. Following the 
restriction digest the reaction mix was treated with calf intestinal phosphatase (CIP; 
section  2.2.4.3.2) to prevent the vector self-oligomerizing during ligation. The vector 
was then purified by running on a 1% agarose gel (Figure 4.1-4) and using the 
Geneclan kit (QBiogene, USA) 
 
1        2                           3      4
 
 
 
 
 
 
Figure  4.1-4: Digested DNA Fragments for cloning. 1% agarose gel showing cut BRETS-Long (lanes 1 and 2) and 
cut pTRE2hyg (lanes 3 and 4). The two bands for BRETS-Long correspond to the Elf5 cDNA fragment  (2.2kb) 
and the 5.4kb vector fragment. Lanes 3 and 4 shown the cut pTRE2Hyg vector, the two DNA fragments are the 
5.2kb vector and the 60bp section removed from the MCS, this would have run off the end of the gel due to it’s 
small size.  
4.1.3.2.4 Ligation of Elf5 into the pTRE2Hyg vector 
T4 DNA Ligase enzyme (Invitrogen) was used to ligate the two DNA fragments 
together. The protocol is given in section  2.2.4.4. Following gel separation and 
Geneclean (QBiogene, USA) the Elf5 DNA fragment was measured using the 
Nanodrop to have a concentration of 21.9ng/µl and the pTRE2hyg vector had a 
concentration of 23.2ng/µl. 5.5µl of each DNA fragment was used to give a molar 
ratio of ~3 moles Elf5 DNA: 1 mole of pTRE2hyg DNA. 
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To work out the number of moles used the equation converting µg of DNA to pmol 
was used:  
pmol of double stranded DNA  =     µg of DNA x 1515                                     Equation 7 
                                                    Number of base pairs     
 
0.036pmol of Elf5 DNA (2200bp) was used to 0.037pmol of pTRE2hyg (5200bp). 
A control ligation was also performed using only 5.5µl of the vector DNA to check for 
the frequency of self ligation of the vector. 
4.1.3.2.5 Transformation and Minipreparation of Ligated DNA 
Transformation of both the ligation mix and the control ligation was carried out as 
given in section  2.2.4.5. The following day the LB/amp plates were inspected to check 
for the presence of colonies. The ligation control plates had one colony, indicating the 
CIP reaction had efficiently removed the 5’ phosphate residues from the vector. The 
ligation plates had 5 colonies on the low concentration plate and 30 colonies on the 
plate spread with a higher concentration of transformed bacteria. 18 colonies were 
picked and minipreps carried out as detailed in section  2.2.4.6. A clone map of the new 
vector was created using Vector NTI 10.1.1 software (Invitrogen Corporation 2005) 
and is shown in Figure  4.1-5 . Restriction analysis of the pTRE-Elf5 vector showed 
that HindIII cuts in two positions in the correct vector, giving two fragments; 6.3kb 
and 1.1kb. If the insert is in the incorrect orientation the fragments will be 6kb and 
1.4kb and if there is no insert then only a 5.3kb linear fragment will be produced.  
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Figure  4.1-5: Clone maps of pTRE-Elf5 showing HindIII restriction sites (A) when the Elf5 gene has been a 
correctly inserted  and (B) incorrectly inserted. 
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3µl of miniprep DNA was digested with HindIII enzyme (section  2.2.2.8). This was 
then run on a 2% agarose gel alongside a1kb ladder (Abgene, UK). The gel is shown in 
Figure  4.1-6 . All clones screened contained the insert, giving two bands. All clones 
also appeared to have the correct sized fragments except clone 1 which it can be seen 
the smaller of the two fragments was larger than the other clones bands; indicating it 
was 1.4kb so not in the correct orientation. Clone 10 was selected and grown up for a 
maxiprep. Some of this was used to make a glycerol stock.  The DNA was sent to the 
Waikato University sequencing facility and sequenced with a forward primer for CMV 
and a reverse primer for the poly-A globin sequence. The sequencing was successful 
and verified the sequence was correct.   
 
  1     2    3     4     5     6     7     8     9   10    11   12  13   14   15  16   17   18   19 
Figure  4.1-6: 1% agarose gel showing 1-18 DNA fragments after  digestion of miniprep samples with HindIII, 
lane 19 is a 1kb ladder (Abgene, UK). 
4.2 STABLE TRANSFECTION WITH THE PTET-ON VECTOR 
4.2.1 Pilot Experiments 
Before the stable transfection was carried out it is recommended in the pTet-On gene 
expression manual (BD Biosciences Clonetech, available from 
www.bdbiosciences.com) that the optimal concentration of selection antibiotics and 
the optimal plating density be determined. The pTet-On vector carries a Neomycin 
antibiotic selection gene to use for selection in mammalian cells. This gives transfected 
cells the ability to survive treatment with G418 (Gibco).  
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4.2.1.1 Optimisation of G418 Concentration 
MTS cells were plated at the recommended fixed cell density of 0.34 x104cells/cm2 in 
20cm2 tissue culture dishes. Six different concentrations of G418 were used between 
0µg/ml and 800µg/ml as recommended by the pTet-On manual. Cells were grown in 
70%CM + F4H + G418 media and the media was replaced every second day. The 
results are shown in Table  4.2-1: G418 antibiotic selection optimisation for mTS cells. 
 
Table  4.2-1: G418 antibiotic selection optimisation for mTS 
cells 
Concentration 
of G418 
(µg/ml)  
Day 1 (% 
dead 
compared 
to 0µg/ml) 
Day 2 (% 
dead 
compared 
to 0µg/ml) 
Day 3 (% 
dead 
compared 
to 0µg/ml) 
Day 4 (% 
dead 
compared 
to 0µg/ml) 
Day 5 (% 
dead 
compared 
to 0µg/ml) 
0 0 0 0 0 0 
50 0 0 0 0 0 
100 0 0 0 0 0 
200 0 0 0 0 0 
400 0 0 0 0 0 
800 0 0 0 <5 <5 
  
After day 5 it was observed there was still very little cell death between the cells treated 
with 0µg/ml G418 and those treated with the highest concentration of G418. The cells 
growing at 0µg/ml and 50µg/ml were also nearing confluency. All cells were then 
subcultured and split 1:20 into new 20cm2 dishes. The experiment was continued for 
two more days before it was noted that the 0µg/ml and 50µg/ml plates were again 
reaching confluency. It was decided to abandon the experiment as the range of G418 
concentrations although slowing growth at the highest concentrations was not causing 
cell death. The pTet-On manual suggests that ‘massive cell death’ should occur at 
around day 5; however this was obviously not occurring in the range trialled. A new 
experiment was begun using six concentrations of G418 between 0µg/ml and 
1500µg/ml. MTS cells were plated into 4cm2 wells at a fixed cell density of 
3x103cells/cm2. The results from this experiment are shown in Table  4.2-2. 
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Table  4.2-2: G418 antibiotic selection optimisation for mTS 
cells, second experiment 
Concentration 
of G418 
(µg/ml) 
Day 2 (% dead 
compared to 
0µg/ml) 
Day 4(% dead 
compared to 
0µg/ml) 
Day 6 (% dead 
compared to 
0µg/ml) 
Day 8 (% dead 
compared to 
0µg/ml) 
0 0 0 0 0 
200 0 0 0 0 
400 0 0 0 0 
800 <5 <5 <5 5 
1000 5 5 10 20 
1500 10 10 20 30 
 
At day nine the cells were confluent in the lowest three concentrations of antibiotics 
used. Massive cell death was still not observed at any of the antibiotic concentrations. 
It was decided to contact James Cross (University of Calgary, Canada) from whom the 
mTS cells had been sourced to ask if he had any experience using G418 on mTS cells. 
Doctor Cross informed us that the mTS cells were derived from the ROSA-26 strain 
mice. These mice constitutively express a neomycin-βGalactose fusion protein and are 
therefore G418 resistant. An alternative strategy was then decided upon: to co-
transfect the pTet-On vector with a puromycin antibiotic resistance vector. If a high 
molar ratio of pTet-On vector to puromycin resitance vector is used, for example 10:1, 
then there is a high chance that cells resistant to puromycin will also be carrying the 
pTet-On vector. 
4.2.1.2 Optimisation of Puromycin Antibiotic Selection Concentration 
MTS cells were plated out at a fixed concentration of 3.3x103cells/cm2 in six 4cm2 
wells. 70%CM + F4H media was added containing different concentrations of 
puromycin in the range 0µg/ml to 10µg/ml as recommended by the Tet On gene 
expression systems manual. The results are shown below in 
 
Table  4.2-3. 
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 Table  4.2-3 Optimisation of puromycin antibiotic for selection in mTS cells 
Concentration 
of puromycin 
(µg/ml) 
Day 1 (% dead 
compared to 
0µg/ml) 
Day 2(% dead 
compared to 
0µg/ml) 
0 0 0 
1 80 100 
2.5 100 100 
5 100 100 
7.5 100 100 
10 100 100 
 
The minimum concentration which caused cell death was 1µg/ml of puromycin. I was 
surprised at the rapid cell death, and I thought perhaps this was due to the medium 
containing puromycin before the cells had even adhered to the plate. The experiment 
was repeated, however the cells were allowed to adhere for a day in media free of 
antibiotics before puromycin was added the following day. The same results were 
observed. A literature search also gave the optimal concentration of puromycin for 
selection of mTS cells as 1µg/ml (Quinn et al., 2006).  
4.2.1.3 Optimisation of Plating mTS Cell Density When Using Puromycin 
Selection 
If cells are plated at too high a density during antibiotic selection, cells will reach 
confluency before selection takes effect (BD Biosciences Clontech, 2005). Optimal 
plating density depends on cell doubling time and cell surface area. Following the 
recommendations in the pTet-On manual mTS cells were plated out at cell densities 
varying from 3.3x105cells/4cm2 well to 0.063x105cells/4cm2 well. The results are shown 
in  
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Table  4.2-4.  
 
 
 
Table  4.2-4: Opimisation of plating density when using 
puromycin selection in mTS cells 
Plating Cell 
Density at 
Day 0 in a 
4cm2 well  
(x105 cells) 
Day 1  Day 2 Day 3 Day 4 
3.3 confluent confluent confluent  confluent 
0.6 Small amount 
of death 
60% dead 90% dead All dead 
0.3 Small amount 
of death 
90% dead All dead All dead 
0.13 Small amount 
of death 
90% dead All dead All dead 
0.06 All dead All dead All dead All dead 
 
The highest plating density which still caused massive cell death before the cells reach 
confluence was 0.6x105cells/4cm2. This corresponds to a cell plating density of 
9x105cells/60cm2 dish.  
4.2.1.4 Conclusions from pilot experiments 
The mTS cells were found to be resistant to G418 selection; high concentrations of 
G418 were used in an attempt to cause cell death and after communication with James 
Cross it was discovered that the cells express a neomycin resistance fusion protein 
which explains the results. As an alternative it was decided to use puromycin antibiotic 
selection, by cotransfecting with pTet-On and a puromycin resistance cassette. The 
optimum concentration of puromycin to be used for antibiotic selection was found to 
be 1µg/ml. This value was confirmed in the literature (Quinn et al., 2006). The optimal 
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plating density was found to be 9x105cells/60cm2 dish. The stable transfection will be 
carried out in a 10cm2 dish which had previously been plated at a density of 4x105cells. 
MTS cell have a doubling time of approximately 24hours (Erlebacher et al., 2004). By 
the time these cells are ready to be plated out for selection this will be two days after 
initial seeding; each well will contain approximately 16x105cells. Cells can then be 
subcultured from each well into two 60cm2 dishes to give a seeding density of 
8x105cells/60cm2, which is slightly below the optimal density. This means cells will be 
diluted 1:12, this is in agreement with the Lipofectamine 2000 protocol (Invitrogen 
Life Technologies, , 2006) which suggests a dilution of 1:10 or greater during 
establishment of a stable cell line.  
4.2.2 Transfection and Screening of mTS cells to create a stable line 
expressing the pTet-On vector 
The first step in establishing an inducible cell line is the establishment of a cell line 
expressing the rtTa protein. A total of three separate co-transfection experiments were 
carried out on the mTS cells with the pTet-On vector (which contains the rtTa coding 
sequence) and the puromycin resistance cassette. Transfections were carried out as 
described in section  2.2.1.7 for establishing a stable cell line; briefly transfections were 
carried out in 6-well plates with one well non-transfected to serve as a control. The 
following day each well was subcultured to give a low concentration of cells to allow 
for selection. Twenty four hours later puromycin was applied at 1µg/ml. Although the 
mechanism is not well understood the foreign DNA can be randomly inserted into the 
genome of a transfected cell. A molar ratio was used so there would be a higher 
number of pTet-On vectors in relation to the puromycin cassette to increase the 
chance that cells resistant to puromycin would also carry the rtTA gene. The 
puromycin resistant cell colonies were then screened with a luciferase reporter gene 
under the control of the TRE element to find the cell line with the greatest ability to 
induce expression in the presence of doxycycline. The specific details relating to each 
transfection experiment and their results are given below. 
4.2.2.1  The first pTet-On co-transfection 
Mouse TS cells obtained from James Cross and at passage 2 at Ruakura  were plated 
into one six well plate at the optimal density of 4 x105 cells per well. The following day 
cells were transfected using a molar ratio of 10 pTet-On : 1 puromycin. The pTet-On 
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vector is 7.4 kb. The Puromycin resistance construct was supplied by Craig Smith and I 
was informed it was 6kb.  
There are two ways of selecting a clone of cells which are resistant to the selection 
antibiotic. One method is to dilute the cells and plate them into a 96 well tissue culture 
dish at a concentration which will give 1-2 cells per-well. The other method is to plate 
cells at a low density into a single large plate. Both methods aim to plate cells at a very 
low density so that any resistant colonies which form have a higher chance of being 
derived from a single cell. As this was the first time a stable transfection had been 
carried out both methods were tried. The day after transfection cells were treated with 
TRYple (Invitrogen) and a cell count performed. Each transfected well of cells was 
then diluted to give a concentration of 200 cells/ml. 10µl of the diluted cell suspension 
was pipetted into each well of a 96 well tissue culture plate and then 150µl of 70% CM 
+ F4H added. This should dilute cells so that 1-2 single cells should be present in each 
well. One 96 well dish was used per transfected well. One 100mm dish per transfected 
well was also plated with approximately 1000 cells per dish. The following day the 
media was changed and 1µg/ml of puromycin added. The media was changed every 
second day always with puromycin. 96 well plates were inspected for colonies; wells 
containing greater than one colony were not used. 10 days after first adding antibiotics 
colonies of cells were clearly visible and were selected. 12 large colonies were ‘picked’ 
as described in section  2.2.1.7.5 from the 100mm dishes and the wells containing a 
single colony in the 96 well dishes were subcultured. All new cell lines were plated 
individually into a well of a 6-well plate. After 8 days these had grown sufficiently to be 
frozen down until they could be screened with the luciferase reporter assay. 
4.2.2.2 The Second pTet-On Transfection 
The procedure was exactly the same as for the first transfection, except mTS cells were 
at passage 6 at transfection and selection was only carried out by plating each well into 
two 100mm plates; this was because this method of selecting an antibiotic resistant cell 
line was more successful in the first co-transfection experiment. It was observed that a 
low number of cells plated as single cells in the 96 well plate format went on to grow 
and divide, and more clones could be obtained by plating cells post-transfection in 
100mm plates. After the second transfection the individual cell lines were grown up in 
6-well plates and frozen down. They were later removed and screened for inducibility 
using the luciferase reporter assay. Cell lines were labelled by transfection number  
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followed by line number, for example cell line 1.1 refers to a cell line from transfection 
1, cell line 1. 
4.2.2.3 Screening of Cells from Transfections One and Two 
Prospective pTet-On mTS cells were screened using a co-transfection of pTRE2Hyg-
luc (firefly luciferase response vector) with the pCH110 vector (expresses β-
Galactosidase constitutively). A 1:1 mass ratio was used between pTRE2Hyg-luc and 
pCH110, which corresponded to a 1:1 molar ratio since the vectors are about the same 
size (7kb and 7.1kb respectively). Each cell line was grown up and used to seed two 
wells of a 12-well plate. They were then transfected as described in section  2.2.1.7.6 
except that for the first assay none of the controls were included. Following 
transfection one of the wells for each line had doxycycline added (1µg/ml) and the 
other was the control well to compare for induction. 48 hours after transfection of the 
reporter gene constructs cell lysates were harvested and assayed for luciferase 
expression (section  2.2.2.1) and β-Galactosidase expression (section  2.2.2.2). 
Luciferase measurements were made in triplicate and β-Galactosidase measurements 
made in duplicate. For each cell line luciferase expression was normalised by dividing it 
by β-Galactosidase expression. The normalised induced luciferase expression was then 
divided by the non-induced luciferase expression level to give the relative induction for 
each cell line. Cells were screened in batches of six to ten and in total 48 cell lines were 
tested for luciferase induction from stable transfections one and two. 
 
Early after the first screening experiment it was discovered that the mTS cells were 
derived from a mouse line which constitutively expresses β-Galactosidase (the Rosa26 
mouse line; James Cross, personal communication). Therefore β-Galactosidase is not 
ideal as a normalising reporter gene, as it is more correlated to absolute cell number 
than transfection efficiency. This will especially be the case if the transfection efficiency 
is low. However at high transfection efficiency the transient expression of β-
Galactosidase would be a more dominant component of the total β-Galactosidase 
expression. Due to the expected induction being greater than a hundred fold, in a good 
cell line, it was thought that β-Galactosidase normalisation although not ideal, would 
suffice.  
4.2.2.3.1 Inducible Luciferase Results 
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Raw luciferase results from the first 13 cell lines obtained from the first transfection are 
shown below in Figure  4.2-61. The maximum normalised induction was around 3 fold 
in line 1.5. Upon inspecting the raw measurements it was found that cells which 
expressed higher levels of induced luciferase also had high basal levels of luciferase 
(without doxycycline). It was thought that perhaps the high background levels could be 
masking the true induction.  
Luciferase Expression With or Without Doxycycline in mTS- 'pTetOn' cells
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Figure  4.2-1 Induction of a luciferase reporter gene under the TRE control in the antibiotic resistant cell 
lines. The average luciferase expression as measured by the luminometer is shown for each cell line (1.1-
1.13) +/- sem, n=3. 
4.2.2.3.2 Trouble Shooting 1: 
Tetracycline contamination of Foetal Calf serum (FCS) used in the media can be a 
problem (BD Biosciences Clontech, 2005) causing expression of the activation of the 
response gene without addition of tetracycline/doxycycline. A small amount of 
certified tetracycline free FCS was supplied in the pTet-On kit, so this was used to 
make media and then a few cell lines which appeared to show some induction from the 
first experiment were tested for induction. The graph below shows that the normalised 
induction was not increased when the certified Tetracycline free medium was used. 
From this it was concluded that tetracycline contamination in the medium was not a 
problem. 
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Figure  4.2-2: luciferase induction in cell lines 1.1, 1.3, 1.4 , 1.12 and 1.5. Cell lines were grown in certified free 
tetracycline medium to see if there was any increase in induction when compared to induction in normal medium 
without doxycycline added.  Luciferase expression was normalised to β-Galactosidase. Shown is mean induction 
level +/- sem, n=3. 
4.2.2.3.3 Trouble Shooting 2 
The next approach to ascertain the reason for the low level of induction was to test the 
doxycyline stock was sufficient to give maximum induction at the concentration used 
(1µg/ml). Doxycycline was made up in water to a concentration of 1mg/ml and, 
stored at -20˚C, can last up to 1 year. However it could have gone off and therefore be 
limiting induction. To test the doxycycline, different concentrations of doxycyline were 
used to induce expression of luciferase in mTS cells co-transfected with pTet-On and 
pTRE2hyg-Luc (as well as β-Galactosidase for normalisation). Figure  4.2-3 shows 
luciferase expression in response to different concentrations of doxycyline inducer. 
From 1µg/ml to 2µg/ml of doxycycline there was no increase in luciferase expression 
indicating doxycyline at 1µg/ml was not limiting induction. 
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Figure  4.2-3: Normalised luciferase reporter expression in the presence of varying concentrations of doxycycline 
inducer 
4.2.2.3.4 Trouble Shooting 3 
As the concentration of doxycycline in ‘no doxycycline medium’ did not increase the 
background level and the concentration of doxycycline used to induce luciferase 
expression was not limiting, the next step was to include a range of controls to try and 
ascertain the levels of luciferase which should be expressed (using a positive luciferase 
control) and to see if the background levels of luciferase was inherent, due to auto-
luminescence from the cells, or due to leakiness of the TRE-Luciferase vector. The 
controls tested were: 
1. To test that the luciferase assay was working and as an indication of the 
possible expression levels of luciferase a CMV-luciferase positive control 
plasmid (pGL3P) was obtained from J. Bracegirdle. This vector expresses the 
luciferase gene under the expression of a CMV promoter, however it lacks an 
enhancer. It therefore will express luciferase, however only basal amounts. If 
the luciferase expression from ‘PTet-On’ cells is not higher than this then it 
would appear induction is not occurring in the cells.  
2. A transient co-transfection with both the pTet-On vector and the pTRE-2hyg-
luc response vector in the presence of doxycycline to give an idea of the 
maximum induction achievable; as neither rtTA protein or luciferase response 
vector will be limiting in this scenario.  
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3. Transfection with only pTRE-2hyg-Luciferase to give an idea of the basal 
expression of luciferase without the presence of any rtTA protein and 
therefore to test the leakiness of the pTRE-Luciferase vector. 
Figure  4.2-4 shows the luciferase expression of some control samples. Mouse TS 
cells which had not previously been transfected with the pTetOn vector were co-
transfected with the pTRE-Luciferase response vector and the pTetOn vector to 
get an idea of the maximum induction in the presence of doxycyline. As can be 
seen, the maximum induction (with doxycycline/no doxycycline) is around four 
fold. The TRE-Luciferase expression is about the same as the non-induced sample. 
The Luciferase CMV positive control vector had a higher expression than the 
positive induction sample. The negative control was not transfected with either 
plasmid and had an auto-luminescence below the detectable level of the 
luminometer. 
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Figure  4.2-4: Normalised Luciferase values for controls. The combination of vectors used in each transfection is 
shown. All transfections were done in mTS cells which had not been previously transfected with the pTet-On 
vector and a β-Galactosidase vector was included for normalisation. ?; expected to contain pTetOn on the basis 
of puromycin resistance. 
4.2.2.4 Dual Luciferase Assays 
As discussed earlier luciferase results were normalised to β-Galactosidase expression, 
however β-Galactosidase was already expressed by the cells making it a less than ideal 
reporter gene. As the induction levels were not as high as expected a second method of 
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normalising the firefly luciferase was sought. The dual luciferase system (Promega, 
USA) uses the fact that the Firefly luciferase enzyme and the Renilla luciferase enzyme 
have distinct substrates. The firefly luciferase enzyme catalyses the oxidation of beetle 
luciferin using ATP while the Renilla luciferase enzyme catalyses the oxidation of 
coelenterate-luciferin (Promega Corporation, 2006). This means both luciferase 
enzymes can be assayed in one reaction mix in the luminometer; first the firefly 
luciferase luminescence is measured, this reaction is quenched and then the Renilla 
luciferase is measured. Both assays are very sensitive and linear over seven orders of 
magnitude. The normalising vector used was pRL-CMV, which expresses Renilla 
luciferase under the control of a CMV promoter/enhancer. The dual luciferase assay 
was carried out as described in section  2.2.2.3. During the assay both the luminescence 
due to the inducible firefly reporter vector and the Renilla luciferase vector were 
measured. The expression of the firefly luciferase enzyme (RLU) was then divided by 
the Renilla expression (RLU) to give a normalised ratio used in inducible calculations. 
4.2.2.4.1 Dual Luciferase Results 
The first time the dual luciferase assay was performed on cell lysate samples it was 
found the expression of Renilla far exceeded that of the firefly expression. The 
transfection was carried out using a 1:1 mass ratio of pTRE2Hyg-luc to pRl-CMV for 
each cell line as described in section  2.2.1.7.6. However the expression of Renilla was 
up to 10 fold greater than the firefly luciferase expression (Results not shown). The 
dual luciferase manual (Promega Corporation, 2006) states that “trans effects between 
promoters on co-transfected plasmids can potentially affect reporter gene expression” 
and this is especially the case when either/both vectors contain strong promoter and 
enhancer elements. Promega recommends using a relatively small quantity of the 
control reporter vector. As both vectors contain strong viral promoters the next 
experiment carried out used a 5:1 ratio of TRE2Hyg-luc to pRl-CMV.  
 The results from the first assay are shown in Figure  4.2-5
 4.2.2.3
. The two cell lines which 
had previously been identified as possibly carrying the rtTA gene were screened 
alongside the three controls described in section . The induction from cell lines 
1.5 and 2.37 was 1.3 fold and 1.2 fold respectively. The expression of the Renilla vector 
however was still around 5 times the expression of the firefly luciferase. The inducible 
control (pTetOn and pTRE2Hyg-luc transiently transfected) showed a maximum 
induction of about 10 fold. Of interest was the fact that the leakiness control (simply 
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transient transfection with pTRE2Hyg-Luc) had a similar level of un-induced 
expression as the inducible control in the absence of doxycycline.   
 
Figure  4.2-5:Results from the dual luciferase assay. Firefly luciferase expression normalised to renilla luciferase 
expression is shown in the presence or absence of 1µg/ml doxycycline for cell lines 1.5 and 2.37. The results 
from the controls checked in the assay are also shown. The controls were all mTS cells which had previously not 
been transfected with the pTetOn vector. The combination of plasmids transiently transfected into the controls 
is shown. 
All isolated cell lines were screened using the dual luciferase assay system except a 10:1 
ratio of pTRE2Hyg-luc was used to pRl-CMV. The ratio of normalised firefly 
luciferase in the presence or absence of doxycyxline for all cell lines screened is shown 
in Table 
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 4.2-5. The results show that none of the cell lines screened show an 
acceptable level of induction. It was decided to perform a third stable transfection. 
 
Table  4.2-5: Dual Luciferase results.  Induction of ‘pTET-On’ cell lines determined by induction of firefly 
luciferase normalised to Renilla luciferase expression. Cell lines previously identified as possibly displaying the 
inducible phenotype have been shaded. 
Cell line 
Normalised firefly 
luciferaseInduction 
(+dox/-dox) Cell line 
Normalised firefly 
luciferaseInduction 
(+dox/-dox) 
1.2 1.18 2.107 0.91 
2.44 0.83 2.37 1.46 
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2.98 0.79 1.3 1.09 
2.86 1.63 2.26 0.89 
2.17 0.34 2.32 1.70 
2.21 1.57 2.74 1.28 
2.42 0.78 2.40 0.77 
1.1 0.72 2.22 0.78 
2.2 2.14 2.72 0.94 
2.75 1.10 2.23 0.45 
1.13 0.46 2.36 1.06 
2.93 0.52 2.24 0.98 
2.21 0.76 2.46 0.92 
2.77 0.57 2.30 0.71 
2.73 1.02 1.8 0.77 
2.31 1.09 2.92 1.80 
1.3 1.22 2.103 1.11 
1.20 0.70 2.25 1.05 
1.14 0.36 2.99 1.35 
1.7 1.12 2.35 1.65 
2.93 0.63 2.41 0.37 
1.4 1.11 1.5 1.32 
 
4.2.2.5 pTetOn stable Transfection Three 
The previous transfections had been carried out using a circular form of the pTetOn 
vector. It was suggested that a linear form of the vector could be more successful. The 
pTetOn vector was digested using the ScaI restriction enzyme which cuts in a single 
location using the protocol described in section  2.2.2.7. The cut vector was purified 
using a phenol/chloroform extraction and ethanol precipitation. The resulting purified 
plasmid was resuspended in 20µl of TE buffer. The concentration as measured by the 
Nanodrop was 1.5µg/µl. After cutting the linearised pTetOn vector was run on a 1% 
agarose gel to check for complete digestion. The linearised puromycin cassette DNA 
supplied by C. Smith to be used for the co- transfection was also run along with its 
undigested precursor. The gel is shown in Figure  4.2-6. As it can be seen from the gel, 
the pTetOn was cut and of the correct size (7.4kb). The uncut vector had a fuzzy band 
due to super-coiling. The cut puromycin vector was 1.4kb, and the uncut version was 
4.7kb. This was a surprise as it had previously been though that the cut puromycin 
vector was simply linearised, however it had been digested to remove only the 1.4kb 
selection cassette.  
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Figure  4.2-6 1% agarose gel showing efficient restriction enzyme digest of the pTetOn and puromycin 
vectors.1) Abgene (UK) 1kb DNA ladder, 2) pTetOn linearised with ScaI digest (7.4kb), 3) pTetOn 
uncut, 4) puromycin vector cut (1.4kb), 5) puromycin vector uncut (4.7kb). 
The stable transfection was repeated at a molar ratio of 4 pTetOn vector to 1 
puromycin cassette vector; transfection conditions and growth/selection of stable cell 
lines was carried out as described in section  2.2.1.7 and section  2.2.1.8. The ratio used 
of pTetOn vector to puromycin selection vector was lower than intended because the 
volumes of DNA used had been calculated using a size of 6kb for the puromycin. 
Because of this and the low success of obtaining an inducible cell line from previous 
stable transfections it was decided to first screen the cell lines using PCR to check if 
they were carrying the rtTA gene. During expansion of the cell lines, each cell line was 
plated into two wells of a six-well plate. When these wells were approximately 70-90% 
confluent one well was used to freeze down the cell line and the other was treated with 
TRYple (Invitrogen) and then screened for presence of the rtTA gene as described in 
section  2.2.1.9. In total 115 cell lines were isolated. 
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 4.2.2.5.1 PCR Screening for the rtTA gene: Results 
Following crude extraction of genomic DNA from each cell line, five samples were 
selected and 1µl of each analysed on the Nanodrop (Nanodrop technologies, USA) for 
concentration, as about 100ng of DNA is best for a PCR reaction. The samples 
contained a wide range of DNA but the average was about 300ng/µl (data not shown). 
Thus 0.5µl was used as template each PCR reaction. Following the PCR, 8µl of each 
reaction was run on a 2% agarose gel. As a positive control 1.4ng of pTet-On plasmid 
was used for PCR and electrophoresed. The negative control was genomic DNA 
extracted alongside the sample from several wells of mTS cells and mEFs which had 
not been transfected with the pTetOn vector. An example of one of the gels is shown 
below. 
 
 
 3.91  3.71  3.92  3.27  3.70 3.36  3.6   3.75 3.33 3.12  3.4  pos  neg  pos   neg       100bp 
                                                                                                                               ladder 
100bp
200bp 
300bp 
 
Figure  4.2-7: PCR Screening for rtTA positive controls. A 2% agarose gel loaded with the PCR product using 
rtTA primers with genomic DNA from several puromycin resistant cell lines (cell lines labelled 3.91-3.4). A 
positive control (pTetOn plasmid DNA) and negative control (non-transfected cell lines) were also run. The last 
lane is a 100bp ladder (Abgene) the rtTA pCR product should be 260bp. 
In total 58 rtTA positive clones were identified and 56 negative clones. The negative 
clones were discarded. The low level (50%) of positive clones detected was most likely 
due to the higher amount of puromycin selection cassette used than intended. Due to 
time constraints the positive cell lines could not be screened for their ability to induce 
the pTRE2Hyg-Luc expression. 
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4.2.3 Discussion on Establishment of a mTS Elf5 inducible Cell Line   
A cell line inducibly expressing Elf5 using the pTetOn system was unable to be 
established due to difficulties in establishing a cell line which expressed the rtTA 
protein in a form which could inducibly activate a firefly luciferase reporter gene. 
However the Elf5 gene was successfully cloned into the pTRE2Hyg vector to create a 
vector which will be able to express Elf5 when bound to by the rtTA. 
Problems with the doxycycline inducer were ruled out as a reason why no induction 
was seen in mTS cell lines previously co-transfected with the pTetOn vector which 
carries the rtTA protein sequence. Induction in mTS cells transiently cotransfected 
with the pTetOn vector and a TRE-luciferase reporter plasmid reached a maximum at 
1µg/µl doxycycline (Figure  4.2-3). This is also reported in the literature (Gossen et al., 
1995b) where induction using rtTA began at concentrations above 100ng/µl 
doxycycline, and was maximum at 1µg/µl or above. 
 
It is believed the primary reason for not being able to establish a suitable mTS-pTetOn 
cell was the unwitting use of a high ratio of the puromycin selection cassette relative to 
the co-transfected pTetOn vector. The puromycin cassette was originally thought to be 
6kb in length, however after running the transfected vector on an agarose gel it was 
found it was only 1.4kb, as the resistance gene had been cut out of the vector. This 
caused a high proportion of cells to carry only the antibiotic selection marker and not 
the pTetOn DNA. For the third transfection a ratio of 5:1 was used of pTetOn : 
puromycin, 50% of the antibiotic resistant cell lines isolated from this transfection 
carried the rtTA gene (coded by the pTetOn vector). For the first two transfections the 
true ratio used of pTetOn to puromycin was actually 2.5:1. This correlates to 25% of 
cell lines isolated from transfection one and two could have carried the rtTA gene. In 
total 48 cell lines were screened from stable transfections one and two, meaning about 
12 of these lines could have carried the rtTA gene.  
Apart from the primary reason of an incorrect transfection ratio, there are several 
possible reasons why none of the cell lines isolated exhibited the inducible phenotype 
to a satisfactory level. The first is that some cell types may not be suitable for 
establishing the pTetOn system (Ackland-Berglund & Leib, 1995). Also it is 
recommended that at least 30 cell lines need to be screened before a suitable line is 
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found (BD Biosciences Clontech, 2005). In a similar experiment, co-transfections with 
the pTetOn vector and a G418 resistance cassette in HeLa cells gave an inducible 
phenotype in 10% of cells screened using a TRE-luciferase gene (Gossen et al., 1995a). 
If the same rate of success was achieved then only 3-4 mTS-pTetOn lines should show 
the inducible phenotype. In all HeLa cell lines which did have an inducible phenotype 
the tTA protein was not detectable by Western blots, showing it is expressed at a low 
level (Gossen & Bujard, 1992). The authors believe the reason for this is that high 
expression of the rtTA protein can be toxic, due to its VP16 activating domain. High 
numbers of cell lines need to be screened to find cell lines which are capable of 
inducing expression in the presence of tetracycline yet have copies of the rtTA gene 
integrated in chromosomal locations such as to be expressed at non-toxic levels.  
 
Finally, it has been observed that in transient transfections used to screen for rtTA 
active cell lines the level of induction is never as high as in cell lines which have the tet 
responsive gene stably integrated into the genome. This is because the background 
level of expression of the TRE-reporter gene is high in transient transfections where a 
high amount of DNA is used. A high level of TRE-reporter gene DNA can also titrate 
out the activator protein (Gossen et al., 1995a). In a stable system the TRE-gene is able 
to be integrated into a ‘transcriptionally silent but activatable’ region, giving low levels 
of background and the high levels of induction sought (>1000 fold, (Gossen et al., 
1995b)). For example it has been reported that transfection of HtTA cells in a 10cm2 
dish with 2µg of DNA gave only a 155-fold induction, however with 1ng the induction 
was 1000-fold (Gossen et al., 1995a). In the screening experiments performed here the 
amount of DNA used was that recommended by the lipofectamine protocol 
(Invitrogen life technologies, 2006), which suggests 1.6µg for a 4cm2 dish. It was also 
noticed that the level of background expression in un-induced samples of the inducible 
control was about that of only the pTRE2Hyg-luc gene (Figure  4.2-4 and Figure 
 4.2-5). This suggests that the background expression of luciferase was due to the 
pTRE2Hyg-luc leakiness and not due to the rtTA gene activating luciferase expression 
in the absence of doxycycline. From the literature this leakiness is most likely due to 
the high amounts of DNA transfected.  
It was interesting to note that although using the first luciferase assay some cell lines 
did look like they could be working in an inducible fashion these same cell lines when 
screened later in the dual luciferase assay showed very low levels of induction. This 
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could be due to the problem of using β-Galactosidase as the normalising gene, when it 
was constitutively expressed by the cells. However it is also known that expression of a 
transgene is often silenced when the cell line is cultured over some time (Pagliaro & 
Praestegaard, 2001). The cell lines which showed some promise of being inducibly 
active were screened several times using the first luciferase assay before they were later 
grown up and screened again with the dual luciferase assay. This means some cell lines 
were perhaps 10 passages older when screened using the dual luciferase assay. Another 
point is the Renilla expression plasmid used as a ‘normaliser’ was driven by the strong 
CMV promoter/enhancer. However the β-Galactosidase gene used to normalise was 
driven by the SV40 viral promoter which is not as strong. Strong viral promoters may 
dilute out transcriptional machinery and affect the expression of the gene being 
measured. This phenomenon has been observed where the normaliser was shown to 
affect the expression of the vector of interest (Farr & Roman, 1992). The Promega 
dual luciferase manual also mentions this problem and suggests transfecting with the 
normalising vector at a higher ratio. Although a 1:10 ratio was used, this still gave very 
strong Renilla luciferase expression and a ratio of 50pTRR2Hyg-Luc : 1 Renilla vector 
could be suitable to minimise promoter cross talk effects. 
 
The use of a PCR screening process was very successful at quickly establishing which 
cell lines contained the rtTA gene, and prevents the un-necessary growth and screening 
of cell lines lacking the rtTA gene. These cell lines can now be screened using the dual 
luciferase assay, except changing the protocol to using an overall low concentration of 
DNA in the transfection, and a much lower molar ratio of the Renilla control plasmid 
relative to the pTRE2Hyg-luc reporter plasmid. These measures should allow the 
confident identification of an inducible cell line. A further option in establishing a 
tetracycline  inducible cell line is to try using the new TetOn advanced system. A 
common problem preventing high levels of induction is unacceptably high background 
levels of the gene of interest under the control of the TRE/CMV minimal promoter. 
The Tet-On advanced system contains a modified TRE/CMV minimal promoter 
which further reduces background expression increasing induction. As some 
consolation a colleague (Craig Smith) has also been trying to establish the Tet-On 
inducible system in bovine embryonic fibroblasts and out of the cell lines generated, 
using the luciferase screening test, he also found none of them exhibited the inducible 
phenotype. 
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CHAPTER 5 : GLOBAL ANALYSIS OF GENE 
EXPRESSION USING A MICROARRAY APPROACH 
5.1 OVERVIEW 
The Affymetrix GeneChip® Expression analysis platform was chosen to use for 
microarray analysis of mTS cell gene expression under different treatments. This array 
uses multiple 25-mer oligonucleotide probes per gene/expressed sequence synthesised 
at predetermined locations on a glass wafer. TS cells of equal passage number were 
treated for 24 hours with either Elf5 specific siRNAs which mediated Elf5 mRNA 
knockdown, negative control siRNA, or TS media containing different combinations 
of Fgf4 and Activin/TGFβ growth factors. Total RNA from these experiments was 
then isolated using the TRIZOL (Invitrogen Life Technologies) method and treated 
with DNase (section  2.2.5.2). Samples were pooled into groups of three and labelled 
according to the Affymetrix GeneChip expression One Cycle target labelling protocol 
(section  2.2.5.4). This consisted in making double stranded cDNA from the collected 
RNA samples using a T7 RNA polymerase oligo dT primer. From the resulting 
cDNA, cRNA was produced using the T7 RNA polymerase which incorporates 
biotinylated ribonucleotide analogues into the RNA being produced. Labelled RNA 
was then hybridized to a GeneChip Mouse genome 430 2.0 Array. Hybridisation and 
scanning of the arrays was carried out commercially at The University of Auckland’s 
Affymetrix facility. After hybridisation the array was stained with a fluorescent dye 
(SAPE) which conjugates to the biotin modified nucleotides. The array was scanned 
and the intensity of each probe set was measured to give a quantitative value for the 
expression of that gene (Affymetrix Inc., 2006a).  
 
Array Intensity data was analysed using a robust means analysis (RMA) algorithm 
(GenStat software package 9th edition; VSN international ltd, UK) which gives a 
normalised average expression level for each gene on each array. This value was then 
averaged across arrays hybridised with samples of the same treatment. Comparisons 
were carried out between control and treated samples. Using predetermined fold 
change cut-offs (section  2.2.5.7.2) genes of interest were identified for each 
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comparison. Expression values of a selection of these genes were then later verified for 
change in expression using quantitative real-time PCR. 
5.1.1 Microarray Technology 
DNA microarrays are a powerful tool to analyse the transcriptional response of a cell 
to a perturbation because they allow the simultaneous measurement of thousands of 
transcripts at once. This facilitates the identification of physical or functional 
connections between gene products (Brown & Botstein, 1999). There is a tight 
connection between the function of a gene product and its expression pattern. 
Therefore by changing the expression of Elf5, the function of this protein, i.e. its down 
stream target genes, was hoped to be determined. Futhermore, expression profiles 
from microarrays hybridised with different targets can be compared and aligned 
allowing similar cellular responses to be identified (Brown & Botstein, 1999). Thus it 
was envisioned that by analysing mTS cells under several conditions which are known 
to affect their ‘stemness’ and lead to their differentiation, such as the expression of 
Elf5 or the presence of Avtivin/Nodal and FgF4 growth factors, common networks of 
genes could be identified which are involved in maintaining the phenotype of mTS 
cells. 
Microarrays consist of a solid support surface (generally a glass slide) with thousands of 
25-75mer oligonucleotide probes fixed to the surface. The DNA/RNA sample (known 
as the target) is fluorescently labelled and applied to the microarray slide where it binds 
to complementary probes (hybridisation).  The oligo probes on a microarray are 
designed to interrogate a particular region of a target and minimise cross-hybridisation 
(Elvidge, 2006). They are either synthesised and mechanically spotted on to the array 
or, in the case of Affymetrix arrays, 25mer probe sequences are synthesised at known 
locations in situ by using light directed synthesis (Lipshutz et al., 1999). This allows 
many more probes to be put on an array than can be mechanically spotted. 
After hybridisation with the target, the array is scanned with a laser which excites the 
target associated fluorescent dye, giving an emission which estimates the relative 
amounts of different transcripts present (Allison et al., 2006). The sample target applied 
to the array can be either cDNA or cRNA. In a cDNA microarray mRNA from 
samples to be compared is reverse transcribed and concomitantly labelled with either 
Cy3 or Cy5 fluorescent dyes. These two different labelled samples are co-hybridised to 
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one array and then the Cy3 and Cy5 fluorescence measured separately. A merged 
image is produced which gives the relative expression from each sample. In a cRNA 
microarray experiment cDNA is also produced from the mRNA sample, this is then 
converted to double stranded cDNA and then to biotinylated cRNA. In this case only 
a single colour of fluorescence is hybridised to each array (Allison et al., 2006).  
5.1.2 Technical Aspects of the Microarray Experiment 
5.1.2.1 Choice of a Microarray Platform 
Gene-expression measurements using hybridization technology, has become a 
common technique in biomedical research. A comprehensive study of the intra-
platform, inter-platform and inter-laboratory reproducibility of ten different platforms 
available for gene-expression studies was carried out by Kuo et al. (2006). The results 
showed that the most consistent results were achieved by commercially available 
platforms rather than arrays generated ‘in house’ (Kuo et al., 2006), and platforms 
which used one dye were more consistent than two-dye platforms. Overall the 
Affymetrix GeneChip® commercially produced one-dye platform appeared to 
perform the best and therefore this platform was chosen for the global analysis of gene 
expression.  
5.1.2.2 Technical aspects of the Affymetrix GeneChip array 
Affymetrix arrays are high density oligonucleotide (25mer) arrays and have the 
advantage of containing thousands more features than cDNA arrays. The high density 
arrays even allow a whole genome of probe sets to be analysed on one array; as is the 
case with the mouse 430 2.0 whole genome array used in this experiment which 
contains 45,000 probe sets. Eleven pairs of probes make up a probe set and are used to 
measure the expression of each sequence represented on the array. Therefore the 
mouse 2.0 array contains 495,000 features. Each pair consists of a perfect match probe 
(PM) and a mismatch probe (MM). The MM probe is the same as the PM probe 
except for a central base substitution and helps to determine the level of non-specific 
binding. Such a high density of features is achieved through the use of 
photolithography and solid phase DNA synthesis (Lipshutz et al., 1999). Light is 
directed to specific areas on the surface of the array, this removes photolabile 
protecting groups at that position. Hydroxyl-protected deoxynucleotides are then 
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incubated with the surface and chemically attach to areas which have previously been 
illuminated (Lipshutz et al., 1999). This process is repeated to synthesise specific DNA 
oligonucleotides at known locations.  
 
The sequence of a probe set is designed to specifically monitor the expression levels of 
as many genes as possible. A probe set is designed from a 200bp to 300bp segment of 
a transcript and then non-overlapping 25mer oligonucleotides are selected. Multiple 
oligonucleotides of different sequences designed to hybridise to different regions of 
the same mRNA improve the signal to noise ratios and reduce the chance of a falsely 
identified differentially expressed transcript; measurements on a typical eukaryotic array 
put the false positive rate as 2% (Lipshutz et al., 1999). The hybridisation signal 
intensities have been shown to be directly proportional to RNA concentration 
5.1.2.3 Image processing Algorithm 
After scanning of the arrays the raw fluorescent intensity needs to be converted into a 
numerical value which is comparable for each probe set between multiple arrays and 
treatments. Although there is some controversy over the best method, the method 
robust multi-array average (RMA) performs well or better than competitors for 
Affymetrix arrays (Allison et al., 2006). RMA analysis involves three steps: background 
correction, normalisation and summarisation. The details on the RMA process are 
given in Analysis of Microarray Data in Genstat, pages 24-26 (Baird, 2006) In brief: the 
background correction removes the mean of the lowest 2% intensities; it also fits a 
noise model to the intensities from the perfect match cells. The normalisation corrects 
the intensities over the slides so that each slide has the same profile (allowing slides to 
be compared). Finally the summary over the probes is done. This calculates the average 
intensity over the 11 probes for each gene taking into account slide effects. 
5.1.3 Microarray Design 
A crucial aspect of microarrays is biological repeats where measurements are taken 
from multiple biological cases (Allison et al., 2006), with technical repeats almost never 
required; therefore no technical repeats were  included in the design. Allison et al (2006) 
also suggest a minimum number of five biological cases per group and that “pooling 
samples can be beneficial when biological variability is high relative to measurement 
error, and when biological samples are inexpensive relative to array cost” as is the case 
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with the experiment carried out here. A further consideration in design of the 
experiment was the fact that RNA interference experiments, such as the siRNA 
experiments performed here can induce non-specific responses (Bridge et al., 2003). 
Samples from the two best siRNAs which knock down Elf5 were both used, as there is 
a low chance that the same non-specific effects will be caused by two distinct siRNA 
sequences (Echeverri et al., 2006). Also the siRNA control oligonucleotide from 
Invitrogen was used to provide a control for sequence independent effects of siRNA 
treatment (Invitrogen Life Technologies, , 2004b). 
 
An experimental design was thus decided on which included three pooled mRNA 
samples per array and either two or three arrays were used per treatment (giving a total 
of six or nine samples per treatment). The number of arrays per treatment (two or 
three) was decided on depending on how important the information gained from each 
treatment was envisioned to be.  Twelve wells of two six well plates were used for each 
treatment. Cells were of a low passage number, and were at passage 7 at the time of the 
experiment, although not all treatment experiments were carried out at the same time.  
To avoid ‘confounding extraneous factors’ (Allison et al., 2006) arrays used were from 
the same batch and all samples were processed after RNA isolation concurrently.  
5.1.4 Total RNA Isolation and Quality Assessment 
Total RNA was isolated using the TRIZOL method (Invitrogen Life Technologies) 
according to the protocol given in section  2.2.3.2 until the end of the ethanol 
precipitation after the DNase reaction. 
Three sources of variation can affect the accuracy of microarray data: biological 
variation; sample preparation (RNA extraction and labelling), and system variation 
(instrument and array variation). Due to internal controls and standardisation of 
techniques system variation is negligible (Affymetrix Inc., 2006b). To minimise 
biological variation RNA samples should be of a high quality. To assess total RNA 
quality RNA after RNA extraction 1µl of total RNA sample was removed and used for 
reverse transcription followed by real-time PCR and a second 1µl was analysed for 
concentration and purity on the Nanodrop spectrometer followed by running on an 
agarose gel (section  2.2.5.2). Any samples which failed the quality control tests were 
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discarded, and in some cases experiments had to be repeated before a satisfactory set 
of RNA samples were obtained for each treatment. 
5.1.4.1 Nanodrop Absorbance Ratio 
RNA isolated should have an absorbance ratio A260/A280 of between 1.6 and 1.9 in 
water. Ratios below 1.6 indicate protein contamination and ratios above 2.1 indicate 
degraded RNA (Affymetrix Inc., 2006b). It was also desirable to have a consistent 
concentration of total RNA, at least above 500ng/µl. The Results from Nanodrop 
analysis of all RNA samples are given in the appendix. 
5.1.4.2 Analysis of Total RNA Quality using an Agarose Gel 
Because RNA is very susceptible to degradation, it was important to check the quality 
of extracted RNA before proceeding. Both ribosomal RNA bands (18S and 28S) 
should be clearly seen on a gel (Perkel, 2006) to ensure good RNA quality. This was 
done by checking the RNA on a gel (section  2.2.2.6).  Below is a sample gel from some 
samples which were successfully isolated. As it can be seen from the gel the two 
ribosomal RNA bands can be clearly seen. Samples which did not have clear bands 
were not used for the microarray. 
 
 
1      2      3      4       5       6      7      9      10    11    12           1kb 
Figure  5.1-1: 1.4% agarose gel of RNA sucessfully extracted from 'Normal' treated mTSsamples. Samples are 
shown 1-12, and a 1kb ladder (Abgene). Two rRNA bands can clearly be seen indicating RNA is good quality. 
Another technique is to use the bioanalyser as suggested by Affymetrix. A high RNA 
Integrity number indicates good quality RNA. During a demonstration of the Agilent 
2100 Bioanalyser (Agilent Technologies Inc, 2006) five left over RNA samples which 
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had been used on the microarray and had subsequently been stored at -80°C for about 
2 months were checked. These gave RNA Integrity Numbers (RIN) between 8.5 and 
9.6 (out of a maximum value of 10). This shows the RNA used was of very good 
quality. 
 
Figure  5.1-2: Analysis of a few of the total RNA samples used in the microarray experiment using the Bioanalyzer 
(Agilent Technologies Inc, 2006). An RIN value ≥8 is acceptable for proceeding to cDNA synthesis. TSA= TS 
cells grown in Trophoblast medium supplemented with Activin; TS= TS cells grown in trophoblast stem cell 
medium containing no added growth factors; 337= TS cells treated with siRNA 337; N=TS cells grown in 
normal growth medium containing Fgf4 and Activin growth factors; P-elf = TS cells transfected with a pTracer-
Elf5 construct. 
5.1.4.3 Analysis of Gene Expression as a quality check 
As described in section  2.2.5.2 1µl of each total RNA sample (12 samples per 
treatment) was reverse transcribed and the resulting cDNA analysed by real-time PCR 
using the ABI realtime PCR machine. Real-time PCR analysis allowed three parameters 
of the samples to be checked: 
i. DNA contamination of the total RNA sample by measuring the Gapdh Ct of 
each cDNA sample and comparing it to the Gapdh Ct obtained from using a 
1/20 dilution of the total RNA sample (not reverse transcribed). 
ii. The normalised copy number of Elf5 mRNA was measured in the siRNA 
treated samples to ensure successful knockdown had occurred as compared to 
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the siRNA negative control samples. Also from previous experiments it was 
known that Eomesodermin expression is very sensitive to changes in the 
availiability of growth factors. Therefore to check the samples grown without 
F4H/Activin had responded in the predicted manner and that control cells still 
maintained a higher expression of Eomesodermin the normalised expression of 
Eomesodermin was evaluated.  
iii. The raw Gapdh Ct was used as a check of the overall quality of the samples 
and to check there was minimal variance between samples indicating a 
consistent RNA extraction. A low Gapdh Ct could indicate RNA had been lost 
or degraded during the RNA extraction. 
For each treatment 12 samples were collected and analysed as described by real-time 
PCR. An example of the normalised Eomesodermin expression relative to the average 
‘Normal’ expression is shown in  
iv. Figure  5.1-3  for three samples each of TS plus activin, TS with Fgf4 and Normal 
media containing conditioned medium and Fgf4. The pattern of Eomesodermin 
expression was as expected; it was reduced in the samples grown without 
growth factors. The relative expression of Elf5 and Eomes for all samples used 
in the microarray is given in the appendix A-3. 
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Figure  5.1-3: Relative expression of Eomesodermin was measured using real-time PCR and used to assess samples were suitable to 
use in the microarray experiment. The RNA isolated from cells grown without activin or Fgf4 growth factors should have a 
lower expression of Eomesodermin relative to the cells grown in Normal growth media. Eomesodermin expression was normalised 
to Gapdh expression and is shown relative to the average expression of the normal samples (+/- sem, n=3). Samples did follow 
the expected pattern of Eomesodermin expression. TS + F4H= TS cells grown in TS medium with Fgf4; TS+ Activin=TS cells 
grown in TS medium with Fgf4; Normal= TS cells grown in normal medium containing both Fgf4 and Activin. 
The expression of Elf5 was measured in samples treated with 337 or 733 siRNA and 
was calculated relative to the expression of siRNA control treated samples. Figure 
 5.1-4 shows the relative Elf5 expression for the first three samples from these 
treatments. Elf5 knockdown appeared greatest in 337 siRNA treated samples and was 
about 80%, 733 siRNA knockdown was on average 62%. Although the knockdown in 
733 treated samples was not optimal the main purpose for using the second siRNA 
oligo was to verify the results from the first oligo and due to time constraints it was 
decided to use these samples. The non-reverse transcribed (RT-) Gapdh Ct of all 
samples used for labelling in the microarray was always greater than six Ct units (in 
general it was about 10 Ct units greater) than the raw Gapdh Ct indicating very little 
DNA contamination in the samples. The raw Gapdh Ct was within 1 Ct unit between 
samples used for labelling, indicating samples had a similar relative abundance. A table 
showing all of the quality control parameters for all samples able to be used for the 
microarray is given in the Appendix A-3. 
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Figure  5.1-4: Relative expression of Elf5 was measured in siRNA treated samples to assess samples were suitable 
for use in the microarray experiment. Elf5 expression was normalised to Gapdh expression and is shown relative 
to the average Elf5 expression of siRNA negative control treated samples (+/- sem, n=3) Knockdown was 
greater than 80% in samples treated with 337-siRNA, and greater than 60% in 733 treated samples. 733=siRNA 
733 treated samples; 337=siRNA 337 treated samples. 
5.1.5 Labelling of RNA samples for the microarray 
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5.1.5.1 Pooling of RNA samples 
Samples were pooled into groups of three based on their RNA concentration (as 
measured on the Nanodrop). Pooling was decided on in the microarray experimental 
design to allow the total number of samples tested to be higher. However pooling 
samples produces a signal for a gene which is like the arithmetic mean of the samples; 
one sample could bias the pooled sample (Affymetrix Inc., 2006b). To minimise the 
influence of a single sample on the pool equal quantities of RNA from each sample 
were added to the pool. This was done by choosing three samples which had passed all 
of the quality checks and had similar concentrations of RNA.and using equal volumes 
of each. The individual volumes were calculated to give an overall concentration of 
10µg of RNA per pooled sample. The total volume was made up to 8µl with RNAse 
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free water so each sample was ready for the first labelling step. An example of the 
amounts used in the first array is shown below:  
Table  5.1-1: Example of the spreadsheet used to calculate the volumes of each sample used for each pool. 
Normal treatment sample number Conc. of sample   
slide 1   (ng/ul) 
ng per 
sample 
 2 2372 3293
  3 2431 3375
  11 2400 3332
  
average conc. 
(ng/ul) 2401   
  Total (ng)   10000
    
volume per sample (ul) 1.39 volume H20 added (ul) 3.84
 
5.1.5.2 Labelling of Pooled RNA samples 
Pooled RNA samples were labelled as described in section  2.2.5.4. The labelling 
process involved creating cDNA by using a T7 oligo dT primer which hybridises to the 
poly-A tail of mRNA. After the first strand of cDNA was made a second DNA strand 
was produced to give double stranded DNA. Following ds-cDNA production two 
samples were run on an agarose gel to check the size distribution of the cDNA 
products. As is can be seen from the gel (Figure  5.1-5) the cDNA ranged in length 
from about 250bp to 3000bp. 
250 
500 
750 
1000 
3000 
       
Figure  5.1-5: ds-cDNA during labelling. 1µl of samples 3 and 11 was run on an agarose gel after the clean up step 
following second DNA strand synthesis. A 1kb Abgene ladder was also run and selected bands are labelled.  
1kb            Sample                 Sample 
Ladder          3                            11 
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 Following cDNA production the ds-cDNA was used to produce cRNA, using biotin 
labelled ribonucleotides. This was then purified using a column. An aliquot of Biotin 
labelled RNA from each sample was diluted 1/100 and then analysed using the 
nanodrop for concentration and purity. The absorbance ratio should also be between 
1.6 and 1.9 for pure RNA in water. The concentration of cRNA had to be adjusted to 
take into account unlabelled total RNA. A 100% carryover was assumed and the 
cRNA yield was calculated using  
Adjusted cRNA yield = RNAm-(total RNAi)(y) Equation 6 (section  2.2.5.4.6).  
The concentration, purity and adjusted cRNA yield of the biotin labelled  is 
 5.1-2: Calculating the adjusted cRNA yield. The purity and concentration of the biotin labelled cRNA 
cRNA
given in Table  5.1-2. 
Table 
measured using the Nanodrop spectrometer. The adjusted cRNA yield was then calculated assuming a 100% 
carryover of total RNA. The adjusted yield was equal to the measured amount of cRNA -10µg x 0.5, since the 
starting amount of total RNA was 10µg and half of the cDNA produced from this was used to make the biotin 
labelled cRNA.  
nanodrop 
measurement 
Absorbance 
Ratio 
x100 
(dilution) x 19ul 
adjusted yield (-
10x0.5) 
Pooled 
Sample 
number ng/ul 260/280 ug/ul ug cRNA ug cRNA 
1 46.2 1.61 4.62 87.78 82.78 
2 51.3 1.62 5.13 97.47 92.47 
3 41.8 1.61 4.18 79.42 74.42 
4 44.2 1.63 4.42 83.98 78.98 
5 41.1 1.67 4.11 78.09 73.09 
6 39.7 1.6 3.97 75.43 70.43 
7 47.1 1.64 4.71 89.49 84.49 
8 47.5 1.66 4.75 90.25 85.25 
9 49.3 1.65 4.93 93.67 88.67 
10 45.4 1.65 4.54 86.26 81.26 
11 39.1 1.63 3.91 74.29 69.29 
12 42.9 1.62 4.29 81.51 76.51 
13 35.3 1.62 3.53 67.07 62.07 
14 40.6 1.65 4.06 77.14 72.14 
15 33.5 1.64 3.35 63.65 58.65 
16 33.1 1.62 3.31 62.89 57.89 
17 44.7 1.59 4.47 84.93 79.93 
18 49.9 1.62 4.99 94.81 89.81 
 
Twen ograms e cRNA lated e a  yield) ented 
as descri d in secti 2.5.4.7. A iquot o men d un-frag d cRNA 
ty micr  of th  (calcu using th djusted  was fragm
be on  2. n al f frag ted an mente
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was run on agarose to check fragme on h d su ully. The 
fragmentation proce ould res  a dis ion o A betwe  
bases. T  gel is n in figu Figure . The unfragmented cRNA was 
distributed mostly b n 250 a 000bp th. r to the ution of 
cDNA s wn in Fi  5.1-5, h er the ente A was a ller than 
250bp long showing entation  occurr ccess ollowing entation 
samples were added to a hybridi n cock sectio .5.5). Th idisation 
cocktail was taken to the Affymetrix faci at A d Univ and the 
hybridisation, washing and scanning was carried out ther iam Williams following 
the stan  protoco tion  2.2.
 
Figure  5.1-6: Non-fragmented and fragmented cRNA. 1.7% agarose gel showing lanes 1 and 38 Abgene 1kb 
ladder (UK), lanes 2-19 un-fragmented cRNA (~1.5µg cRNA per lane); lanes 20-37 fragmented cRNA (~1µg 
cRNA per lane). Fragmented cRNA was mostly smaller than 250bp. 
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5.1.6 Microarray Analysis 
Following washing and scanning (section  2.2.5.6) of the arrays the raw intensity da
w
ta 
nalysed as detailed in section  2.2.5.7. Briefly the intensity data was read from the 
Affymetrix GCOS software v1.4 (Affymetrix Inc. 2005) into the GenStat statistical 
software program (9th edition, VSN International Ltd, UK) and an RMA analysis 
p erage log2 intensity value for each probe set was used to perform a 
single channel ANOVA to find significant differences between the average expression 
intensity of a treatment and its appropriate control. The growth factor experiments 
were all compared to the ‘Normal’ treated samples, while the Elf5 siRNA treated 
samples were compared to the siRNA negative control slides. A contrast between the 
siRNA negative control treated samples and the Normal treated samples was also 
performed as a quality control measure to identify genes which may be significantly 
changed simply due to siRNA treatment. The contrast values, their significance (
values) as well as the log2 intensity data for every probe set were exported to Excel fo
identification of target genes. 
5.1.7 Quality Control of Microarray Data 
Several quality control parameters were investigated following the advice given in the 
Affymetrix data analysis fundamentals manual. A brief description of each parameter is 
5.1.7.1 Probe Array image Inspection
as a
erformed. The av
p 
r 
given below along with the result. 
 
The ted to check for image artifacts such as scratches or  .dat files were visually inspec
bubbles, or a high background. All of the JPG image files looked OK, except for a 
criss cross pattern. Liam at Auckland University was contacted regarding this 
observation. He stated that this pattern was simply a display anomaly (Liam Williams, 
personal communication). 
 
5.1.7.2 B2 Oligo Performance 
The Hybridisation cocktail had been spiked with the B2 control Oligo. This labelled 
RNA oligo should hybridise to the slide in a checkerboard pattern and it should also 
hybridise in a pattern which reveals the chip name (as seen in Figure 5.1-8). 
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5.1.7.3 Average Background and Noise Values 
The background value is a measure of the signal intensity caused by autoflourescence 
of the array surface and non-specific binding of the target or fluorescent stain 
mol e sensitivity of the experiment. Affymetrix 
3 
 
e 
ave similar levels of noise. 
 5.1-3: Background flourescence and noise vlaues for the 18 microarray slides. Background should be lower 
than 100 and noise values all similiar between arrays. 
ground Noise 
Figure  5.1-7: Hybridisation of the B2 oligo gave the correct checkerboard pattern and the chip name pattern. 
ecules. A high background reduces th
suggests a background value of between 20 and 100. As can be seen from Table  5.1-
the background was always within this range for all arrays. 
The noise is a measure of pixel to pixel variation due to electrical noise of the scanner
and sample quality. Noise values should be similar for all the arrays. From the tabl
below all arrays appear to h
Table 
   
Back
Array 
number Average 
Standard 
Deviation Average 
Standard 
Deviation 
1 69.75 1.02 3.69 0.09 
2 65.42 0.78 3.81 0.46 
3 64.52 1.04 3.13 0.07 
4 59.2 0.8 3.2 0.07 
5 58.81 0.08 0.87 2.96 
6 67.65 0.07 0.85 3.34 
7 61.64 0.1 0.89 3.35 
8 60.97 0.09 0.75 3.18 
9 63.08 0.06 0.72 3.34 
10 57.66 0.1 0.83 3.04 
11 57.93 0.82 3.19 0.06 
12 60.01 0.47 3.11 0.06 
13 60.6 0.78 2.95 0.08 
14 66.96 1.02 3.32 0.06 
15 62.12 0.59 3.48 0.07 
16 64.56 0.66 3.29 0.08 
17 71.13 1.14 3.71 0.07 
18 67.74 0.88 3.37 0.05 
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5.1.7.4 Poly-A Controls 
Poly-A RNA controls were spiked in at the beginning of the labelling process. These 
controls are five B. subtilis genes which have been modified by the addition of a poly-A 
 
thr 1
dap 1 in 75 0
All of the Poly- ls sh  pr  in  si sity according 
to the ratios spiked in, i.e. lys est, da largest. An exam e expression 
profile from the poly-A contro hown ure  5.
tail. The poly-A controls were spiked in to each 10µg total RNA starting sample and 
contain known concentrations relative to the total RNA population: 
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Figure  5.1-8: Raw intensity signal of the spiked in poly-A controls. The first array is shown as an example. Three 
probe sets existed for each poly-A control gene, a 5', 3' and m probe set which measure expression of that 
p e Poly A co t respective order.  articular area of the gene. Th ntrols were present in the correc
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.1.7.5 3’/5’ Ratio of Housekeeping Genes5  
The ratio of the 3’/5’ intensit usekeeping genes, actin and Gapdh can be 
n then the 3’/5’ ratio would 
be 1, however this doesn’t occur and the 3’ intensity is larger. Affymetrix recommends 
a 3’/5’ ratio smaller than 3. Table  5.1-4 shows the 3’/5’ ratio for β-actin and Gapdh. In 
all slides this ratio was less than 3; surprisingly the Gapdh 3’/5’ ratio was smaller than 
one indicating that the intensity for the 5’ probe was greater than the 3’ probe. This 
could be due to a labelling bias.  
Table  5.1-4: 3’/5’ ratio for βactin and Gapdh; two housekeeping genes. A ratio less than 3 is acceptable as it 
indicates cDNA synthesis reactions went mostly to completion. Interestingly the Gapdh ratio is smaller than 1 
indicating the intensity measured for the 5’ probe was greater than for the 3’ probe. 
Array 
Number β actin 3'/5' Gapdh 3'/5' 
y of the ho
used to measure the number of cDNA synthesis reactions which went to completion. 
Reverse transcription synthesises cDNA starting from the 3’ end of an mRNA and 
ends at the 5’ end. If all cDNA reactions went to completio
1 1.35 0.82 
2 1.37 0.82 
3 1.42 0.83 
4 1.44 0.82 
5 1.46 0.83 
6 1.50 0.80 
7 1.46 0.84 
8 1.70 0.90 
9 1.81 0.89 
10 1.75 0.93 
11 1.76 0.82 
12 1.55 0.82 
13 1.80 0.86 
14 1.83 0.85 
15 1.50 0.85 
16 1.79 0.85 
17 1.42 0.80 
18 1.47 0.81 
 
5.1.7.6 Percent Present 
The expression of a probe should be called ‘present’ at least 35% of the time, however 
this factor depends on the biological sample, i.e. which genes are being expressed. A % 
present lower than 35% can mean poor sample quality. As shown in the table below 
the % present was between 46.2-52.5% for all slides. The ‘present’ call for a probe set 
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is determined by the GCOS software and depends on the background and a number 
of statistical factors. 
Table  5.1-5: Percentage of probes called present by the Affymetrix GCOS software. A % present lower than 35% 
can indicate poor samp
Array Number Tre nt % Present 
le quality. 
atme
1 Normal 13 49.
2 Normal .4 47
3 Normal .8 50
4 TS + activin .7 51
5 TS + activin .8 49
6 TS + F4H .8 49
7 TS + F4H 1 5
8 TS Only 50.2 
9 TS Only 46.8 
10 TS Only 48.1 
11 si negative .7 50
12 si negative .5 52
13 si negative 8 4
14 337 siRNA .1 46
15 337 siRNA .8 48
16 337 siRNA 8 4
17 773 siRNA .1 49
18 773 siRNA 47.2 
 
5.1.7.7 Spiked cRNA Controls 
n at varying concentrations (GeneChip® Hybridisation Control 
Kit; Affymetrix Inc, California, USA): 
1.5 
bioC 5 
bioD 25 
Cre 100 
 
BioB is at the level of dete ion (1:100,000 complexity ratio) an ld be called 
present 50% of the time.  this experime called present in all of the arrays. 
BioB, bioC and bioD are genes of the biotin synthesis pathway in E. coli, and cre is the 
recombinase gene from the p1 bacteriophage. These were supplied as biotinylated 
cDNA controls which were spiked into the hybridisation cocktail just prior to 
hybridisation, washing and scanning of the arrays. The cRNA controls were supplied 
as a premixed solutio
 final concentration pM 
bioB 
ct d shou
 In nt bioB was 
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Figure  5.1-9 shows the ra intensity value NA spik controls for the 
first array. The cRNA co ls were pres rrect rati tive to each other.  
 
tensity signal for the spiked cRN ntrols, spiked in at the hybridisation cocktail stage just 
to hybridisation, washing and scanning of the r array #1. The controls show the correct ratios 
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cy 
by the GCOS software. This scaling factor can give an indication of low quality 
samples and should not differ by more than 3 fold in arrays to be compared. The 
largest difference in scaling factor was about 2 fold, so within the limits recommended 
by Affymetrix. Another way of judging the scaling performed on each array by GCOS 
is to look at the intensity of the cRNA controls added. Because these are independent 
of RNA concentration, their intensity reading should be equal in all arrays, however in 
bad arrays they would be scaled higher. As it can be seen in Table  5.1-6 at the 
measurement from the 5’ cre cRNA control is closely related to the global scaling 
factor. The arrays with the greatest level of scaling are arrays 13, 14 and 16. 
To compensate for differences in the overall intensity for each array due to factors
independent of transcript abundancy, such as pipetting error, hybridisation efficien
and staining efficiency the global array intensity for each array was scaled automatically 
ioC-5'
AFFX-
BioC-3'
AFFX-
BioDn-5'
AFFX- 
BioDn-3' 
AFFX- 
CreX-5' 
AFFX-
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Table  5.1-6: Scaling factor and 5' cre cRNA control intensity measurements for the arrays. A high scaling factor 
indicates a poor quality sample, cre measurement is independent of RNA quality and directly related to the scaling 
factor; so a high cre measurement also indicates larger scaling. 
Array number Treatment Scaling factor 5' cre cRNA  Intensity 
1 Normal 1.88 15877 
2 Normal 2.32 16017 
3 Normal 1.71 16956 
4 TS + activin 1.73 16943 
5 TS + activin 2.37 19843 
6 TS + F4H 2.04 15845 
7 TS + F4H 2.41 17500 
8 TS Only 1.96 19083 
9 TS Only 2.88 20248 
10 TS Only 2.87 21659 
11 si negative 2.39 20401 
12 si negative 1.79 18900 
13 si negative 3.55 23901 
14 337 3.74 21395 
15 337 2.65 20858 
16 337 2.94 25451 
17 773 2.14 18671 
18 773 2.79 17302 
 
5.1.
The same procedure was done for the average Log2 expression for each probe set to 
own in the absence of activin but 
8 Global Analysis 
As shown in Table  5.1-5 above, the percent of probes called present was about 50% 
for all arrays. There was no obvious increase or decrease in this value based on 
treatment indicating the treatments did not have a large overall effect on gene 
expression levels. 
Using Data Desk software programme (v 6.1, 1999, Data description Inc, NY) the 
Log2 expression levels for 337 (Figure  5.1-10) and 733 (Figure  5.1-11) Elf5 siRNA 
treatment were plotted against siRNA negative control expression levels for every 
probe set. The overall correlation was 0.998 and 0.994 respectively; indicating the 
expression levels of the vast majority of probe sets remained unaltered by the 
treatments; however 773 treatment had a greater effect than 337 treatment.  
look at the overall correlation between the normal control cells (grown with Fgf4 and 
conditioned medium) and those grown in the absence of Fgf4 but supplemented with 
activin (TS + A; Figure  5.1-12), or those gr
 133
supplemented with Fgf4 (TS+F; Fig fina absence 
of both growth facto gure  5.1- he correlations 991, 0.996 and 
0.983 r ectively. T ndicates t ver the twenty our period of 
treatme there was in over ne expression; r on the whole 
Fgf4 de tion had a t than a etion, and r of both growth 
factors had the larges pected. rrelations also s 4 removal 
and bo c al had a greater effect on gen ssion than the 
siRNA ted samp ot was also created betwee iRNA negative 
control ted cells al non- d cells (Figure  5 The correlation 
was 0.9 tin little effect on gene express  to the siRNA 
control o or the trans cedure
ure  5.1-13), or lly those grown in the 
rs (TS; Fi 14). T were 0.
esp his also i hat o  four h
nt  little change all ge howeve
ple  greater effec ctivin depl emoval 
t effect as ex The co how that Fgf
th growth fa tor remov e expre
trea les. A scatterpl n the s
 trea and the norm treate .1-15). 
95, indica g there was ion due
 olig fection pro .  
 
Figure  5.1-10: Scatter-plot of the siRNA negative control Log2 expression values versus 337 siRNA treated 
samples. R=0.998 
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igure  5.1-11: Scatter plot showing the overall correlation (R=0.994) between siRNA negative control and 733 
RNA Log2 expression values 
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Figure  5.1-12: Scatter plot showing the overall correlation (R=0.991) between the normal growth medium control 
and TS medium with activin Log2 expression values 
TS medium + activin (no Fgf4)
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TS + Fgf4 (no Activin)
Figure  5.1-13: Scatter plot showing the overall correlation (R=0.996) between the normal groth medium control 
and TS medium + Fgf4  Log2 expression values 
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Figure  5.1-14: Scatter plot showing the overall correlation (R=0.983) between normal growth medium control 
and TS medium (without Fgf4 or Activin) Log2 expre
TS only (no growth factors)
ssion values 
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Figure  5.1-15: Scatter plot showing the overall correlation (R=0.995) between normal growth medium control 
and siRNA negative control Log2 expression values 
Arbitrary fold change cut-offs were chosen to obtain a workable set of genes. At first a 
fold change cut of 2 was chosen, as a 50% change in expression of the transcription 
factor Oct3/4 in ES cells has been shown to cause upregulation of mesoderm specific 
genes in only 24 hours (Niwa et al., 2000). This shows small fold changes in gene 
e on can lead to significant changes in downstream gene expression and 
a tion of cell fate.  However for the siRNA treated samples the fold change cut off 
h o be lowered as the maximum fold change for Elf5 was just over 2-fold for the 
337 siRNA treated samples and 3-fold for the 733 siRNA treated samples (Table 
 5.1-8); hence any down stream genes would be expected to have a smaller change than 
this. To obtain a suitable number of genes the 337 cut off was set at 1.4 fold and the 
733 cut off was 1.5 fold. The fold change cut off for the growth factor arrays (removal 
of either Fgf4 or Actvin, or both) was kept at 2 fold. However for the list of target 
genes that were affected by cha , the cutoff was increased 
siRNA negative Control
xpressi
ltera
ad t
nges in growth treatment only
to 3.5 fold. 
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he total number of probe sets identified as differentially expressed were combined 
and then duplicate probe sets removed; the resulting target set consisted in 1209 
unique probe sets. To correct for non-specific effects due to siRNA treatment alone 
probe sets which showed a greater than 1.5 fold change in expression between the 
siRNA control treated samples and the non-treated (‘normal’) sample were removed 
from the sets of genes identified as differentially expressed using Elf5 siRNA 
treatment, 134 probe sets were removed. The number of probe sets identified for each 
treatment and the fold change cut off used is shown in  
 
T  5.1-7 for each treatment comparison. In general all the treatments appeared to 
have a predominantly negative effect on gene expression, with 68% of probe sets were 
regulated. A total of 92 probe sets were identified as differentially expressed for 
treatment with the 337 siRNA compared to the siRNA control, of which 12 showed 
significant control siRNA: Normal differences leaving 80 probe sets. Treatment with 
the siRNA 733 resulted in 391 probe sets as differentially expressed. From this set 122 
were removed as possibly being affected by siRNA treatment alone. The gr ater 
numb robe sets identified du  compared to the siRNA 
 of Elf5 expression seen in these samples; 
however it could also be influenced by the fact that the 733 samples were collected 
th factors had the greatest effect.    
T
able 
e
er of p
control reflects the greater knock-down
e to 733 siRNA treatment
using a cell line grown much later. Although mTS cells were always grown under the 
same conditions and the same passage number was used, the fibroblast conditioned 
medium cells were grown in is inheriently variable (Hay et al., 2004). The 337 and 
siRNA negative control samples were collected using the same lot of cells grown in the 
same conditioned medium. However the 733 cells were grown later and in different 
conditioned medium, so the change in expression of some probe sets could simply be 
reflecting this fact. To counteract this the ‘normal’ treated samples were collected and 
grown concurrently with the 733 cells, so the probe sets identified as different in the 
normal vs siRNA control samples and removed should remove this effect.  
 
The number of probe sets identified as changing their expression also varied 
depending on the growth factors removed. Removal of Fgf4 growth factor had a much 
larger effect on gene expression than removal of Activin, however as expected removal 
of both grow
  
Table  5.1-7: Fold change cut off and the number of probe sets identified for each treatment comparison in
microarray experiment. 
Fold 
change 
Number 
of probe 
sets 
 the 
cut off identified Upregulated 
Down-
regulatedContrast 
337 siRNA vs siRNA control 1.4 80 5 75 
733 siRNA vs siRNA control 1.5 269 87 182 
TS medium + activin (no 
Fgf4) vs Normal medium 2.0 182 71 111 
TS medium + Fgf4 (no 
activin) vs Normal medium 2.0 28 5 23 
TS medium (no growth 
factors) vs Normal medium 2.0 516 173 343 
 
5.1.9 Elf5 Expression  
The greater number of probe sets identified as changed in the 733-siRNA/siRNA-
control compared to those of the 337 siRNA treated samples came as a surprise given 
previous real-time PCR results which showed 733 treated samples as having a greater 
expression of Elf5. However this result also corresponds with the greater reduction in 
Elf5 expression compared to the siRNA treated control samples seen in the 733 
mple. A real-time PCR measurement for Elf5 was repeated using cDNA from three 
of the same samples used for the microarray. However this time the run was 
time PCRs were done prior to 
sa
performed on the Corbett machine and with a new primer set designed to detect Elf5 
(due to the shorter extension time on the Corbett machine). The greater reduction of 
Elf5 expression in 733 siRNA treated samples was confirmed. The reason for this 
apparent contradiction could be because when the real-
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the microarray 12 samples for each treatment was analysed for Elf5 and Gapdh in each 
run. Due to space limitations on the plate only one treatment was analysed per plate, 
and the efficiency of each reaction was estimated using four dilutions of one of the 
normalised Elf5 expression for a control measured in a different 
reaction. This could introduce errors due to differences in the reaction conditions. 
Another source of error was t  th series of one sample as an 
estimator for the efficiency of al in a on. The efficiency is m to 
the power of the Ct to give a calculated copy number. Therefore small errors in 
n th py numb ese errors could contribute to 
the incorrect knockdown efficiency calculated. Subsequent to the microarray the 
expression of Elf5 was measured using the Rotor gene 6000 (Corbett Life Sciences, 
sampl  each tr t were a ed, enab he 
pared from a single run. Also the quantitative 
n (Corbett life sciences, Australia) allo  an efficiency to 
be calculated for each reaction. This meant samples with an unusual efficiency were 
ed for expression analysis.  
The microarray contained two independent probe sets for Elf5. The fold change is 
Elf5 e sets m ured by th croarray, and the 
lative expression of Elf5 measured by real time rt-PCR. There was a close correlation 
between the Elf5 change in expression measured by the Affymetrix microarray and that 
tment comparisons. For example the average 
 
samples. This meant the normalised Elf5 expression calculated for a treatment was 
compared to the 
he use of
l samples 
e dilution 
 reacti ultiplied 
efficiency can cause a large error i e co er. Th
Australia). In these runs three es of eatmen nalys ling t
expression of all samples to be com
analysis software applicatio wed
easily detected and not us
shown in Table  5.1-8 for the two  prob eas e mi
re
measured using real-time PCR for all trea
fold change measured for the 337 siRNA was 2.2 fold; using real-time PCR analysis on
three samples gave a change of 2.85 fold. The average Elf5 fold changed measured 
using the microarray for the 733 siRNA treated samples was 3.09, using real time PCR 
the fold change measured was 4.15.  
Table  5.1-8: Elf5 difference in expression between treatments and their control and the relative Elf5 expression 
measured using real time PCR. 
 
Microarray results for 
Elf5 probe set 1 
 
Microarray results for 
Elf5 probe set 2 
 
RT-PCR for Elf5 
 
Contrast change P change P change  (n=3) P 
 Fold  Fold Fold StDev 
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337 siRNA vs 
siRNA control 2.07 1.51E-10 2.34 8.21E-11 2.85 0.05 1.95E-04 
733 siRNA vs 
siRNA control 3.17 3.50E-12 3.01 1.62E-11 4.15 0.03 1.88E-03 
TS medium 
(no growth 
factors) vs 
Normal 
medium 2.57 9.38E-12 3.43 1.40E-12 3.12 0.02 1.05E-02 
TS medium + 
activin (no 
Fgf4) vs 
Normal 
medium 1.94 1.43E-09 2.07 1.38E-09 2.01 0.03 1.78E-02 
TS medium + 
Fgf4 (no 
activin) vs 
Normal 
medium 1.17 1.22E-03 1.36 9.39E-06 1.18 0.07 1.73E-01 
 
Further confidence in the results generated by the microarray experiment was the 
observation that the probe sets measured to have the greatest change in the Elf5 
siRNA treated were the two probe sets which corresponded to Elf5. The top 10 probe 
sets changed for the 337 and 733 siRNA treated slides are shown in Table  5.1-9 and 
Table  5.1-10
Table  5.1-9: Top ten probe sets differentially expressed in 773 siRNA traeted samples compared to siRNA 
control samples [highlighted genes are those changed by both 773 and 337 siRNA treatment.]. 
Product change GeneName 
Fold 
Elf5 E74-like factor 5 -3.17 
Elf5 Elf5 probe set 2 -3.01 
LCP1/Pls2 lymphocyte cytosolic protein (plastin 2, L) +2.64 
Kap kidney an tein drogen regulated pro -2.59 
Cyr61 cysteine rich protein 61 -2.54 
Cd24a CD24a a  -2.47  ntigen
LA6 lymphocyte antigen 6 complex -2.47 
Cyr61 cysteine rich protein 61 -2.39 
HS3ST3B1 heparan s (glucosamine) 3- otranulfate O-sulf sferase 3B1 -2.35 
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Fxyd5 related to ion channel, -2.30 
 
 
 
 
Ta p ten probe sets differentailly expressed in 337 siRNA treated samples compared to siRNA 
ne le ligh h ang 37 siRN atmen
GeneName Product 
Fold 
change 
ble  5.1-10: The to
gative control samp s [high ted genes are t ose ch ed by both 773 and 3 A tre t.]. 
Elf5 Elf5 probe set 2 -2.34
Elf5 E74-like factor 5 -2.07
SYNPO2L synaptopodin 2 like -1.76
Hst3st3b1 heparinsulfate (glucosamine) 3-O-sulfotransferase 3B1 -1.76
PPP6C protein phosphatase 6, catalytic subunit -1.73
Cyr61 cysteine rich protein 61 -1.71
CXADR cocksackie virus and adenovirus acceptor -1.63
Dbt dihydrolipoamide branched chain transacylase E2 -1.62
PSAT1  phosphoserine aminotransferase -1.61
Cyr61 cysteine rich protein 61 -1.60
HBXIP hepatitis B virus x interacting protein -1.60
Serinc1/Tde1l tumor differ e like entially xpressed 1, -1.58
 
Functional Analysis 
In athwa alysis (IPA v 1.3, 20
associate biological functional processes, pathways and diseases affected by the 
 displays the functional groups which are over-represented in the set of 
genes identified as being significantly changed. A p value was also calculated by 
up 
compared with the total number of genes belonging to that functional group in the 
data set of al  this depends on the num es known/categorised
that functio roup. This  is preferred to grouping genes differenti  
express  their e  
groups ide  as signif ted in the set of genes differenti  
expressed f ch treat  5.1-16 to Figure  5
5.1.10 
genuity P y An 07) was used to analyse the results to 
treatments, and therefore to associate some overall biological meaning to the results. 
This was done for each treatment contrast by importing into the software all of the 
log2 contrast expression values and their associated p value for every probe set. The cut 
offs described above were also used in this analysis and a p value of 0.05 was set. IPA 
software then
comparing the number of genes identified as changed for a particular functional gro
l probes; ber of gen  into 
nal g type of analysis ally
ed based on xpression patterns (Allison et al.). The top 20 functional
ntified icantly over-represen ally
or ea ment are shown in Figure .1-20.
 Figure  5.1-1 -represented in the set of probes dif y e d (≥1.4 fold chang en 337 siRNA treated 
mTS cells an ftware. The threshold shown indica p value=0.
6: The top twenty functional categories (ranked by p value) which are significantly over
d siRNA negative control treated mTS cells. Analysis was carried out using IPA 4.0 so
feren
tes a 
tiall xpresse
05. 
e)betwe
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Figure  5.1-17 The top twenty functional categories (ranked by p value) which are significantly over-represented in the set of probes differentially expressed (≥1.5 fold change) between 733 siRNA treated 
mTS cells and siRNA negative control treated mTS cells. Analysis was carried out using IPA 4.0 software, a threshold of p=0.05 is shown. 
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Figure  5.1-18 The top twenty functional categories (ranked by p value) which are significantly over-represented in the set of probes differentially expressed (≥2 fold change)between mTS cells grown in 
TS medium supplemented with Fgf4 growth factors, however without activin, compared to mTS cells grown in normal growth medium containing Fgf4 and activin growth factors. Analysis was carried 
out using IPA 4.0 software. The threshold shown is for a p value of 0.05. 
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Figure  5.1-19 The top twenty functional categories (ranked by p value) which are significantly over-represented in the set of probes differentially expressed between mTS cells grown in TS medium 
supplemented with avtivin growth factor, however without Fgf4, compared to mTS cells grown in normal growth medium containing Fgf4 and activin growth factors. Analysis was carried out using 
IPA 4.0 software, the threshold shown indicates a p value of 0.05. 
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Figure  5.1-20: The top twenty functional categories (ranked by p value) which are significantly over-represented in the set of probes differentially expressed between mTS cells grown in TS medium 
wi e thout any Fgf4 or activin supplementation, compared to mTS cells grown in normal growth medium containing Fgf4 and activin growth factors. Analysis was carried out using IPA 4.0 software, th
threshold shown indicates a p value of 0.05. 
5.1.10.1 Functional groups affected by Elf5 knockdown 
To see if there was a common effect of knocking down Elf5 using either siRNAs the 
functional groups identified for each of the Elf5 s treatments were combined.  
The total number of functional groups identified a ed by treatment with either 
siRNA was 70; of these 55 functional groups we d to be significantly over-
represented in common between the two siRNA treatments. The functional groups 
were ordered based on their p value and the top 2 ps in common identified in 
order to establish the major pathways affected by Elf5 knockdown. These are listed in 
the following table. 
 
Key pathways and biological functions identified as ed due to Elf5 knock down 
were cancer, cellular growth and proliferation and cell cycle progression. This matches 
the type of functions expected since Elf5 is crucial for maintenance of the trophoblast 
stem cells, so would be expected to be involved in lling proliferation as well as 
cell cycle control. Elf5 is also a member of the ily of transcription factors 
(Zhou et al., 1998) of which many of its members are associated with cancer. The 
functional group of embryonic development was al tified as would be expected. 
Reproductive system disease was also identifi his is significant because 
malfunctions in the reproductive process as a resul ozygouse knockout of Ets 
family genes such as Ets2, Gabpα, Erf (all involved in pl ntal development) Pea3, and 
Erm (involved in male fertility) make the reprod process the most common 
target of Ets family transcription factors (Papadaki e
 
Table  5.1-11: The top 20 functional groups (ranked by p value)  whi gnificant expression changes with 
treatment of both 337 and 733 Elf5 directed siRNAs compared to t l treated siRNA. Functional group 
analysis was done using IPA 4.0 software v.3 
Functional 
group 
description 
337 siRNA 
 p value 337 no. of genes
NA        
e 733 no. of genes
iRNA 
s affect
re foun
0 grou
 chang
 contro
Ets fam
so iden
ed. T
t of hom
ace
uctive 
t al., 2007). 
ch show si
he contro
733 siR
p valu
Cancer 
1.1E-03-4.95E-
02 10 
8.34E-
 97 
5.78E-09-
03
Cellular Growth 
and Proliferation 
1.1E-03-4.21E-
02 3 
8.34E-
 90 
1.99E-06-
03
Cell Cycle 
1.95E-03-4.21E-
02 5 
7.39E-
 42 
1.09E-05-
03
Cell Death 
1.95E-03-4.93E-
02 7 
7.75E-
 77 
8.34E-06-
03
Amino Acid 
Metabolism 
4.49E-05-4.95E-
02 18 
7.67E-
 18 
6.09E-05-
03
 148
Tissue 1.95E-03-4.77E- 4.47E-06-8.34E-
Development 02 6 03 63 
Cell Morphology 
1.95E-03-3.83E-
02 3 
8.18E-05-8.34E-
03 43 
Small Molecule 
Biochemistry 
4.49E-05-4.95E-
02 20 
4.05E-04-4.69E-
03 14 
Connective 
Tissue 
Development 
and Function 
3.9E-03-3.64E-
02 2 
2.08E-05-6.22E-
03 31 
Cell-To-Cell 
Signaling and 3.9E-03-4.95E- 3.71E-05-7.34E-
Interaction 02 4 03 53 
Embryonic 
Development 
1.95E-03-4.77E-
02 5 
2.25E-04-8.3E-
03 31 
Gene Expression 
3.9E-03-2.89E-
02 3 
2.22E-05-6.08E-
03 62 
Reproductive 
System Disease 
3.9E-03-4.95E-
02 8 
4.99E-06-6.55E-
03 50 
Cardiovascular 
System 
Development 
and Function 
7.78E-03-4.95E-
02 4 
1.42E-10-8.34E-
03 41 
Respiratory 
Disease 
1.95E-03-3.27E-
02 2 
2.27E-04-5.53E-
03 13 
Endocrine 
System 
Development 
and Function 
1.95E-03-3.46E-
02 3 
4.47E-04-4.
03 
69E-
7 
Tumor 
Morphology 
3.9E-03-1.55E-
02 1 
1.28E-05-7.96E-
03 27 
Skeletal and 
Muscular System 
Development 
on 
3.9E-03-3.64E-
02 2 
3.69E-05-7.42E-
03 24 and Functi
Molecula
Transport 
r 7E-
 3 
1.01E-03-4.7
02 8 
2.04E-03-2.04E-
0 2 
Tissue 
Morphology 
3.9E-03-4.95E-
02 3 
3.69E-05-8.3E-
03 48 
 
5.1. y analysis
The pr y changed in the 733 and 337 siRNA treated 
sam ared  negative control sed to perform a 
pat is(with IPA software), to ga n understand of the known lecular 
11 Pathwa  
obe sets identified as significantl
ples comp
hway analys
 to the siRNA samples were u
ing in a  mo
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interactions which occur in this set of genes.  The IPA software uses published 
in pr in/nucleo eque a netwo of the 
known interactions. The network produced is shown in Figure  5.1-21. Key genes 
i p athway h ever no e micro y were 
vascular endothelial growth factor C (VEGF-C), Errβ, TGFβ, and MYC.  
teractions of otein or prote tide s nce to create rk 
ndicated to be im ortant in the p ow t identified in th arra
 
F y a ftware to show the know en genes identified as 
sign  by 337 and  Elf5 siRNA oligon eotides compared ntrol siRNA treatm
5.1. ctions of atments 
o lower the false discovery rate (the number of probe sets identified as differentially 
expressed when they are not) and to find probe sets which were affected by more than 
unique probes which had made the cut-offs were filtered for 
igure  5.1-21: Pathwa
ificantly affected
nalysis using IPA so
 733
n interactions betwe
to coucl ent. 
12 Interse Tre
T
one treatment, the list of 
intersections. The Venn diagram, which shows the number of probe sets affected by 
more than one treatment, is shown below (Figure  5.1-22) 
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Figure  5.1-22: Venn diagram showing the number of probe sets differentially expressed with a 
common treatment. 
A siRNA oligo may produce off target effects (Bridge et al., 2003) therefore the set of 
ich are differentially expressed when both siRNA 
oligos are used. A set of 22 probe sets were identified as having changed when either 
gated were the intersections 
 
 
genes of greatest interest are those wh
Elf5 siRNA oligo was used. This set was then further analysed to see if any of these 
probe sets are also altered when the growth factors activin/Fgf4 were removed, to 
indicate genes which may be involved in both growth factor maintenance of mTS cells 
and regulated by Elf5. A subset of nine probesets was found (indicated in red in the 
Venn diagram). The other overlapping treatments investi
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of either Elf5 siRNA oligos with the growth factor experiments. There were 53 probe 
sets in common between 733 siRNA treatment (1.5 fold) and removal of activin/Fgf4. 
Only 14 probe sets were changed by growth factor removal (2 fold) and 337 siRNA 
treatment. A significant group of probe sets was unique to each oligo. The biggest 
reason for this is the 733 oligo had a greater effect on Elf5 expression, therefore it 
would be expected that a greater number of down stream genes would also be 
significantly changed; however with 337 treatment the change in Elf5 could have not 
been great enough for these genes to appear significantly changed. The other reason 
for the different sets of genes identified could be non-specific effects due to the 
particular sequence of each of the oligos, causing RNA interference effects on genes 
other than Elf5.   
5.1.12.1 Annotation of Genes of Interest 
The probe sets from the intersection of: 
i. 337 and 733 and any of the growth factor removal treatments (9 probesets) 
ii. 337 and 733, but not any of the growth factor treatments (13 probe sets) 
iii. 337 and any of the growth factor treatments, but not 733 (14 probe sets) 
iv. 733 and any of the growth factor treatments but not 337 (53 probe sets) 
v. The set of genes which changed by greater than 3.5 fold in any of the growth 
factor experiments (57 probe sets)  
 gene name, description and an outline of the function of that gene 
sing IPA 4.0 software (Ingenuity pathway analysis, v3, 2006). Many of the probe sets 
were annotated for
u
which, using the Affymetrix annotation had not been previously associated with a gene 
name, were found to be for the same gene. For example in the set of “unique” probe 
sets for the 337/733/GF all union, Cyr61 was found to occur twice. The annotated 
table of genes showing the affymetrix probe number, matching gene name, description 
as well as the fold change and the p value are given in Table  5.1-12.  
Several genes known to be involved in placental development were identified as 
significantly changed. In the set of probes of key interest (the union of 
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l and early embryonic development (Kovacs et al., 2002; Wang et 
al., 1998).  
I val of Fgf4 and activin growth factors were a 
number of genes that are well known to be expressed in mTS cells and their 
differen d 
Errβ. Eomes and Errβ are genes downstream of Fgf4 signalling and are required for 
m ce when 
Fgf4 signalling was removed. Mash2 is expressed in the mTS down stream 
sp gio th 
th T
M  o o 
play a ro TS cell maintenance and differentiation. 
These genes also followed the expected pattern such as up or down regulation with 
 
337/733/growth factor treatments) the genes matched were: Cyr61 (twice), Sox2, Elf5 
(twice), Hst3st3B1, Wdr40b, Synopl and a probe set not matched by ingenuity. The fact 
Elf5 was identified in this union gives some confidence to the results of the 
microarray. The other union of key interest is that between 337 and 733 siRNA 
treatments. Of the 22 genes in this group was Follistatin which is known to be 
expressed in placental tissue and to be important in controlling activin/Tgfβsignalling 
(Jones et al., 2002). Tgfβ signalling is one of the pathways essential for maintenance of 
mTS cells (Erlebacher et al., 2004). Vasorin was also identified in this set of genes and 
is known to be involved in the Tgfβ pathway as well (Ikeda et al., 2004). Calca 
(calcitonin) has been implicated to play an important role in calcium transport and 
signalling in placenta
n the set of genes annotated from remo
tiated subtypes. These genes included Bmp4, Ascl2/Mash2, Mmp9, Eomes an
TS ll proliferation (Cross et al., 2003), these genes were both down regulated 
on trophoblast cell type (Cross et al., 2003) and was upregulated, consistent wi
e m S cells undergoing differentiation.  
any f the genes found to be differentially expressed were ones which are known t
le in placental development or m
differentiation. These results indicate that the microarray results do have biological 
meaning and the genes differentially expressed are valid. 
 
Table  5.1-12: The complete set of probes of inte er, 3) id
classified based on common to unions of treatme  unio s 33
2 fold respectively; i.e. the set of genes which are dow 337 
removal (1.4 fold and 1.5 fold respectively; i.e. robe rowth fac
respectively; i.e. specific effects of the 337 siRNA an rowth fac
respectively; i.e. specific to the 733 siRNA oligo);  by .5-fold or 
i.e. genes which are Elf5 independent. . Shaded b et t
matched term name descri
rest (affymtrix probe numb
nts. The probe sets for each
affected by both Elf5 knock
Elf5 regulated only)green=p
 oligo); purple=probe sets ch
grey=probe sets not changed
oxes are those values which m
ption 
matched to a gene using IPA 4.0 software v 
n are colour coded. Red= the union of siRNA
n and growth factor removal); blue=union of 
 sets affected by 337 siRNA treatment and g
ged by both 733 siRNA oligo treatment and g
elf5 siRNA treatment however affected by a 3
he fold change cutoffs. 
entified after fold-change cutoffs had been applied and probe sets 
7 and 773 and by all growth factor treatments(1.4 fold, 1.5 fold and 
and 733 but not identified as significantly changed by growth factor 
tor removal, however not 733 treatment (1.4 fold and 2 fold 
tor removal but not 337 siRNA treatment(1.5 fold and 2 fold 
greater with removal of growth factors (activin, Fgf4 or both), 
TSA 
vs N 
TSF 
vs N 
TS 
vs N 
337 
vs Si- 
773 
vs Si- 
N vs 
Si- 
Pvalue Pvalue 
TSF vs 
N 
Pvalue 
TS vs 
N 
Pvalue 
337 vs 
Si- 
Pvalue 
773 vs 
Si- 
Pvalue 
N vs 
Si- 
TSA vs 
N 
 1416039_x_at, 
1438133_a_at  CYR61 
 cyste
angio
induc 1.56
ine-rich, 
genic 
er, 61 -1.30 - -2.02 -1.60 -2.39 
-
1.21
1.33E-
02
3.81E-
04
2.48E-
06
1.00E-
04
8.78E-
07
3.71E-
02 
1438133_a_at cyr61 
 cyste
angio
inducer, 6 1.57
ine-rich, 
genic 
2 -1.31 - -2.18 -1.71 -2.54 
-
1.14
6.76E-
03
1.77E-
04
3.77E-
07
1.34E-
05
1.86E-
07
1.07E-
01 
 1416967_at  SOX2 
 SRY (sex
determini
region Y)-
2 
 
ng 
box 
-2.33 -1.07 -8.62 -1.44 -1.88 1.00
1.03E-
06
4.70E-
01
1.71E-
11
6.54E-
04
1.67E-
05
9.87E-
01 
 1419555_at, 
1419556_at  ELF5 
 E74-like 
factor 5 (e
domain 
transcripti
factor) 1.17
ts 
on 
-1.94 - -2.57 -2.07 -3.17 
-
1.08
1.43E-
09
1.22E-
03
9.38E-
12
1.51E-
10
3.50E-
12
3.78E-
02 
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1419556_at Elf5 
factor 5 (ets 
domain 
transcription 
factor) 
 E74-like 
-2.07 -1.36 -3.43 -2.34 -3.01 1.03
1.38E-
09
9.39E-
06
1.40E-
12
8.21E-
11
1.62E-
11
3.73E-
01 
 1433977_at HS3ST3B1 se 3B1 
 
 heparan 
sulfate 
(glucosamine) 
3-O-
sulfotransfera
-2.35 1.22
8.33E-
07
9.73E-
01
2.04E-
10
1.15E-
05
6.10E-
07
2.43E-
02 -2.29 -1.00 -5.17 -1.76
 1434170_at  WDR40B 
 WD repeat 
domain 40B -3.79 -1.30 -3.32 -1.43 -1.58 9
-
4 3 1.31
5.80E-
09
9.18E-
03
5.36E-
0
5.69E-
04
1.84E
0
4.30E-
0
 1447657_s_at  SYNPO2L 
 synaptopodin 
-1.34 -2.22 -2.01 1.20
2.10E-
03
2.86E-
07
1.91E-
10
2.75E-
06
1.05E-
06
1.71E-
02 -4.17 -1.762-like 
1455961_at 
No term 
via 
ingenuity 1.11 -2.57
matched 
  -2.59 
-
1.14
2.42E-
01
2.36E-
07
1.93E-
07
3.12E-
04
2.21E-
07
1.21E-
01 -2.37 -1.48
1437325_x_at ALDH18A1 
e 
-1.60 1.04 1.63
aldehyde 
dehydrogenas
18 family, 
member A1 -1.61 1.46
8.23E-
04
7.42E-
01
2.62E-
04
1.44E-
03
7.25E-
04
1.66E-
03 -1.48
-
1444038_at AU015836 
expressed 
sequence 
AU015836 -1.96 1.00 1.95
-
1.44
8.31E-
05
3.96E-
02
2.05E-
05
9.51E-
06
2.14E-
06
6.94E-
05 -1.47 -2.27 
1433599_at BAZ1A 
omodomain 
 zinc 
 
-1.17 -1.09 1.02
br
adjacent to
finger domain,
1A -1.74 
-
1.20
1.90E-
02
1.66E-
01
7.40E-
01
8.61E-
06
9.68E-
07
3.93E-
03 -1.48
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1452004_at CALCA 
calcitonin/calcit
d 
-1.95 -1.60 -1.96
onin-relate
polypeptide, 
alpha -1.63 1.01 3.61E-06 9.41E-05 1.13E-06 
1.90E-
04 6.71E-05 
8.36E-
01 -1.47
-
1.37
6.89E-
01
4.84E-
02
5.37E-
08
1.10E-
07
1.53E-
08
9.21E-
07 1452828_at FBXO21 
F-box protein 
21 -1.02 -1.08 1.52 -1.48 -1.70 
1437200_at FCHO2 
main 
1.27 1.06 1.17
FCH do
only 2 -1.50 -1.65 1.31
1.64E-
01
7.06E-
01
3.00E-
01
1.75E-
02
1.01E-
02
8.53E-
02 
-
1416221_at FSTL1 
-like 1 
-1.41 -1.20 -1.12
follistatin
-1.74 
-
1.06
4.34E-
05
4.97E-
03
3.84E-
02
5.57E-
06
4.54E-
07
2.25E-
01 -1.47
asparaginyl-
se 
tRNA 
syntheta -1.39 1.04 1.451452866_at NARS -1.49 -1.74 
-
1.48
5.08E-
05
4.66E-
01
6.37E-
06
3.16E-
06
3.81E-
07
3.79E-
06 
1428666_at, 
1452866_at NARS 
asparaginyl-
tRNA 
synthetase -1.50 -1.00 1.16 -1.68 
-
1.40
3.54E-
05
9.43E-
01
2.09E-
02
1.50E-
05
3.46E-
06
6.75E-
05 -1.49
1454607_s_at PSAT1 
phosphoserine 
aminotransfera
se 1 
-1.63 1.10 1.29 -1.61 -1.55 
-
1.25
4.30E-
03
5.09E-
01
5.99E-
02
2.52E-
03
8.13E-
03
9.96E-
02 
1424556_at PYCR1 
pyrroline-5-
carboxylate 
ductase 1 re -1.41 -1.14 1.43 -1.66 
-
1.37
3.49E-
06
9.68E-
01
1.29E-
06
2.11E-
04
5.12E-
07
3.26E-
04 -1.47
1455812_x_at VASN 1.33 1.06 1.36
vasorin 
-1.47 -1.57 1.19
1.13E-
02
5.26E-
01
4.25E-
03
8.29E-
04
6.07E-
04
6.02E-
02 
-
1443924_at WNK3 
 
ase 3 
1.05 -1.23 -1.27
WNK lysine
deficient 
protein kin
-1.87 1.2
3.73E- 3.29E- 4.80E- 6.37E- 1.86E- 2.66E--
1 01 03 04 06 07 03 -1.48
1416530_a_at NP -1.29 -1.12
nucleoside 
phosphorylas
e -1.42 -1.25 
-
1.40
1.18E- 2.13E- 3.04E- 2.13E- 2.87E- 3.10E-
-2.75 04 02 11 06 04 06 
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1418152_at  
l 
NSBP1
nucleosoma
binding 
protein 1 -2.02 1.18 1.18
- 1.09E- 1.03E- 7.64E- 1 7.80E- 3
1.08 05 01 02
.40E-
03 01
.89E-
01 -1.42 -1.03 
1418681_at ALG13  
n 
og 
-1.33 -1.39
asparagine-
linked 
glycosylatio
13 homol
(S. cerevisiae) -1.48 -1.46 1.2
3.0 1.1 1.7 1.2 3.7 1.9
-2.64 0
6E-
03
2E-
03
7E-
08
2E-
04
8E-
04
2E-
02 
1423271_at 
GJB2/conn ta 
exion26 
gap junction 
protein, be
2, 26kDa 1.22 1.08 3.26 -1.10 
-
1.04
4.03E-
03
2.05E-
01
6.62E-
11
1.05E-
05
9.61E-
02
4.62E-
01 1.45
1427355_at CALCA 
ci
d 
calcitonin/cal
tonin-relate
polypeptide, 
alpha -1.52 -1.43 1.19
1.83E-
07
1.05E-
05
1.54E-
08
6.30E-
05
5.67E-
04
2.31E-
02 -2.36 -1.77 -2.65
1436905_x_at
lysosomal 
associated 
ng 
 LAPTM5 
multispanni
membrane 
protein 5 -1.18 -1.44 -2.41 -1.40 1.21
3.83E-
02
2.45E-
04
1.85E-
08
1.46E-
05
4.63E-
04
1.04E-
02 -1.57
1438750_at ATRX 
thalassemia/m
linked (RAD54 
. 
-1.38 -1.03
alpha 
ental 
retardation 
syndrome X-
homolog, S
cerevisiae) -1.50 -1.05 1.2
1.74E- 8.12E- 2.42E- 2.58E- 6.65E- 3.07E-
 -3.20 9 02 01 07 03 01 02
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1440910_at ESTs 
No match 
found in IPA -1.66 1.13 -4.02 -1.21 1.19
1.51E-
05
1.02E-
01
1.46E-
10
2.05E-
05
1.79E-
02
1.53E-
02 -1.55
No match 
found in IPA -1.44 -1.14 1.17
7.50E- 7.68E- 9.47E- 2.65E- 4.14E- 2.93E-
1442073_at ESTs -2.64 1.05 -5.68 05 01 08 02 01 01 
1437059_at 
 
SOX21 
SRY (sex 
determining 
region Y)-box
21 -1.50 -1.34 1.2
5.81E- 8.20E- 1.39E- 3.58E- 6.81E- 1.17E-
-2.49 1.02 -3.23 7 07 01 08 04 03 02 
1451835_at SOX21 
SRY (sex 
determining 
region Y)-box 
22 -1.46 -1.41 1.07
7.00E- 2.26E- 6.59E- 9.61E- 8.73E- 8.47E-
-2.10 1.12 -2.30 08 04 09 06 04 04 
1455195_at RPS24  
ribosomal 
protein S24 -1.46 -1.29 1.25
8.89E-
04
5.36E-
01
2.62E-
07
9.54E-
04
1.25E-
03
1.67E-
01 -2.01 -1.35 -2.19
1455425_at BB001228 
 
nce 
-1.50 -1.06
expressed
seque
BB001228 -1.43 -1.47 1.13
1.09E-
02
9.38E-
01
2.83E-
06
7.08E-
04
2.93E-
03
3.11E-
01 -2.42
1456036_x_at GSTO1 
S-
-1.36 -1.01
glutathione 
transferase 
omega 1 -1.51 -1.46 1.10
8.14E-
06
2.75E-
01
8.96E-
07
9.11E-
04
4.11E-
03
4.32E-
01 -2.17
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1416630_at ID3 
inhibitor of 
DNA binding 
-
loop-helix 
protein -1.18
3, dominant 
negative helix
2.20 
-
1.32
1.49E-
03
4.09E-
10
4.41E-
10
1.16E-
01
4.19E-
10
5.75E-
06 2.20 2.01 -1.06
1417185_at LY6A -1.51 -1.80
lymphocyte 
antigen 6 
complex, 
locus A 2.47 
-
1.14
3.46E- 1.13E- 6.04E- 8.59E- 1.37E- 3.14E-
 -5.25 -1.01 05 06 12 01 08 02
1417328_at ERCC1 
on repair 
air 
deficiency, 
complementat
  -1.49 -1.04
excisi
cross-
complementin
g rodent 
rep
ion group 1 -1.66 
-
1.36
1.13E- 4.38E- 1.03E- 6.88E- 1.08E- 4.07E-
-2.04 -1.10 05 01 08 02 06 05 
1417426_at 
(includes 
EG:5552) 
 
1, secretory 
PRG1 proteoglycan
granule 2.26 
-
1.33
1.49E-
05
1.28E-
03
2.67E-
10
8.65E-
02
6.71E-
06
1.04E-
02 -2.11 -1.55 -7.01 -1.19
no match found 
in ingenuity 
1110070A0
2  -1.12 -1.32
RIKEN 
cDNA 
 -1.68 
-
1.13
2.26E- 7.59E- 2.09E- 6.87E- 8.54E- 1.34E-
 -2.39 -1.03 01 03 07 01 05 01
1417487_at FOSL1 
FOS-like 
antigen 1 -2.02 -1.24 -2.26 -1.17 -1.68 
-
1.46
1.60E-
06
1.71E-
02
1.19E-
07
4.06E-
02
2.90E-
05
1.76E-
04 
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1418296_at FXYD5 
ain 
 
-1.45 -1.12
FXYD dom
containing ion
transport 
regulator 5 2.30 
-
1.34
2.28E-
04
1.19E-
01
9.99E-
08
2.59E-
01
1.16E-
07
6.01E-
04 -2.13 -1.08
1418762_at CD55 
 
nt 
r blood 
-1.60 -1.55
CD55 
molecule, 
decay 
accelerating
factor for 
compleme
(Crome
group) -1.61 1.02
5.79E-
05
1.08E-
04
1.04E-
10
2.35E-
01
4.92E-
05
7.73E-
01 
-
-4.72 -1.09
1443906_at, 
1460242_at CD55 -1.61 -1.61 -1.61 
-
1.11
6.63E-
04
7.03E-
04
8.21E-
09
4.12E-
02
6.51E-
04
2.89E-
01   -4.10 -1.23
  CD55   -1.59 -1.89 -6.26 -1.53 
-
1.12
1.00E-
04
5.79E-
06
2.89E-
11
5.26E-
01
2.12E-
04
1.42E-
01 -1.05
-1.83 1.1
2.03E- 2.54E- 8.62E- 4.61E- 3.43E- 1.03E-
 1418805_at SCT secretin 2.21 2.17 2.16 -1.30
-
9 09 09 10 05 08 03
1420498_a_a
disabled 
homolog 2, 
mitogen-
sponsive 
rotei
hila) t DAB2 
re
phosphop
n (Drosop 2.55 -2.42 -1.01 -1.88 
-
1.18
6.39E-
11
1.17E-
10
8.07E-
01
6.66E-
02
4.45E-
09
4.65E-
04 -1.07
1420911_a_at MFGE8 
globule-EGF 
factor 8 
protein -1.00 -1.86
milk fat 
-1.56 
-
1.03
9.67E-
01
9.26E-
08
5.72E-
09
1.30E-
01
2.61E-
06
4.97E-
01 -2.07 -1.08
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1421882_a_at ELAVL2 
vision, 
hila)-
-1.59 -1.61
ELAV 
(embryonic 
lethal, 
abnormal 
Drosop
like 2 (Hu 
antigen B) -1.97 
-
1.11
1.23E-
04
9.82E-
05
5.12E-
07
1.33E-
01
3.72E-
06
1.60E-
01 -2.10 -1.12
1422776_at SERPINB8 
lbumin), 
member 8 -1.22 -1.83
serpin 
peptidase 
inhibitor, clade 
B (ova
-1.88 1.12
3.45E-
02
1.50E-
05
9.16E-
07
1.58E-
03
1.02E-
05
1.47E-
01 -2.06 -1.36
-
1422851_at HMGA2 
high mobility 
oup AT-
hook 2 
gr
-2.15 -1.46 -1.62 -1.26 -2.18 
-
1.11
1.59E-
06
7.72E-
04
4.26E-
05
9.38E-
03
1.34E-
06
1.72E-
 01
1450780_s_at, 
1450781_at     -2.10 -1.39 -1.49 -1.18 -1.93 1.08 06 03 04 02 05 01 
- 4.03E- 3.29E- 3.61E- 6.00E- 1.24E- 3.52E-
      -1.80 
-
1.01
1.13E-
07
1.67E-
05
3.99E-
07
5.48E-
03
2.08E-
06
8.93E-
01 -2.19 -1.60 -1.86 -1.22
Zic family 
member 3 
heterotaxy 1 
(odd-paired 
homolog, 
Drosophila) -2.29 1.08
8.59E-
07
7.85E-
03
2.03E-
09
6.78E-
01
4.39E-
05
5.27E-
01 1423424_at ZIC3 -3.51 -1.51 -7.47 -1.05
-
1438737_at ZIC4   -2.05 -1.25 -2.39 -1.22 -1.62 
-
1.04
7.35E-
06
3.22E-
02
3.51E-
07
3.31E-
02
2.45E-
04
6.12E-
01 
 161
1423747_a_at PDK1 
pyruvate 
nas
e 1 
dehydroge
e kinase, 
isozym -2.22 
-
1.03
1.35E-
03
8.39E-
01
4.68E-
01
4.87E-
01
5.67E-
04
8.66E-
01 -2.03 -1.04 -1.12 -1.11
-1.87 
-
1.14
2.98E-
08
7.95E-
06
1.10E-
07
4.29E-
01
1.55E-
07
2.16E-
02 1423952_a_at KRT7 keratin 7 2.08 -1.52 -1.78 -1.04
1424938_at STEAP1 
ran
e epithelial 
antigen of the 
-1.17
six 
transmemb
prostate 1 -1.57 
-
1.06
2.60E-
02
3.73E-
08
1.79E-
06
3.27E-
04
1.34E-
05
3.39E-
01 -2.26 -1.65 -1.32
1425811_a_at CSRP1 
cysteine and 
glycine-rich 
protein 1 2.00 -1.39 -1.96 -1.78 
-
1.06
4.26E-
07
3.99E-
04
1.96E-
07
9.91E-
01
2.79E-
06
3.28E-
01 -1.00
1426243_at CTH 
onase 
tathionine 
gamma-lyase) -1.17 -1.70
cystathi
(cys
-1.55 1.00
8.91E-
03
4.60E-
07
1.22E-
10
7.49E-
05
3.20E-
06
9.55E-
01 
-
-2.82 -1.32
1426258_at 
ORL1 
(includes 
EG:6653) 
ortilin-related 
receptor, 
DLR class) S
s
L(
A repeats-
containing -1.54 
-
1.09
9.68E-
07
9.16E-
04
5.81E-
09
7.92E-
01
3.32E-
04
2.59E-
01 -2.27 -1.46 -3.34 -1.02
1427364_a_at ODC1 
e 
-1.58 -1.14
ornithine 
decarboxylas
1 -1.84 
-
1.4
4.44E- 8.92E- 1.82E- 9.24E- 2.86E- 1.68E-
-2.05 -1.01 2 05 02 07 01 06 04 
1428187_at CD47 molecule 
CD47 
-1.75 1.3
7.3 6.3 2.4 1.5 2.2 7.2
2.20 -1.34 -1.24 -1.09
-
0
0E-
08
2E-
04
5E-
03
0E-
01
1E-
06
2E-
04 
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-1.80 
-
1.24
2.35E-
08
1.17E-
05
1.43E-
04
2.45E-
02
1.34E-
07
5.33E-
04 1449507_a_at CD47   2.01 -1.45 -1.29 -1.12
1428209_at BEXL1 
X-
brain 
expressed 
linked-like 1 -1.90 -2.11 -1.33 -1.36 -2.01 
-
1.06
1.01E-
08
2.11E-
09
1.12E-
05
5.84E-
06
4.43E-
09
1.40E-
 01
1428622_at DEPDC6 
ain 
ning 6 
DEP dom
contai -1.34 -1.50 -2.26 -1.78 
-
1.13
1.40E-
04
8.34E-
06
1.98E-
09
8.18E-
03
2.48E-
07
2.54E-
02 -1.16
1443579_s_at, 
1451348_at DEPDC6   -1.49 -1.60 -2.67 -1.73 
-
1.00
1.05E-
05
2.01E-
06
3.15E-
10
9.18E-
02
4.53E-
07
9.85E-
01 -1.09
  DEPDC6 -1.35 -1.62  -1.86 1.0
3.59E- 9.65E- 4.46E- 4.66E- 9.63E- 5.88E-
 -2.59 -1.18
-
4 03 05 08 02 06 01
1428662_a_at HOP 
homeodom
-only protein 
ain
-1.35 -1.21 -2.22 -1.78 
-
1.13
3.18E-
04
6.51E-
03
8.67E-
09
3.76E-
02
7.24E-
07
3.38E-
02 -1.13
1451776_s_at HOP 
homeodomain
-only protein -1.28 -1.23 -1.64 
-
1.18
1.70E-
04
6.05E-
04
1.63E-
09
1.21E-
01
2.37E-
07
1.53E-
03 -2.04 -1.07
1429646_at 
1700
3RIK 
112C1
RIKEN cDNA 
1700112C13 
gene -2.38 -2.16 -3.03 -1.23 -2.19 
-
1.05
1.67E-
08
5.81E-
08
3.72E-
10
2.63E-
03
4.88E-
08
3.63E-
01 
1429759_at RPS6KA6 
ribosomal 
protein S6 
kinase, 
90kDa, 
polypeptide 6 -1.13 -1.11 2.27 -2.16 
-
1.27
1.18E-
01
1.78E-
01
8.45E-
08
2.80E-
01
5.04E-
07
4.18E-
03 -1.08
-1.55 1.2
4.20E- 1.15E- 1.89E- 1.15E- 8.07E- 1.35E-
 1429761_at RTN1 -1.61 -1.18reticulon 1 2.68 -1.30
-
9 04 01 07 02 04 02
1434025_at 
no matc
found in 
h 
ity ingenu Klf5 -1.60 -1.30 -2.80 -1.11 -1.84 
-
1.14
2.05E-
04
1.08E-
02
3.73E-
08
2.04E-
01
2.07E-
05
1.18E-
01 
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1437277_x_at TGM2 
ansglutamin
(C 
erase) -1.93
tr
ase 2 
polypeptide, 
protein-
glutamine-
gamma-
glutamyltransf
-1.60 1.01
1.78E-
07
7.91E-
08
6.18E-
08
1.65E-
01
5.06E-
06
8.00E-
01 2.04 -1.92 -1.08
-
1438118_x_at -1.53 
-
1.28
4.65E- 5.89E- 6.45E- 5.18E- 1.49E- 3.48E-
VIM vimentin -1.62 -2.15 -1.97 -1.05 05 07 07 01 04 03 
1439341_  
NA 
equence 
AK220484 at AK220484
cD
s
2.20 -1.56 -1.37 -1.13 -1.69 
-
1.31
7.11E-
10
2.71E-
07
3.00E-
06
5.97E-
03
5.51E-
08
1.33E-
05 
1447640_s_at PBX3 
pre-B-cell 
leukemia 
transcription 
factor 3 -3.39 -1.39 -4.13 -1.10 -1.64 
-
1.07
3.31E-
09
8.04E-
04
2.04E-
10
1.59E-
01
2.98E-
05
3.43E-
01 
1448562_at UPP1 
uridine 
phosphorylas
e 1 -1.49 -2.69 -1.46 -4.98 
-
1.39
7.37E-
04
1.78E-
07
4.80E-
04
4.60E-
01
1.11E-
09
1.33E-
03 -1.06
1448752_at CA2 II -1.86 -1.56
carbonic 
anhydrase -1.57 
-
1.06
5.68E-
09
1.72E-
07
4.31E-
11
6.72E-
01
1.55E-
07
1.19E-
01 -2.39 -1.02
1448804_at CYP11A1 
cytochro
P450, family 
11, subfamily 
me 
ide A, polypept
1 -1.59 -1.26 -2.19 -1.16 2.13 
-
1.14
3.30E-
06
1.24E-
03
5.13E-
09
9.96E-
03
2.41E-
08
1.95E-
02 
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1449235_at FASLG  6) -1.13
Fas ligand 
(TNF 
superfamily, 
member -1.79 
-
1.21
2.89E-
02
7.56E-
09
6.86E-
03
2.11E-
01
1.34E-
07
1.31E-
03 2.16 -1.16 -1.06
1449852_a_at EHD4 -1.82 -1.42
EH-domain 
containing 4 -1.88 
-
1.29
7.40E- 7.83E- 2.74E- 4.46E- 4.58E- 3.44E-
-2.55 -1.06 06 04 08 01 06 03 
1450791_at NPPB 
etic 
 B 
natriur
peptide 
precursor -1.73 -1.57 -2.89 2.38 
-
1.49
8.49E-
06
5.06E-
05
3.27E-
09
2.50E-
04
8.68E-
08
5.91E-
05 -1.40
1453304_s_at LY6E 
 
-1.62 -1.03
lymphocyte
antigen 6 
complex, 
locus E -1.76 
-
1.27
1.47E-
05
6.52E-
01
1.94E-
08
3.10E-
01
3.18E-
06
1.89E-
03 -2.30 -1.06
1454869_at WDR40B 
WD repeat 
domain 40B -3.13 -1.20 -3.65 -1.73 
-
1.42
1.15E-
05
2.47E-
01
1.18E-
06
3.35E-
02
4.16E-
03
2.45E-
02 -1.39
1456326_at GM784 
odel gene m
784, (NCBI) -1.98 
-
1.2
9.00E- 6.18E- 3.43E- 4.19E- 3.80E- 2.95E-
-4.50 -1.91 -3.28 -1.33 4 11 07 10 04 07 03 
1458667_at KIAA0980 
0980 
-1.91 -1.11
KIAA
protein -1.62 1.0
4.7 5.6 6.5 1.3 2.4 8.9-
2
4E-
03
7E-
01
0E-
04
1E-
01
1E-
02
4E-
01 -2.16 -1.31
1430516_at 
4930428B0
1Rik 
 
RIKEN cDNA 
4930428B01
gene -3.52 -1.08 -1.00 
-
1.23
1.56E-
08
2.40E-
01
5.71E-
10
2.58E-
01
9.97E-
01
8.38E-
03 -2.80 -1.09
1434528_at AARD 
amin 
containing 
protein 
alanine and 
arginine rich 
do
-5.62 -1.07 -1.13 
-
1.07
7.84E-
09
1.37E-
01
1.24E-
13
1.26E-
01
2.01E-
02
1.12E-
01 -2.00 -1.07
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1417976_at Ada 
adenosine 
deaminase -1.57 -1.43 -3.73 -1.38 -1.10 
-
1.32
1.70E-
05
1.37E-
04
8.77E-
11
1.21E-
04
1.64E-
01
3.80E-
04 
1454822_x_at 
d1/EI
G180 
s 
i 
downregulate
 
Apcd
adenomatosi
polyposis col
d/ethanol 
induced gene
product 
EIG180 -3.77 -1.09 -1.11 1.29
3.07E-
06
2.25E-
03
2.83E-
09
2.71E-
01
2.66E-
01
7.06E-
03 
-
-2.12 -1.41
1422396_s_at Ascl2 
e 
-1.57 -1.16
mammalian 
achaete scut
homolog 2 4.17 -1.13 -1.04 
-
1.09
1.20E-
04
8.36E-
02
3.83E-
10
1.00E-
01
6.23E-
01
2.27E-
01 
1432018_at 
s
h2 
scute 
 -1.90 -1.40
Ascl2/Ma
achaete-
complex 
homolog 2 
(Drosophilia) 5.27 -1.24 -1.23 1.2
1.4 1.2 4.3 5.8 9.8 6.2-
3
2E-
04
9E-
02
8E-
09
7E-
02
2E-
02
6E-
02 
1460514_s_at 
Ascl2/Mas
ute 
 
-1.68 -1.30h2 
achaete-sc
complex
homolog 2 
(Drosophilia) 4.91 -1.25 -1.17 
-
1.2
2.78E- 5.58E- 9.94E- 7.99E- 5.84E- 9.69E-
4 05 03 11 03 02 03 
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1420947_at ATRX 
a/m
ental 
-1.44 -1.18
apha 
thalassemi
retardation 
syndrom X 
linked, X-
linked nuclear 
protein -3.70 -1.03 -1.18 
-
1.06
2.10E-
02
2.57E-
01
3.30E-
07
8.27E-
01
2.48E-
01
6.22E-
01 
1440156_s_at AV026525 
expressed 
sequenc
AV02652
e 
5 -3.05 -1.12 -4.73 -1.08 -1.10 
-
1.02
2.32E-
08
1.78E-
01
2.10E-
10
3.05E-
01
2.76E-
01
7.91E-
01 
1422912_at Bmp4 
bone 
morphogeneti
c protein 4 -5.20 -1.37 -5.55 -1.59 
-
1.83
5.98E-
10
3.02E-
03
1.19E-
10
9.15E-
01
1.70E-
04
5.55E-
06 -1.01
1453651_a_at Brp44l 
brain protein 
44-like -1.34 -1.33 2.66 
-
1.53
1.15E-
03
1.22E-
03
2.71E-
11
1.08E-
02
1.46E-
08
2.10E-
05 -4.84 -1.20
1418507_s_at s2 protein 2 
Cish2/Soc
cytokine 
inducible 
SH2-
containing 
-4.83 -1.05 -1.48 1.16
4.11E-
11
1.41E-
02
3.10E-
12
3.20E-
01
1.77E-
05
1.06E-
02 -4.01 -1.17
-
1449109_at 
Cish2/Soc
s2 
cytokine 
inducible 
SH2-
containing 
protein 2 -4.14 -1.25 -5.11 -1.33 
-
1.26
9.53E-
10
1.16E-
02
6.43E-
11
7.59E-
02
2.84E-
03
5.63E-
03 -1.14
1419430_at Cyp26a1 
cytochrome 
P450, 26, 
retinoic acid -6.49 -1.16 -1.07 
-
1.84
2.38E-
09
3.91E-
02
3.52E-
10
1.32E-
01
4.98E-
01
2.96E-
05 -5.75 -1.27
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1428834_at DUSP4 
dual 
specificity 
phosphatase 
4 -1.49 -1.41 
-
1.61
1.31E-
07
1.03E-
03
3.66E-
09
5.37E-
04
3.74E-
03
1.34E-
04 -3.02 -1.51 -4.03
1415834_at Dusp6 
dual 
specificity 
phosphatase 
6 -6.84 -1.07
-
11.2
-1.31 2.53
1.31E-
08
6.31E-
01
3.51E-
10
7.96E-
03
6.46E-
02
6.58E-
06 0 -1.46
1426001_at 
eomes/Tbr
2 
mi
-1.67 -1.01
eomesoder
n homolog -3.99 -1.01 -1.16 
-
1.0
1.56E- 8.64E- 1.46E- 8.26E- 1.96E- 4.72E-
4 06 01 11 01 02 01 
1435172_at 
Eomes/tbr
2 
eomesoder
n homolog 
mi
-1.58 -1.08 -3.62 -1.09 -1.30 
-
1.04
7.56E-
08
5.20E-
02
3.36E-
13
1.88E-
02
1.59E-
05
2.77E-
01 
1436926_at Esrrb 
estrogen 
related 
receptor, beta -3.03 -1.27 -6.31 -1.02 -1.02 
-
1.51
6.61E-
09
5.94E-
03
8.42E-
12
7.48E-
01
7.89E-
01
4.13E-
 05
1428816_a_at Gata2   -1.27 -1.57 4.04 1.17 
-
1.11
2.64E-
02
4.64E-
04
3.07E-
09
6.35E-
01
1.07E-
01
2.14E-
01 -1.04 -
1450333_a_at Gata2 
ding 
n 2 -1.85
GATA bin
protei 5.11 -1.13 -1.19 
-
1.50
2.02E-
08
2.01E-
09
1.72E-
13
8.18E-
03
2.39E-
03
4.72E-
07 2.15
1430357_at H3f3b 
H3 histone 
family 3B -1.59 -1.33 4.46 -1.07 -2.63 
-
3.42
3.32E-
05
1.55E-
03
6.78E-
11
2.92E-
01
2.30E-
08
5.60E-
10 
1454159_a_at 
 
tor 
Igfbp2 
insulin-like
growth fac
binding 
protein 2 3.74 -1.31 -1.39 -1.14 -1.28 
-
1.18
8.75E-
11
5.64E-
04
3.84E-
05
2.33E-
02
9.84E-
04
5.99E-
03 
1418045_at Inpp1 
inositol 
polyphospha
e-1-
phosphatase
t
 -3.52 -1.23 -7.12 -1.16 -1.06 
-
1.24
4.25E-
09
2.02E-
02
1.07E-
11
5.76E-
02
4.58E-
01
8.45E-
03 
 168
1423294_at Mest 
derm 
-1.28 -1.28
meso
specific 
transcript -3.86 -1.09 -1.09 
-
1.4
1.35E- 1.61E- 3.52E- 1.39E- 1.80E- 3.15E-
3 03 03 11 01 01 05 
1416298_at Mmp9 
atrix 
llopeptid
m
meta
ase 9/ 
gelatinase - -1.14 -1.38 
-
1.11
3.12E- 7.79E- 9.30E- 9.63E- 1.81E- 1.51E-
 -3.80 -1.62 5.24 09 05 11 02 03 01
1448291_at Mmp9 
matrix 
metalloprotein
ase 9 -2.78 -1.60 -6.73 -1.13 -1.28 
-
1.10
1.03E-
06
9.40E-
04
4.90E-
10
2.27E-
01
3.90E-
02
3.56E-
01 
1422771_at mSmad6 Smad6 -1.43 -1.19 -4.64 -1.43 
-
1.14
4.61E-
05
9.05E-
03
5.03E-
12
4.55E-
03
5.27E-
05
2.49E-
02 -1.19
1428942_at Mt2 
oneimetallothi
n 2 4.60 -1.13 -1.17 
-
2.0
1.95E- 8.13E- 1.03E- 1.38E- 7.09E- 3.87E-
2.34 -1.01 4 09 01 12 02 03 09 
1436702_at NAT8L 
N-
acteyltransfer
ase 8-like -3.25 -1.18 -3.53 -1.00 -1.13 
-
1.10
4.56E-
09
4.11E-
02
6.67E-
10
9.72E-
01
1.18E-
01
1.68E-
01 
1450976_at Ndr1 
N-myc 
downstream 
regulated 1 -1.80 -1.33 4.32 -1.41 
-
1.68
1.09E-
04
1.61E-
02
4.58E-
09
2.28E-
01
5.80E-
03
1.22E-
 04-1.12
1456174_x_at Ndr1 
m 
N-myc 
downstrea
regulated 1 -1.91 2.03
1.62E-
05
4.43E-
03
3.66E-
09
2.05E-
01
8.32E-
05
1.41E-
05 
-
2.18 -1.47 4.97 -1.14
1420760_s_at Ndrl 
m 
-
N-myc 
downstrea
regulated
gene-1 5.49 -1.15 -1.50 2.00
6.78E-
05
6.43E-
03
8.36E-
09
2.44E-
01
7.53E-
03
6.08E-
05 2.15 -1.51
-
1434270_at NPTXR 
pentraxin 
receptor -2.43 -1.29 -4.67 -1.16 -1.42 
-
1.18
1.49E-
06
2.31E-
02
1.60E-
09
1.06E-
01
3.56E-
03
7.61E-
02 
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1417760_at Nr0b1 
0, 
nuclear 
receptor 
subfamily 
group B, 
member 1 -1.90 1.77
3.22E-
12
4.90E-
08
9.74E-
13
2.53E-
01
1.12E-
06
1.19E-
06 -8.49 -2.39 -8.46 -1.07
-
1428140_at Oxct 
3-oxoacid 
CoA 
transferase -1.86 -1.48 -3.51 -1.07 -1.14 
-
1.14
8.26E-
06
4.17E-
04
1.95E-
09
3.33E-
01
1.29E-
01
9.61E-
02 
1417837_at PHLDA2 
pleckstrin 
homology like 
 family domain,
A, member 2 -1.69 2.04 3.76 -1.12 -1.08 
-
1.39
1.01E-
04
6.10E-
06
3.68E-
09
1.71E-
01
4.10E-
01
1.69E-
03 
1417553_at PLAC1 
placenta 
specific 1 -1.76 2.21 6.06 -1.11 -1.01 
-
1.62
1.09E-
04
5.16E-
06
3.48E-
10
2.52E-
01
9.29E-
01
1.62E-
04 
1423933_a_at  plet1 
placenta 
expressed 
transcript 1 -3.05 -1.04 -4.54 -1.07 -1.66 
-
1.60
1.04E-
08
6.24E-
01
1.22E-
10
3.49E-
01
2.72E-
05
1.80E-
05 
1454254_s_at plet1 
placenta 
expressed 
transcript 1 -3.19 -1.14 -5.07 -1.75 
-
1.62
1.22E-
07
1.91E-
01
1.10E-
09
5.95E-
01
1.26E-
04
1.65E-
04 -1.05
1460038_at POU3F1 
 
POU domain 
class 3 
transcription
factor -3.55 -1.21 -1.25 1.27
5.27E-
08
7.37E-
01
9.82E-
11
4.63E-
03
3.56E-
03
9.70E-
04 -2.19 -1.02
-
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1438671_at PPP2r2C 
protein 
phospha
2 regulatory 
subunit B, 
gamma 
isoform 
tase 
-1.12 -1.33 -4.04 -1.03 -1.28 
-
1.10
1.23E-
01
1.78E-
03
1.69E-
10
6.31E-
01
4.77E-
03
1.65E-
01 
1420664_s_at Procr 
protein C 
receptor, 
endothelial -2.27 -1.20 -3.63 -1.33 
-
1.42
1.04E-
08
6.54E-
03
2.41E-
11
4.18E-
02
2.67E-
04
1.74E-
05 -1.12
1417928_at 
Ril-
pending -1.82 -1.08
reversion 
induced LIM 
gene 3.76 -1.12 -1.15 
-
1.2
1.39E- 3.46E- 1.44E- 1.56E- 1.23E- 1.05E-
5 05 01 09 01 01 02 
1423025_a_at Schip1 
schwannomin 
g interactin
protein 1 -1.72 -1.20 -4.01 -1.04 -1.20 
-
1.37
1.78E-
06
1.02E-
02
2.88E-
11
4.77E-
01
1.04E-
02
9.30E-
05 
1436584_at Spry2 
sprouty 
homolog 2 
(Drosophila) -3.27 -1.14 -5.01 -1.30 -1.38 
-
1.33
7.60E-
08
1.97E-
01
9.21E-
10
9.81E-
03
5.58E-
03
5.95E-
03 
1427072_at S   TARD8
START 
domain 
containing 8 -1.27 -2.14 -4.23 -1.37 
-
1.06
1.59E-
02
2.03E-
06
8.94E-
10
5.11E-
02
3.58E-
03
4.42E-
01 -1.18
1451458_at TMEM2 
ntransmembra
e protein 2 -3.68 -1.02 -1.16 1.02
6.99E-
07
3.37E-
02
1.59E-
09
8.29E-
01
9.21E-
02
7.47E-
01 -2.25 -1.22
-
1417122_at VAV3 
vav 3 
oncogene -1.11 -1.07 3.56 -1.37 
-
1.19
2.97E-
01
4.98E-
01
7.82E-
09
1.43E-
02
5.80E-
03
5.53E-
02 -1.27
1456140_at Zic5 
zinc finger 
protein of the 
cerebellum 5 -5.00 -1.01 -1.10 
-
1.35
1.75E-
09
2.16E-
02
2.84E-
11
9.01E-
01
2.08E-
01
5.20E-
04 -3.41 -1.20
1456219_at Zic5 
Zic family 
member 5 -5.96 -1.02 -1.14 
-
1.47
1.16E-
06
2.03E-
01
8.36E-
09
8.40E-
01
3.22E-
01
6.61E-
03 -3.44 -1.19
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1434705_at ZRANB1 
ger zinc fin
RAN binding 
domain 
containing 1 -2.28 -1.00 -3.76 -1.17 -1.25 
-
1.25
1.41E-
05
9.83E-
01
4.23E-
08
1.39E-
01
7.25E-
02
4.66E-
02 
1425
DNA 
J11 
887_at   
RIKEN c
4930511
gene -2.72 -1.39 -3.78 -1.20 -1.02 
-
1.01
1.55E-
08
5.21E-
04
2.30E-
10
1.37E-
02
8.30E-
01
8.26E-
01 
1427518_at   
Mus musc
mRNA for zin
finger protein,
partial cds 
ulus 
c 
 
-2.11 -1.20 -3.57 -1.23 -1.06 
-
1.43
6.97E-
07
3.46E-
02
8.13E-
10
1.02E-
02
4.49E-
01
2.05E-
04 
1439535_at   ESTs -1.31 -1.19 3.77 -1.09 -2.04 
-
2.48
3.90E-
03
4.05E-
02
5.89E-
10
2.44E-
01
1.17E-
06
3.28E-
08 
1448600_s_at 
n 
  
Unknow
(protein for 
MGC:27838) -1.10 -1.10 3.74 -1.25 -1.22 
-
1.20
2.31E-
01
2.60E-
01
8.98E-
10
8.36E-
03
2.58E-
02
2.53E-
02 
1460121_at   
ESTs, Hi
similar to
S12207 
ghly 
 
] 
hypothetical 
protein 
[M.musculus -1.99 -1.80 4.00 -1.01 -1.05 
-
1.43
1.81E-
07
8.64E-
07
3.35E-
11
8.40E-
01
4.24E-
01
3.77E-
05 
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5.1.12.2 Real Time PCR validation of expression 
Because microarray data is subject to many sources of variation (Affymetrix Inc., 
2006b), and even with a low p val e, r tho nds of genes em would be 
expected to “change” simply due to chance. The gold standard has been verification of 
expre ev antita ., 2006). Usin otated set of 
genes PCR primers were desig fo me e genes iden ch union that 
had b signed a name and d P e design amed 
genes tified as changed w 7 eatments, h er not all primers 
design re ssful. Th  w btained fro trez and Primers 
design as d  2.2.3.3.3  T cont  expression f d via the microarray 
and the corresponding relative expression found using real time PCR for each gene 
investig   5.1-13- 5.1-14).  
In gener e fo hange found u g l tim CR had a hig orrelation with the 
microarray results, and in fact many times a greater folds change was found. Only two 
genes measured had a fold change expres  diff om that measured using the 
microarray, and of these it was not for all of the different treatments. To test if genes 
which app ared e down regul h Elf5 nockdown were up-regulated with 
Elf5 over-expression, an Elf5 expressing construct (pTracer-Elf5) was transiently 
transfec into  2 .7.4) is gave a 5 fo  up-regulation in 
Elf5.expr ion twenty-four hour enes C 1 and Baz1a which 
had sho egulation f5 k down, show a significant up-
regulatio he  Spi8 also sho  regulation, ever this was not 
significant.  
 
u  ove usa some of th
ssion l els using qu tive PC
ned 
R (Ku
r so
o et al
of th
g the ann
tified in ea
een as
 iden
escri
ith 
ption. 
33 and 3
rimers wer
37 tr
ed for all of the n
owev
ed we
ed 
 succe
escribed in 
e sequ
.
ences
he 
ere o
rast
m En
oun
ated is shown below (tables
al th ld c sin  rea e P h c
sion erent fr
e to b ated wit  k
ted  mTS cells (section .2.1 . Th ld
ess
wn a do
s after transfection. The g
 with
yr6
ed wn r  El nock
n. T gene wed a 1.5fold up how
Table  5.1-15: Validation of differentially expressed genes usi the he 733 
siRNA treatment, 337 siRNA treatment and any of the growt mple e  
control.  Bold P<0.05, Bold and Italics P<0.01. 
  
  
  
  
Fold Change measured by the 
microarry 
 Relati R 
g
n
ng real time PCR. The fold change difference measured using 
h factor experiments. Also included is relative expression of sa
ve Expression measured using real time RT-PC
microarray and by real-time PCR for selected in the union of t
s transiently transfected with an Elf5 construct compared to th
 
Standard deviation of real time RT-PCR 
results (n=3) 
A
e
blank
reem
t 
TSF/N TS/N 337/Si- 733/Si- 
elf5 over-
expressio
n/blank 
control 
TSA/
N 
TSF/
N 
TS/
N 
337/
Si- 
733/
Si- 
elf5 
over-
express
ion/bla
nk 
control  
Gene 
name 
TSA TSF TS vs 337 773 vs TSA/
vs N vs N N vs Si- Si- N 
 
CYR61 -1.30 -1.56 -2.02 -1.60 -2.39 -1.25 1.40  -1.65 -3.43 -1.81 -3.52 0.03 0.07 0.08   0.17 0.87 Y
 SOX2 -2.33 -1.07 -8.62 -1.44 -1.88 -2.53 1.11  -1.14 -11.69 -1.30 -1.62 0.04 0.06 0.01 0.11 0.07 0.27 Y
 ELF5 -1.94 -1.17 -2.57 -2.07 -3.17 -2.01 5.5  -1.18 -3.12 -2.85 -4.15 3 0.03 0.07 0.02 0.05 0.03 1.52 Y
 
HS3ST
3B1 -2.29 -1.00 -5.17 -1.76 -2.35 -1.07 1.01
 f
R
 for 
F 2.07 -3.61 -2.67 -2.53 0.14 0.35 0.08 0.06 0.09 0.46
Y
si
N
G
or 
NA, 
 
WDR4
0B -3.79 -1.30 -3.32 -1.43 -1.58 -4.02 1.27  -1.43 -4.66 -1.26 -1.61 0.08 0.06 0.03 0.13 0.07 0.19 Y
 
SYNP
O2L -1.34 -2.22 -4.17 -1.76 -2.01 -1.25 1.29  -1.69 -3.39 -1.68 -2.67 0.13 0.07 0.04 0.14 0.06 0.23 Y
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Table  5.1-16 Validation of differentially expressed genes using real time PCR. The fold change difference measured using the microarray and by real-time PCR for selected in the union of the 733 
siRNA and 337 siRNA treatment however exclucding genes differentially expressed by growth factor removal. Also included is relative expression of samples transiently transfected with an Elf5 
construct compared to the blank control.  Bold P<0.05, Bold and Italics P<0.01.   
the microarray Relative Expression (real time PCR) 
Standard deviation (n=3) 
     Fold Change measured by 
elf5 over-expression/blank  
33
 Elf5 over-expression/blank 
Gene Name 337 vs Si- 773 vs Si- 337/si 733/si control 7/si- 733/si- control Agreement 
ALDH18 .4 -1.72 -1.80 Y A1 -1 8 -1.61 1.36 0.08 0.08 0.20
BAZ1A - 0 8 Y -1.48 -1.74 -1.47 1.54 1.64 .10 0.0 0.28
CALCA -1.47 -2.59 -3.39 -1.14 0.18 0.13 0.21 Y -1.63
FBXO21 48 -1.7 -1. 1.23 0.0 0 0. Y -1.  -1.70 5 77 9 .09 19
FCHO2 50 -2. -1. 1.29 0.0 0 0. Y -1. -1.65 09 51 9 .28 34
FSTL1 -1.47 -1.74 -2.00 -1.02 0 0 0 Y -1.90 .21 .09 .27
NARS -1.49 -1.74 -1.83 -2.05 1.45 0.09 0.08 0.33 Y 
PSAT1 -1.61 -1.55 -1.83 -1.96 -1.17 0.10 0.14 0.17 Y 
PYCR1 47 -1.9 -2.5 1.01 0.0 0 0. Y -1.  -1.66 7 3 8 .06 25
WNK3 -1.48 -1.87 -1.64 -1.76 -1.05 0.03 0.12 0.24 Y 
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Table  5.1-17: Validation of differentially expressed genes using real time PCR. The fold change difference measured using the microarray and by real-time PCR for selected genes in the union of the 733 
siRNA and any of the growth factor experiments excluding genes differentially expressed by 337 siRNA treatment. . Also included is relative expression of samples transiently transfected with an Elf5 
construct compared to the blank control.  Bold P<0.05, Bold and Italics P<0.01.   
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he fold change difference measured using the microarray and by real-time PCR for selected in genes differentially 
expressed by greater than 3.5 fold by removal of either Fgf4 or activin or both. Bold P<0.05, Bold and Italics P<0.01. 
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Table  5.1-18 Validation of differentially expressed genes using real time PCR. T
Fold Change Standard deviation 
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Ascl2 7 -1.16 17 1.72 2.69 6 2.12 5.32 Y -1.5 4. .81 0.93
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Gata2 -1.27 -1.57 4.04 1.41 2.62 4.28 0.71 0.84 2.34 Y 
Mmp9 -3.80 -1.62 -5.24 -2.78 -1.53 -8.64 0.15 0.17 0.03 Y 
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CHAPTER 6 : DISCUSSION 
o model system. TS cells are 
ed from the polar trophectoderm of the blastocyst and appear to faithfully 
recapitulate the early in vivo development of the placenta requiring Fgf4 and Nodal 
gnalling for their maintenance, thereby recapitulating the in vivo signalling from the 
epiblast to the adjacent polar trophectoderm(Erlebacher et al., 2004; Tanaka et al., 
1998). Futhermore, TS cells express the same set of genetic markers as expressed by 
the polar trophectoderm and extra-embryonic ectoderm. TS cell differentiation can be 
induced by removing growth factor signalling (Fgf4 and/or Activin) whereupon they 
differentiate into the same downstream cell types seen after in vivo differentiation of 
the ExE (giant cells, syncytiotrophoblasts) (Hemberger et al., 2004). TS cells have also 
been shown to be able to contribute to all cell types of the placenta in mouse chimeras 
(Tanaka et al., 1998). Therefore the in vitro study of Elf5 target genes in TS cells 
seemed warranted. The experimental approach consisted in modulating Elf5 
expression in TS cells and then measuring the resulting changes in gene expression to 
identify possible target genes. A similar approach has been used in identifying the 
target genes of other transcription factors such as the target genes of Oct4 in 
embryonic stem cells (Babaie et al., 2007; Matoba et al., 2006). Modulation of Elf5 
expression was attempted using two approaches: siRNA mediated silencing of Elf5 and 
inducible over-expression of Elf5.  
6.2 DEVELOPMENT OF AN Elf5 INDUCIBLE TS CELL LINE 
A TS cell line was unable to be developed which inducibly expressed the Elf5 gene 
using the TET On system (BD biosciences). This was because a TS cell line was unable 
to be established which expressed the rtTA protein in a position where it could 
inducibly express a luciferase reporter plasmid. The main reason for this is that a co-
transfection was used in which the puromycin selection cassette was transfected at a 
6.1 TS CELL MODEL OF ELF5 TARGET GENES 
Elf5 is essential for the development of the murine placenta; in particular, Elf5 mutants 
did not develop an extra-embryonic ectoderm (ExE). The absence of the ExE 
precluded an in vivo subtractive approach for determining Elf5 target genes. We 
therefore used trophoblast stem (TS) cells as an in vitr
deriv
si
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much higher molar ratio to the pTetOn vector carrying the rtTA gene than intended. 
Oth tTA protein may have also played a role in 
the difficulty of establishing a cell line which expressed this protein in high amounts 
(Acklan
ecause it allowed seeding of the wells with TS cells 
prior to transfection at a confluency that was not too low, so they did not differentiate. 
It also on, they 
er effects such as cellular toxicity of the r
d-Berglund & Leib, 1995).  
6.3 SIRNA MEDIATED KNOCK DOWN OF ELF5 
Successful siRNA induced silencing of Elf5 mRNA was achieved using two Elf5 
siRNA oligonucleotides of the four designed. The efficiency of Elf5 knockdown was 
influenced by two main factors; the transfection efficiency using Lipofectamine 2000 
(Invitrogen Life Technologies) and the efficacy of a particular siRNA sequence to 
direct knockdown of the Elf5 mRNA target.  
After the identification of the two siRNA oligonucleotides which gave knockdown the 
transfection efficiency was optimised. The main factor influencing transfection 
efficiency is the ability to transfect cells at a stage when they are healthy and 
proliferating at a maximum rate (Ausubel et al., 1999). A standard protocol was 
established which allowed cells to be seeded the day before transfection and to be at 
the recommended confluency at transfection to minimise toxicity effects of the 
Lipofectamine. Experiments were harvested twenty four hours following siRNA 
transfection to give a greater chance of identifying direct target genes of the Elf5 
transcription factor. Longer experimental timeframes would have allowed more 
secondary interactions to occur and influence the gene expression profile. TS cells are 
quite sensitive to perturbations in culturing conditions, leading to their differentiation. 
In fact a low level of spontaneous differentiation in the TS cell populations was always 
seen by the observance of giant cells. Precocious giant cell differentiation could be 
induced with over-pipetting the cell suspensions.  A twenty four hour time period for 
the experiment was advantageous b
 meant that by the time the cells were harvested the day after transfecti
were at 80-90% confluency. A longer experimental time period would have resulted in 
over growth of the colonies and differentiation, so that the gene expression changes 
could be due to culture conditions and not siRNA treatment.   
 The best concentration of siRNA to use in a transfection was also optimised and 
consistently the knockdown rate of Elf5 with the best siRNA (called 337) was greater 
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than 80%, although in one experiment a 95% reduction in Elf5 expression was 
measured. Transfection with a fluorescently labelled siRNA oligonucleotide also 
showed a high level of transfection efficiency; green fluorescence could be seen in 
more than 80% of cells twenty four hours following transfection. The establishment of 
a high knockdown of Elf5 was important in order to detect downstream targets. Mice 
hete  (Donnison et al., 2005; 
Zhou et al., 2005) indicating a high level of Elf5 reduction is required to see a 
ection efficiency. Errors in cell counting 
ng. They are also very 
abundant, as they are found in all organisms including bacteria. The best defense 
rozygouse for the Elf5 mutant allele are normal and viable
phenotypic effect. Additionally, because the entire population of TS cells was analysed 
for changes in gene expression, changes in individual cells as a result of successful 
transfection would be averaged across the gene expression profile of all the cells in the 
experimental well. Despite the standard protocol established, siRNA knockdown was 
still variable. This is due to the variable transf
and seeding of the wells, passage number at transfection, and quality of the 
conditioned medium, all influence cell health and proliferative ability. Therefore 
following each transfection the exact knockdown of Elf5 had to ascertained compared 
to a siRNA negative control treated well. This was particularly important in generation 
of samples for measurement of candidate gene and microarray analysis. Expression of 
Elf5 in the siRNA treated samples was measured using reverse-transcription real time 
PCR (RT-PCR). 
6.3.1 Real time PCR Measurement of Gene Expression 
The extraction of RNA, in order to measure the gene expression of Elf5 targeted 
siRNA treated cells relative to controls, involved many steps which could all be sources 
of error and therefore influence the absolute expression of a gene measured. An in 
house protocol was used which was based on the TRIZOL (Invitrogen Life 
Technologies) extraction method. However during the course of this work two 
problems were found with using this protocol.  
Firstly there was a large amount of variation in the Ct measured of the housekeeping 
gene, indicative of RNA being lost or degraded during the isolation process. RNase 
contamination is very easy to get as RNAse enzymes are able to spontaneously reform 
their active state even following processes such as autoclavi
against RNases is to remove all sources of contamination (Sambrook & Russel, 2001b). 
Using RNAse free technique the primary source of contamination is the RNA source 
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itself. The TRIZOL product insert advised applying 1ml of TRIZOL directly to cells 
while still in their dishes. This is because Trypsin enzyme can be a source of RNase 
contamination and adding TRIZOL immediately to the samples prevents the action of 
endogenous RNAses (Invitrogen life technologies, 2003). Previously 400µl of 
TRIZOL had been added to the cell pellet in a minicentrifuge tube following 
harvesting with the recombinant Trypsin enzyme. Following these changes a consistent 
level of total RNA was isolated from all samples in an experiment. These results 
indicate the Trypsin enzyme had been a possible source of contamination and the 
amount of RNAse inhibitory guanidinium salts (in the TRIZOL) was unable to 
overcome this.  
Secondly, the reverse transcription negative control samples for some RNA extractions 
had a Ct value very close to that of the corresponding cDNA sample. This indicated 
DNA contamination, and an inefficient DNAse step. Following concentration analysis 
of total RNA it was obvious the amounts of total RNA and correspondingly DNA 
were too high for the amount of DNAse enzyme used. The DNAse step was 
consequentially altered to use a four fold greater amount of enzyme and the incubation 
time doubled. The laboratory protocol previously used was a generic one that was also 
used for isolation of total RNA from embryos; it was obviously not adapted to 
procedures isolating large amounts of RNA such as the experiments performed here.  
 During the course of this work a number of changes were also made to the methods 
le before expressing it relative to the 
control (Livak & Schmittgen, 2001). The first changes were in how the amplification 
in calculating the relative expression of a gene of interest in an Elf5 targeted siRNA 
treated sample compared to a control treated sample (section  2.2.3.3). Real time PCR 
analysis of gene expression was particularly suitable in this case because it allowed the 
sensitive detection of changes in gene expression of as little as 25% (Gentle et al., 
2001). Relative expression calculations were based on the 2-ΔΔCt method which uses a 
housekeeping gene to firstly normalise a samp
efficiency was calculated. Using the 2-ΔΔCt an amplification efficiency of 2 is assumed 
for both the gene of interest and the housekeeping gene. The amplification efficiency 
has a large impact on the normalised copy number calculated. For example, a 5% 
difference can make one gene appear twice as abundant after 26 cycles (Freeman et al., 
1999). To overcome this, four serial dilutions of one of the samples being analysed 
were also measured for each primer set used. Efficiency was then calculated for a 
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particular primer set for each run by graphing the Cts of the dilution series. The 
calculated amplifications were incorporated into the relative expression calculations in 
place of ‘2’. Although this was more accurate it still had problems; the amplification 
efficiency of one sample may not represent the amplification of all samples due to the 
presence of different levels of inhibitory compounds in different samples (such as 
DTT used during reverse transcription reactions). A line of best fit was used to 
calculate the efficiency.  However, the points were often not exactly linear, especially at 
higher dilutions. For real time PCR validation of the microarray results a third method 
of calculation was used.  Expression levels were quantitated on the Rotor gene 6000 
which allows an individual measurement of amplification efficiency per sample. This is 
a more accurate way of obtaining the amplification efficiency (Tichopad et al., 2003; 
Wong & Medrano, 2005).  
6.3.2 Effects on TS Cells of siRNA Mediated Elf5 Knockdown 
6.3.2.1 No Interferon Response was Induced 
One of the reported effects of using RNAi to reduce gene expression is the induction 
of an interferon immune response (Bridge et al., 2003). This is a natural reaction of a 
cell to dsRNA introduced in a viral infection and can cause changes in gene expression 
to be measured which are not as a result of changes in the target gene expression. To 
check this was not the case, two genes from the viral responsive group of Interferons 
were measured, Interferon-α4 and Interferon-β, (Samuel, 2001) using real-time PCR for 
induction. Interferon expression of 337 siRNA treated cells compared to non-treated 
cells showed no difference in interferon expression levels. Although an interferon 
response due to the 733 siRNA was not measured, later analysis in the microarray 
experiment confirmed a lack of interferon response as in the set of top twenty 
functional groups affected by both Elf5 siRNAs the immune response functional 
group was not present.  
6.3.2.2 No Changes in Cell Morphology/DNA Content as an Indication of TS 
Cell Differentiation 
Upon differentiation of TS cells giant cells are commonly formed (Tanaka et al., 1998). 
These cells are characterised by their large size and by the fact they replicate their DNA 
without undergoing mitosis to become polyploid (Simmons et al., 2007). Because Elf5 
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is essential for maintaining the proliferative ability of extra-embryonic cell precursors, it 
was hypothesised that a reduction of Elf5 could lead to increased differentiation of the 
TS cells. Casual observation the day after a transfection indicated this was not the case. 
This was later confirmed by flow cytometry which showed no overall increase in the 
DNA content per cell in a population of Elf5 siRNA treated TS cells. The reason for 
this is likely to be that the timeframe for morphological changes to occur was too 
short. Even upon complete growth factor withdrawal TS cells do not morphologically 
differentiate into giant cells until about four days later (Erlebacher et al., 2004). 
 
  
6.3.3 Candidate Gene Expression Changes as a Result of Elf5 Silencing 
Following successful knockdown of Elf5, some of these samples were analysed for 
changes in the expression of genes known to have important roles in trophoblast 
diff s in expression of the pro-protein 
protease Furin, a regulator of Nodal signalling (Beck et al., 2002), and Eomes no 
6.4 MICROARRAY ANALYSIS  
ality Analysis 
erentiation in vivo. Apart from possible change
significant changes in gene expression were observed as a result of changes in Elf5 
expression (Figure  3.3-2). Changes were however observed in the expression of some 
of the candidate genes (Bmp4, Errβ, Eomes, Fgfr2 and Tcfap2c) when the growth factors 
were removed. Some of the genes were not changed even with growth factor removal 
in the twenty four hour time period (Hand1, Cdx2, Stra13 and Spc4). The lack of genes 
which were significantly changed when analysed by candidate gene analysis was later 
confirmed with the microarray. All of the genes tested previously in the candidate gene 
analysis also showed no change in expression due to Elf5 silencing, including Furin and 
Eomes. There was a perfect correlation between those genes seen to go up or down in 
expression with growth factor removal between the microarray results and the real 
time PCR candidate gene analysis results.  
6.4.1 Microarray Qu
6.4.1.1 Technical Quality of RNA Samples and Arrays 
Before microarray analysis was carried out, RNA samples to measure changes in gene 
expression as a result of Elf5 silencing or growth factor removal were rigorously tested 
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for quality as well as for Elf5 knockdown.  This is because the greatest source of 
controllable variability is in the quality of the RNA labelled (Affymetrix Inc., 2006b) 
Following labelling and hybridisation of the RNA samples, several control parameters 
of the microarrays were analysed to ensure the experiment had been technically 
successful. All control parameters were found to be within the limits advised by the 
manufacturers (Affymetrix).  
6.4.1.2 Biological Validation  
To ensure the results of the array were biologically relevant some genes observed as 
nificantly changed via the microarray were also analysed using real time PCR. 
Biologi at 
had been identified as changed on the microarray by real-time PCR. There was a close 
tes that overall the majority of genes were 
unchanged by od. The 733 siRNA treatment had a 
greater effect on global gene expression than 337 siRNA treatment, as shown by the 
slightly lower correlation between 73 siRNA treated samples and siRNA control 
treated samples. This result was confirmed by the fact that the Elf5 microarray probe 
sets ersus a 2 fold change in 
337 siRNA treated samples. The greater knockdown of Elf5 by the 733 siRNA oligo 
sig
cal validation of the array was done by analysing a selection of the genes th
correlation between the fold change (up or down) measured using the microarray and 
using real-time PCR. An important observation was that the top two probe sets 
changed in arrays treated with either Elf5 targeted siRNA (733 or 337) mapped to Elf5. 
Annotation of probe sets significantly changed for gene name revealed a number of 
them were known to be involved in TS cell differentiation. This was especially the case 
with the set of 57 genes changed by greater than 3-fold upon growth factor withdrawal. 
This set included genes such as matrix metalloproteinase 9 (Mmp9), Ascl2, Errβ, Tcfap2c 
and Eomes and all of which are known to be expressed in derivatives of the polar 
trophectoderm (Auman et al., 2002; Luo et al., 1997; Russ et al., 2000; Scott et al., 2000; 
Sharma, 1998).     
6.4.2 Global Analysis Results 
The Log2 expression per probe set between samples treated with 337 or 733 Elf5 
targeted siRNA and the siRNA control treated samples showed a high correlation 
(0.998 and 0.994 respectively). This indica
Elf5 knockdown over the time peri
3 
 showed a 3 fold change in 733 siRNA treated samples v
came as a surprise and was contrary to previous results whereby 337 siRNA induced 
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knockdown had always been more successful (section  3.2.2.2). Elf5 real time PCR 
analysis using the Rotor gene 6000 (Corbett) on three of the same samples used in the 
microarray analysis also showed the same result; Elf5 was down regulated over 4 fold 
in 733 siRNA treated samples compared to 2.9 fold in 337 treated samples. The 337 
and 733 transfection experiments were carried out at separate times. The health and 
proliferation ability of cells is the biggest influence on transfection efficiency (Ausubel 
et al., 1999). Although cells at the same passage number were used for the different 
exp ng protocol was used. It is quite likely that factors 
st removing the conditioned medium alone. This implies another 
source of Tgfβ was present in the culture conditions apart from that supplied by the 
con  al., 2004). The authors suggest the source is a 
combination between that produced by the trophoblast cells themselves and from the 
eriments and a standard seedi
such as quality of the conditioned medium used and previous handling of the cells 
(such as pipetting too vigorously) could have affected cell health and therefore growth 
and transfection efficiency. This could have contributed to the poorer than usual 
knockdown seen in the 337 siRNA treated samples.   
Log2 expression correlation between each of the growth factor treatments versus the 
non-treated normal cells also showed high correlation. As expected TS cells grown 
without both Fgf4 and Activin had the lowest correlation with cells grown in normal 
medium (0.983). Removal of Fgf4 had a much greater overall effect on gene expression 
than Activin removal; the correlations were 0.991 and 0.996 respectively. This suggests 
Fgf4 signalling has a greater number of target genes than Activin signalling. Erlebacher 
et al (2004) observed a greater rate of differentiation when the Activin/Tgfβ source 
(conditioned medium) was removed along with the addition of anti-Tgfβ neutralising 
antibodies than ju
ditioned medium (Erlebacher et
(20%) fetal calf serum used in the medium. The culture system used in this experiment 
was very similar to that used by Erlebacher et al (2004); a concentration of 20% fetal 
calf serum was also used in the medium. Therefore other sources of Tgfβ could be 
compensating for the activin removal, giving only small changes in gene expression.  
A plot of Log2 expression of the normal treated sample versus the siRNA negative 
control treated sample showed a high correlation of 0.995. This is important because it 
indicates that treatment simply due to siRNA treatment/transfection with 
Lipofectamine 2000 had little effect on the gene expression of the cells. The high 
correlation was also significant because as mentioned above experiments were carried 
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out at different time points for practical reasons. Also in order to get high quality RNA 
some transfection experiments had to be repeated a number of times. This was 
particularly the case with the 733 siRNA transfected samples which were collected 
months after the first samples. Changes in the conditioned medium quality and cell 
handling could cause subtle changes in gene expression over time, so some genes could 
appear differentially expressed as an artefact. The siRNA negative control treated 
sample was harvested at the same time as the collected 337 siRNA treated samples. To 
counteract this and the effects of the transfection procedure on the TS cells, genes 
which were differentially expressed between siRNA negative control treated samples 
and the normal treated samples were discarded from the set of genes identified as 
being changed using the Elf5 directed siRNA oligonucleotides.  
6.4.3 Identification of Genes of Interest 
expressed by greater than 2 fold with growth factor removal. A pathway analysis of the 
Arbitrary fold change cutoffs were applied to the Log2 contrast value (section  2.2.5.7). 
for each probe set between a treatment and its relative control (siRNA control or 
normal growth medium control) to obtain a set of probes of interest. The p values for 
the probes identified as significantly changed were inspected to ensure they were 
significant (<0.05). Using a p value alone as a measurement of significance would have 
increased the rate of false positives (genes identified as having changed by chance 
alone). This is because the standard p value for biological significance is 0.05, meaning 
1 out of 20 probe-sets would be incorrectly identified as ‘significantly’ changed. Over 
the 45,101 probe sets in the Affymetrix mouse genome expression chip, many genes 
would be wrongly selected. The fold change cut offs selected were chosen purely in 
order to obtain a manageable set of genes changed for each treatment. The fold change 
cut offs were 1.4 fold for 337 siRNA treated samples, 1.5 fold for 733 siRNA treated 
samples and 2 fold for any of the growth factor treated samples.    
6.5 BIOLOGICAL MEANING 
Intersections of treatments were carried out, to identify the set of genes affected by 
siRNA treatment using either 733 or 337 siRNA. Because the genes in this set are 
changed by both siRNAs, the chance of them being differentially expressed due to the 
off target effects of one siRNA is small. A total of 22 probes were identified in this set. 
The set could be further divided into those probes (9) which were also differentially 
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probes identified as significantly changed in either 337 or 733 siRNA treatments 
showed TgFβ signalling is an important part of the network. This is as would be 
expected because Tgfβ signalling is required for TS cell maintenance (Erlebacher et al., 
2004). This indicates overlapping networks between genes regulated by Elf5 and genes 
involved in TGFβ mediated stem cell maintenance.  
Consistent with previous results showing Elf5 is regulated by Fgf4 signalling 
(Donnison et al., 2005; Metzger et al., 2007), Elf5 was found to be significantly down 
regulated in samples grown in medium without Fgf4 (2 fold down regulation).  
However, it was less affected by Activin removal, showing only a slight down 
regulation of 1.25 fold.   
6.5.1.1 Possible Elf5 and Growth Factor regulated genes 
 (Cyr61) were 
identified as significan section between 337/733 siRNA 
treatment and all growth factors. This gene is associated with Insulin growth factor 1 
The set of probes identified as the most interesting were those changed by Elf5 siRNA 
treatment with either 337 or 733 siRNAs and growth factor removal. Nine probe sets 
fell within this set and they corresponded to the genes Elf5, Cyr61, Sox2, Hst3st3b1, 
Wdr40b, Synop2l and a probe set unable to be matched (using Ingenuity Pathway 
Analysis Software). The biological soundness of these genes is highest because they are 
changed by both siRNAs (thereby removing the chance they are changed due to non-
specific RNAi effects (Echeverri et al., 2006). It is envisioned this set of genes are 
common members in both Elf5 mediated TS cell renewal and growth factor induced 
TS cell renewal. The expression of all genes identified in this set was validated by real 
time PCR. The relative fold change up or down regulation measured by real-time PCR 
quantification agreed with the microarray results for all of these genes except Wdr40b, 
which was found not to change significantly in the 337 siRNA treated samples. 
Two independent probe sets for cysteine rich angiogenic inducer 61
tly changed in the inter
(IGF-1) signalling and has been shown to augment growth factor induced DNA 
synthesis in endothelial cells (Ingenuity Pathway Analysis annotation). Aberrant 
expression of Cyr61 is associated with breast cancer, wound healing, cell adhesion and 
migration (Mo et al., 2002). Of most interest is the fact Cyr61 homozygous knockout 
mice die as a result of failure in placental development, in particular chorioallantioic 
fusion and vascularisation of the placenta (Mo et al., 2002). This information gives 
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soundness to the result from the microarray that Cyr61 is expressed in TS cells and 
down-regulated with differentiation or Elf5 knockdown. Perhaps, like endothelial cells, 
Cyr61 plays a role in the proliferation of the TS cells as a result of Elf5 transcription 
factor activity and Fgf4/Activin growth factor signalling.  
The finding that Sox2 was down regulated in this intersection was interesting as Sox2 is 
os fail just after implantation, with a failure to maintain the 
ICM/epiblast.  Wild type ES cells (which contribute only to the ICM) used to make a 
chim e a failure to 
 
 
a transcription factor associated with pluripotency cell lineages and is essential for the 
development of the placenta (Avilion et al., 2003). Sox2 is expressed in the same pattern 
as the well known pluripotency transcription factor, Oct4.  However, it is also 
expressed in the multipotent cell lines of the extra-embryonic ectoderm. Sox2 
homozygous mutant embry
era could only rescue embryos until day 7.5, when they died du
develop the chorion.  Hence, TS cells were unable to be derived from Sox2 
homozygote knockouts, indicating Sox2 plays a role in the proliferation and 
development of the extra-embryonic ectoderm (Avilion et al., 2003). 
Hst3st3b1 is one of the variants of heparin sulphate 3-O-sulfotransferase enzymes; 
these enzymes produce anticoagulant heparin sulphate and the particular form here
(3b) is highly expressed in liver and placental tissue (Shworak et al., 1999). A mouse 
knockout of Hst3st caused intrauterine growth retardation; pups born were smaller 
and survived only a few days after birth. Contrary to expectation blood clotting was 
not the reason for death and placental tissue was found to be histologically normal 
(Shworak et al., 2002). More recently Hst3b1 has been shown to be involved in Notch 
signalling, which is a key gene in many developmental pathways (Kamimura et al., 
2004). From the microarray data and real-time PCR data, Hst3st3b1 was significantly
down regulated by Elf5 knockdown. It is also down regulated by Fgf4 removal; this is 
an interesting result and may indicate Hst3st3b1 also plays a role in placental 
development. 
 
Very little information is known about Synaptopodin 2-like (Synpo2l), so it is difficult to 
speculate its role in TS cells.  It is only known that it is part of the cytoskeleton and is 
upregulated in human colorectal cancer (Nakamura et al., 2004).  Unlike the other 
genes in the 733/337 and growth factor intersection, Synpo2l was the only gene 
 189
significantly down regulated by Activin removal alone; this result was confirmed by 
real-time PCR to be significant. Wdr40b is a member of the large WD-repeat protein 
family (so far it has 126 members in humans). These proteins all share four or more 
repeating units of a 40 amino acid repeat (Li & Roberts, 2001). The functions identified 
for this family vary widely and include signal transduction, transcription regulation, cell 
enta (Ikeda et al., 
nd extraembryonic trophoblast tissue (source: Unigene; 
http://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?ORG=Mm&CID=328014
cycle control and apoptosis. However, they are all mediated through protein-protein 
interactions (Li & Roberts). There is very little known information about Wdr40b, and 
this gene could be playing any of one of the above roles in TS cells. 
 
The second intersection of greatest interest was the set 13 probes differentially 
expressed upon treatment with either Elf5 targeted siRNA but not significantly 
affected by growth factor removal. Among this set was Follistatin (Fstl).  A negative 
regulator of Activin signalling, it binds tightly to Activin preventing it from interacting 
with Activin type II receptors (Shimonaka et al., 1991). Elf5 reduction also leads to a 
reduction in Fstl transcription, perhaps increasing the cells’ susceptibility to Activin 
signalling. Vasorin binds to Tgfβ and is expressed in human plac
2004).  However, in this experiment Vasorin was not significantly changed by Activin 
signalling and instead was identified as changed through siRNA mediated Elf5 
knockdown. Baz1a is expressed in embryonic stem cells and is involved in ATP 
dependent chromatin remodelling (Bozhenok et al., 2002).  It is perhaps a common 
stem cell gene required for maintenance and proliferation of TS and ES stem cells. 
 
Expressed sequence AU015836 is a cDNA sequence which from homology to a C. 
elegans protein (28%) and a hypotheticial S. cerevisae protein is predicted to also code 
for a protein. Interestingly cDNA fragments of this sequence have been identified in 
several cDNA libraries, including libraries created from whole mouse embryos E6.5-
11.5, mouse embryonic germ cells, enriched cDNA from a 1 cell embryo, mouse 
embryonic stem cells a
 accessed 
/9/07).  These observations indicate it could play a role in embryonic development.  5
6.5.1.2 Genes Identified as Being Changed upon Growth Factor Withdrawal 
Annotation of the set of probes changed by greater than 3.5 fold upon growth factor 
removal (and therefore induction of TS cell differentiation) revealed several genes 
 190
which have previously been reported to be expressed in early placental tissue. In 
particular placenta expressed1 (Plac-1) was seen to increase 6 fold when mTS cells 
where induced to differentiate by removal of both Fgf4 and Activin. Plac-1 is 
specifically detected in the trophoblast cell types of the EPC, giant cells and labyrinth 
cells from embryonic day 7.5 to 14.5 (Cocchia et al., 2000). It is upregulated upon 
differentiation to the syncytiotrophoblast fate in human placenta (Massabbal et al., 
2005). 
It was interesting to note that Socs2 was one of the genes identified as down regulated 
1.8 
ld) than Fgf4 removal (1.5 fold). It was up regulated 4.5 fold on removal of both 
, 
invasion and proliferation. Its expression and involvement in mediating placental 
inva e 
(Sharma, 1998; Staun-Ram et al., 2004).  
in mTS cells when Fgf4 growth factor was removed. Both Socs2 and Elf5 are known to 
be essential for mammary gland development by playing key roles in prolactin 
signalling (Harris et al., 2006). However, the Elf5 siRNA treated samples did not show a 
significant down regulation in Socs2 expression, so it seems Elf5 does not directly 
regulate Socs2.   
 
Consistent with the process of TS cell differentiation to giant cells, Dusp4 and Dusp6 
were significantly down regulated on Fgf4 removal; these genes are phosphatases and 
negatively regulate MAPK/ERK family which are associated with cellular proliferation. 
 
Gata2 was an interesting gene; unlike most genes it showed a significant up-regulation 
upon growth factor removal, and it appeared more affected by Activin removal (+
fo
Fgf4 and Activin showing a synergistic effect. Gata2 expression is essential for 
haematopoietic stem cells and has been described as a “gatekeeper” to maintain their 
immaturity, with down regulation leading to differentiation (Minegishi et al., 2003). 
Gata2 is also known to bind alongside the Ets transcription factor Elf1 to the enhancer 
of the SCL gene, whose expression is essential for the initiation of haematopoiesis and 
the formation of Haematopoietic stem cells (Gottgens et al., 2002).  
 
Mmp9 is a peptidase enzyme which degrades collagen and is involved in migration
sion has been extensively studied in both human and mouse trophoblast tissu
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Ndrg1 was down-regulated 8 fold upon loss of Fgf4, indicating it is very sensitive to 
changes in this signalling pathway. Ndrg1 has been shown to be expressed in the early 
embryo in both the trophectoderm and in the derived trophoblast cell types.  Under 
hypoxia expression of this gene is up-regulated (Clipsham et al., 2004). In ES cells 
knockdown of Ndrg1 leads to differentiation. In combination with the results from this 
microarray experiment which show Ndrg1 down regulation upon Fgf4 removal 
induced differentiation this indicates this gene is a common element to maintaining 
stem cell pluripotentcy.  
es and Errβ due to Fgf4 withdrawal, and less so to Activin withdrawal. 
rlebacher et al (2004) observed a similar decrease in Mmp9 and Cdx2 expression with 
gulated.  
6.5.1.3 Improvements/problems:
 
In a similar experiment the effects of withdrawal of either Fgf4 or TGF-β/activin was 
investigated in mTS cells by monitoring the expression of the genes Eomes, Errβ, Cdx2, 
Mmp9, Id2 and Fgfr2 (Erlebacher et al., 2004). In agreement with the results found here, 
over the three day period following growth factor withdrawal there was a rapid down-
regulation of Eom
E
either Fgf4 or Activin withdrawal. In this experiment Mmp9 was also found to be 
significantly down-regulated, however, to a greater extent with Fgf4 withdrawal. In 
contrast to Erlebacher et al’s (2004) findings, Cdx2 was not significantly down-
re
 
Retinoblastoma tumour suppressor gene (Rb) has recently been shown to play a critical 
role in TS cells (Wenzel et al., 2007). In contrast to this study Rb was not found to be 
significantly changed (using microarray analysis). The greatest change seen was a 1.3 
fold reduction in 733 treated cells which was smaller than the 1.5 fold cut off. This may 
be due to the short time period after measurement.  However, Rb does not appear to 
be a direct target of Elf5. 
 
 
ock-down. This meant the overall knockdown 
measured was reduced, compared to a population of cells which had all received the 
A major disadvantage of the experimental system used when Elf5 knockdown was 
being studied was that the cells used for transcriptional analysis came from a 
population of cells which would all have been transfected to different degrees and 
therefore all have different levels of kn
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knock down treatment. Consequently, the downstream effects of the knockdown were 
also diluted out by the overall population, and it was this effect which meant overall 
fold changes of Elf5 as measured by the microarray were a maximum of 2.3 fold for 
the 337 treated samples and 3.2 fold for the 733 treated samples. This resulted in the 
next biggest change in a genes expression of 1.8 fold for 337 and 2.6 fold for 733. 
Another factor in the low level of fold change was that the analysis was carried out 
after only twenty four hours; a longer period could have given greater fold changes. 
However there would have been the confounding factor that the siRNA transfection 
as only transient and so therefore the knockdown could not be maintained over 
 studies with a similar approach, using siRNA to reduce Oct4 expression was 
alidation of the microarray results was carried out on cDNA generated from the 
same samples used in the microarray experiment. This could increase the false 
disc s in gene expression could be due to anomalies 
transfected and treated separately), so the chance all three are anomalies is low. 
w
longer periods of time. 
 
 In a similar paper to measure downstream targets of the Oct4 transcription factor in 
ES cells, a Oct4+/- cell line was used which could inducible express Oct4 when 
tetracycline was removed from the medium. In this experiment the fold change in Oct4 
after one day was just 1.2-fold at day two and 2-fold at day 3.  Using the siRNA 
approach gave a similar fold change as these results. They also had log ratio changes 
which varied between -2 and +2. Therefore, although the changes appeared small they 
are similar to other experiments altering transcription factor expression.  
 
In
followed by global microarray analysis; 36% of probes were down regulated.  This is 
contrary to the results from this experiment, where the majority of probe sets found to 
be differentially expressed were down regulated (68%) as cells lost their stemness. Oct4 
is a transcription factor required for ES pluripotency, and a change of 50% of Oct4 in 
embryonic stem cells induces differentiation.  
 
V
overy rate because identified change
from a particular experiment, and not indicative of the result when carried out in a 
different experiment (Allison et al., 2006). It is therefore recommended that validation 
of microarray results should be carried out using new biological cases. This effect is 
mitigated to some degree, however, by the fact three samples of each treatment were 
used for validation, and each can be considered a separate biological case (they are each 
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Concordance of the microarray results with the results from the candidate gene 
expression analysis, which was carried out on samples generated in a separate 
experiment, support the soundness of the findings. In future it would be better to 
generate a new set of samples for validation. 
6.6 FURTHER RESEARCH 
The targets identified as possible Elf5 targets need to be further investigated to show 
they are expressed at the correct time and place for Elf5 regulation. This could be 
achieved using in situ hybridisation on mouse embryos which identifies the location and 
me a transcript is expressed. Another confirmation of target genes is to use the 
en confirmed 
 coincide with Elf5 expression, the role of that gene could also be investigated (for 
of certain transcription factors such as 
dx2 is enough to drive ES cells into the trophectoderm lineage (Niwa et al., 2005; 
ti
recently published Elf5 DNA binding sequence: (T/a)A(T/a)AAGGAAGT(A/t)(A/t) 
(Choi and Sinha, 2006) for in silico analysis. The sequences within or near the possible 
target genes can be searched using bioinformatics algorithms to see if they contain 
conserved enhancer binding regions of DNA coding for the consensus Elf5 DNA 
binding site.  
 
Once the spatio-temporal expression of the potential target gene has be
to
example, by generating a knockout mouse) and therefore by using Elf5 as a starting 
point the molecular networks underlying early placental development may be 
elucidated. This is of particular importance given the placenta’s role in a variety of 
functions all essential to an embryo’s survival.  
 
Studies have shown that the over-expression 
C
Tolkunova et al., 2006). It would be interesting to see if over-expression of Elf5 in ES 
cells has the same effect. 
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APPENDICES 
SEQUENCING OF PTRE-ELF5 DATA 
A-1: With the poly-a globin primer 
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A-2: Sequencing of the ptre-elf5 co V promoter Primer nstructWith the CM
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A-3: Summary of the quality analysis performed on RNA samples prior to 
microarray analyses. 
 Samples were analysed for concentration and purity absorbance ratios on the 
nanodrop (Nanodrop Technologies). The absolute Gapdh Ct was measured on the ABI 
real-time PCR machine. Elf5 and Eomes expression levels were normalised to Gapdh 
before being expressed relative to the siRNA negative or normal medium control. TS 
= Trophoblast stem cell medium, Fgf4 = fibroblast growth factor 4, Normal= TS cells 
grown in medium containing both Fgf4 and Activin.  
Sample 
Name 
Harvesting 
method 
Concentra
tion of 
total RNA 
ng/µl 
Absorban
ce Ratio 
260/280 
RT- 
Gapdh Ct 
Absolut
e 
Gapdh 
Ct 
(1/10 
dilution 
of 
cDNA) 
Relative 
Elf5 
expressi
on (to 
avg 
siRNA 
negative
) SEM 
Relative 
Eomes 
expressi
on (to 
avg 
normal) SEM 
TS + Fgf4 
1 TRIZOL 1734 2.04 25.81 17.71     0.766 0.04
TS + Fgf4 
2 TRIZOL 2797 1.97 27.01 17.17   0.774 0.04
TS + Fgf4 
3 TRIZOL 2881 1.97 25.98 17.13   0.865 0.04
TS + Fgf4 
4 TRIZOL 2798 1.99 26.96 16.94   0.796 0.04
TS + Fgf4 
5 TRIZOL 2516 2.01 26.18 17.24   1.010 0.04
TS + Fgf4 
6 TRIZOL 3271 1.90 26.48    0.000 0.04
TS + Fgf4 
7 TRIZOL 2011 2.04 33.40 16.32   1.006 0.04
TS + Fgf4 
8 TRIZOL 2079 1.98 28.23 18.03   1.050 0.04
TS + Fgf4 
9 TRIZOL 1676 2.04 25.97 18.01   0.960 0.04
TS + Fgf4 
10 TRIZOL 1663 2.04 26.00 18.21   1.121 0.04
TS + Fgf4 
11 TRIZOL 1883 2.01 >35 18.25   1.077 0.04
TS + Fgf4 
12 TRIZOL 1892 2.04 >35 17.92   0.916 0.04
TS + 
activin 1 TRIZOL 2018 2.04 32.37 17.27     0.515 0.01
TS + 
activin 2 TRIZOL 2070 2.04 24.34 17.20     0.537 0.01
TS + 
activin 3 TRIZOL 2069 2.06 31.92 17.53   0.538 0.01
TS + 
activin 4 TRIZOL 2246 2.03 25.63 17.29   0.533 0.01
TS + 
activin 5 TRIZOL 2653 2.00 30.25 17.03   0.571 0.01
TS + 
activin 6 TRIZOL 1215 2.04 27.26 18.32   0.580 0.01
TS + 
activin 7 TRIZOL 1800 2.03 25.49 17.39   0.619 0.01
TS + 
activin 8 TRIZOL 1716 2.05 28.16 17.95   0.642 0.01
TS + 
activin 9 TRIZOL 2030 2.03 25.00 17.40   0.524 0.01
TS + 
activin 10 TRIZOL 2099 2.03 24.00 17.81   0.602 0.01
TS + 
activin 11 TRIZOL 1868 2.04 25.83 17.76   0.589 0.01
TS + 
activin 12 TRIZOL 1811 2.04 25.27 17.67     0.560 0.01
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No 0.05rmal 1 TRIZOL 2327 2.00 25.81 17.33     0.961 
No 2 2.00 27.01 17.04   0.986 0.05rmal 2 TRIZOL 237
No 1 2.00 25.98 17.32   0.950 0.05rmal 3 TRIZOL 243
Normal 4 TRIZOL 2254 2.01 26.96 17.49   1.181 0.05
Normal 5 TRIZOL 2194 2.02 26.18 17.53   1.099 0.05
Normal 6 TRIZOL 2782 1.98 26.48 16.94   0.905 0.05
Normal 7 TRIZOL 3100 1.93 33.40 16.77   1.105 0.05
Normal 8 TRIZOL 2664 1.98 28.23 17.21   1.085 0.05
Normal 9 TRIZOL 2922 1.96 25.97 17.20   1.123 0.05
Normal 10 TRIZOL 2527 2.00 26.00 17.55   1.134 0.05
Normal 11 TRIZOL 2400 2.00 26.00 17.77   0.928 0.05
Normal 12 TRIZOL 2314 2.01 27.00 17.73     0.5418 0.05
TS media 
only 1 TRYPLE 3889 1.7-1.95 19.74 17.07 0.0001
0.00
00     
TS media 
only 2 TRYPLE 3935 1.7-1.95 20.01 17.57 0.0001
0.00
00    
TS media 
only 3 TRYPLE 4075 1.7-1.95 25.7
0.00
00    17.21 0.0001
TS media 
only 4 TRYPLE 3148 1.7-1.95 22.47
0.00
00   17.17 0.0001  
TS media 
only 5 TRYPLE 26.63
0.00
00   4058 1.7-1.95 16.42 0.0001  
TS medi
only 6 
a 0.00
TRYPLE 4180 1.7-1.95 27.35 16.52 0.0001 00    
TS media 
only 7 TRYPLE 3666 1.7-1. 0.0001 00    95 27.07 16.65
0.00
TS media 
only 8 TRYPLE 3782 1.7-1. 0.0001
0
00    95 27.42 16.52
0.0
TS media 
only 9 TRYPLE 3596 1.7-1. 0.0001
0
00    95 27.41 16.62
0.0
TS media 
only 10 TRYPLE 3305 1.7-1. 0.0001
0
00    95 27.55 16.75
0.0
TS media 
only 11 TRYPLE 2940 1.7-1. 0.0001
0
00    95 28.02 17.44
0.0
TS media 
only 12 TRYPLE 2970 1.7-1. 32 0.0000
0
00     95 28.18 18.
0.0
siRNA-
337-1 TRYPLE 3084 1.7-1. 0.158
0
6     95 25.69 17.08
0.0
siRNA-
337-2 TRYPLE 3407 1.7-1. 0.180
0
6    95 26.36 16.82
0.0
siRNA-
337-3 TRYPLE 3511 1.7-1. 0.200
0
6    95 31.65 16.65
0.0
siRNA-
337-4 TRYPLE 3467 1.7-1. 0.188
0
6    95 26.89 17.22
0.0
siRNA-
337-5 TRYPLE 3093 1.7-1. 2 0.157
0
6    95 5.86 17.29
0.0
siRNA-
337-6 TRYPLE 3727 1.7-1. 2 0.176
0
6    95 9.48 16.19
0.0
siRNA
337-7 
-
1.7-1. 0.137
0
6    TRYPLE 3572 95 26.66 16.56
0.0
siRNA
337-8 
-
TRYPLE 3374 1.7-1. 0.154
0
6    95 30.31 16.82
0.0
siRNA
337-9 
-
TRYPLE 3687 1.7-1. 0.177
0
6    95 28.12 16.19
0.0
siRNA
337-10 
-
TRYPLE 3815 1.7-1. 0.195
0
6    95 29.19 16.38
0.0
siRNA
337-11 
-
TRYPLE 3880 1.7-1. 0.190
0
6    95 28.9 16.39
0.0
siRNA
337-12 
-
TRYPLE 3747 1.7-1. 0.213
0
6     95 31.02 16.32
0.0
si neg
control 1 
ative 
1.7-1. 1.093
2
8     TRYPLE 3370 95 31.09 16.56
0.0
si neg
control 2 
ative 
1.7-1. 1.216
2
8    TRYPLE 3541 95 30.98 16.75
0.0
si neg
control 3 
ative 
1.7-1. 1.012
2
8    TRYPLE 3815 95 30.43 16.56
0.0
si neg
control 4 
ative 
1.7-1. 0.922
2
8    TRYPLE 3688 95 30.36 16.79
0.0
si neg
control 5 
ative 
TRYPLE 3911 1.7-1. 0.945
2
8    95 29.76 16.29
0.0
si neg
control 6 
ative 
TRYPLE 3408 1.7-1. 0.838
2
8    95 29.01 16.64
0.0
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si negative 
control 7 TRYPLE 3425 1.7-1. 0.903
2
8    95 30.29 16.46
0.0
si negative 
control 8 TRYPLE 3274 1.7-1. 1.057
2
8    95 31.52 16.9
0.0
si negative 
control 9 TRYPLE 3549 1.7-1. 0.969
2
8    95 29.13 16.56
0.0
si negative 
control 10 TRYPLE 3660 1.7-1. 1.018
2
8    95 29.91 16.43
0.0
si negative 
control 11 TRYPLE 2323 1.7-1. 1.001
2
8    95 25.94 17.73
0.0
si negative 
control 12 TRYPLE 3478 1.7-1.95 1.026
2
8     27.39 16.97
0.0
siRNA-
733 1 TRIZOL 2687   0.40 1     26.62 16.46 0.0
siRNA-
733 2 TRIZOL 2345 2.03 31.79 16.88 0.38 1    0.0
siRNA-
733 3 TRIZOL 2480 2.02 27.85 17.06 0.35    0.01 
siRNA-
733 4 TRIZOL 2409 2.03 29.66 16.81 0.35    0.01 
siRNA-
733 5 TRIZOL 2058 2.04 28.01 16.98 0.36    0.01 
siRNA-
733 6 TRIZOL 2172 2.04 28.08 17.07 0.36    0.01 
siRNA-
733 7 TRIZOL 2180 2.03 32.17 17.21 0.35    0.01 
siRNA-
733 8 TRIZOL 2277 2.03 32.70 17.03 0.34    0.01 
siRNA-
733 9 TRIZOL 2095 2.05 35.23 16.95 0.38    0.01 
siRNA-
733 10 TRIZOL 2219 2.03 29.77 17.36 0.42    0.01 
siRNA-
733 11 TRIZOL 2260 2.04 26.80 17.20 0.35    0.01 
siRNA-
733 12 TRIZOL 1756 2.04 >35 17.52 0.39     0.01 
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